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Abstract 
Progesterone administration reduces the risk of preterm labour in high-risk women 
with singleton pregnancies but has no effect in women with a multiple pregnancy. 
However, it should be noted that it is not clear why progesterone is effective in the 
singleton pregnancies and in addition stretch-induced preterm labour is an attractive 
but not fully proven explanation. The data from my studies showed that progesterone 
did not inhibit stretch-induced MAPK activation or gene expression possibly 
explaining why progesterone is ineffective in the prevention of preterm labour in 
multiple pregnancies. Although stretch did reduce PR expression in a NF-κB-
dependent manner, this was not sufficient to inhibit progesterone action, suggesting 
that it is not responsible for the functional progesterone withdrawal observed with the 
onset of human labour.  
Progesterone is thought to reduce the risk of preterm labour by inhibiting 
inflammatory cytokine-induced increases in prostaglandin synthesis. Initially, I 
demonstrated that IL-1 inhibited progesterone-driven PRE activation via p65. 
Conversely, p65-driven NF-B reporter construct activity was reduced by 
overexpression of PR-B and this was enhanced by the addition of MPA. Both MPA 
and progesterone repression of IL-1-driven COX-2 expression was lost by 
knockdown of GR. Subsequently, a series of in vitro studies suggested that 
progesterone acted via progesterone-induced and GR-mediated MKP-1 activation to 
repress IL-1-driven COX-2 and that although the interaction between p65 and PR-B 
might be involved in the repression of progesterone-driven gene expression, it did not 
seem to be responsible for progesterone repression of IL-1-induced COX-2 
expression. 
Finally, the cDNA microarray analysis showed that the PR and GR regulated distinct 
gene networks and cellular functions in the absence or presence of ligand. However, 
the ability of progesterone to modulate gene expression can be mediated via both PR 
and GR. These data broaden our view of progesterone action and suggest alternative 
roles for PR and GR in human parturition.  
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1. Introduction 
1.1. Human parturition 
Parturition is defined as the process of giving birth, which is composed of five 
separate and independent physiological actions including increased myometrial 
contractility, membrane rupture, cervical maturation, placental separation, and uterine 
involution [1, 2]. These events occur gradually in the gestational tissues, such as 
uterus, decidua, placenta, and fetal membranes (Figure 1-1) [3-6]. In different species 
of mammals, many aspects of physiology are similar. However, reproduction is a very 
important exception where humans are unique [7]. For example in the chimpanzee, 
although almost 95% of its genomic DNA sequences are identical to those of humans, 
most of the genes related to reproduction are in that 5% of differences between these 
two species [8, 9]. Moreover, the evolution of the female pelvis, due to the upright 
posture and the increases in the size of the cranium, also contribute to the unique 
nature of human parturition [10]. 
 
Figure 1-1 The gestational tissues.  
A schematic diagram of the gestational tissues. Adapted from McGraw-Hill Human Sexuality Image Bank. 
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Normal human pregnancy lasts for between 37 and 42 weeks with minor variations 
between ethnic groups (about 38 weeks after conception or about 40 weeks from the 
last normal menstrual period) [11]. Until a combination of signals from both mother 
and fetus, both endocrine and mechanical stimulation trigger the onset of labour [12, 
13]. The timing of labour has to be well controlled; any aberrations within the timing 
of these signals may result in the abnormalities of parturition, such as preterm labour, 
postterm labour and stillbirth.  
1.1.1. Term labour 
Physiologically, labour at term is considered to be a release from the system which 
maintains uterine quiescence during pregnancy rather than an active process initiated 
by uterine stimulants [14]. Although some evidence suggest that the fetus controls the 
timing of labour, the final pathway for labour must reside in the uterus. The process of 
human pregnancy and labour can be divided into four distinct phases [15-17]: 
Phase 0 (quiescence) covers most of pregnancy and is characterised by myometrial 
quiescence, which is achieved predominantly by progesterone. Other factors that are 
considered to be involved in maintaining uterine quiescence are prostacyclin, relaxin, 
corticotrophin-releasing hormone (CRH), human placental lactogen, adrenomedullin, 
nitric oxide, parathyroid hormone-related peptide, calcitonin gene-related peptide and 
vasoactive intestinal peptide. Although these factors play their function in different 
ways, they all finally increase intracellular concentrations of cyclic adenosine 
monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which inhibit 
intracellular calcium release causing a reduction in myosin light chain kinase activity 
and, therefore, myometrial contractility.  
Phase 1 (activation) is characterised by activation of uterine function, including a 
change in steroid environment by a rise in estrogen and mechanical stretch [16, 18, 
19]. An important event in this activation phase is the up-regulation of a group of 
genes encoding contraction-associated proteins (CAPs), such as myometrial receptors 
for prostaglandins and oxytocin, connexin 43, and genes related to certain ion 
channels. Another important change is the increase in the number and size of gap 
junctions between neighboring myometrial cells, which permits the development of 
electrical synchrony and helps the initiation of rhythmic contractions (Figure 1-2).   
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Phase 2 (stimulation) after activation, the uterus is prepared for stimulation by 
uterotonins, such as prostaglandins, oxytocin, and CRH. Labour finally occurs and the 
fetus and placenta are delivered.  
Phase 3 (involution) is the last phase, which is primarily mediated by oxytocin and 
during which the uterus return to its pre-conception state. 
In this series of events, the initiation of parturition has been described as the transition 
of the myometrium from quiescence (Phase 0) to activation (Phase 1) where most of 
mechanical and biochemical changes occur, including uterine stretch, pro-
inflammatory cytokines, and prostaglandins.  
 
Figure 1-2 The uterine myometrium during labour.  
Panel A shows that in the uterine myometrium individual myocytes have relatively low connectivity. Panel B 
shows that the uterine myometrium is converted into a tissue with extensive physical connections during labour. 
The physical connections occur through pores formed by multimers of connexin 43. Biochemically, the release of 
prostaglandin F2α and increased intracellular calcium also contribute to these connections during labour. Through 
this extensive physical and biochemical connectivity, the depolarization in individual myocytes can be passed to 
neighboring cells in order to form extensive waves of depolarization and generate contraction over large areas of 
the uterus. This leads to increased intrauterine pressure, progressive dilatation of the cervix, and expulsion of the 
fetus. Adapted from Smith, R., N Engl J Med, 2007. 356(3): p. 271-83 [7]. 
1.1.2. Preterm labour 
Preterm birth (less than 37 weeks of gestation [11]) is the most important cause of 
perinatal mortality and morbidity, accounting for 75% of neonatal deaths and more 
than 50% of long-term morbidity [20]. According to gestational age, it can be further 
divided into four subcategories: extreme prematurity (~5% of preterm births occur at 
less than 28 weeks’), severe prematurity (~15% at 28-31 weeks’), moderate 
prematurity (~20% at 32-33 weeks’), and near term (60-70% at 34-36 weeks’) [21]. In 
Chapter 1: Introduction 
- 23 - 
Europe and some other developed countries, the preterm delivery rates are generally 
5-9%, whereas the situation in the US is even worse with rates of 12-13% [22, 23]. 
The data reported by Martin et al. show that the frequency of preterm birth in the US 
has increased by over 30% in the last 20 years although we have more knowledge 
about the risk factors and mechanisms of preterm labour and better public health 
system and medical interventions [24, 25]. Between 22 and 26 weeks’ gestation, 65% 
of babies will die at the time of delivery or in the neonatal intensive care unit (NICU), 
while 90% of neonates survive at 30 weeks of gestation [26, 27]. Although the 
survival rate has improved with the gestational age, they are at high risk of developing 
permanent disabilities and complications such as lung disease, cerebral palsy, 
disorders of behavior and emotion, blindness or deafness, and epilepsy [24, 28]. The 
impact of the complications of being born prematurely is far greater in terms of 
“disability adjusted life years” than other common chronic conditions such as 
ischaemic heart disease, depression and stroke [29], since the expense of preterm birth 
is not only in the immediate neonatal care but also in the long-term care of lasting 
morbidities which is potentially due to prematurity [30-33]. In the UK, besides the 
cost of NICU, the cumulative cost of hospital care during the first 10 years of life 
averaged to approximately £18,000 for babies born before 28 weeks of gestation, 
which is 10 times higher than that of those born after 37 weeks of gestation [34]. 
Preterm labour is better defined as a syndrome rather than a specific diagnosis 
because the causes are varied, such as vascular insult, uterine overdistension, 
abnormal allogenic recognition, and stress [35]. Physiologically, term and preterm 
labour maybe the same process except that they occur at different gestational ages 
[36], but this remains to be proven. In preterm labour, the mechanisms responsible for 
maintaining uterine quiescence are either short-circuited or overwhelmed [17], 
resulting in increased uterine contractility, cervical ripening (dilatation and 
effacement), and decidua/membrane activation [37];  thus, the underlying molecular 
mechanisms of term and preterm labour are likely to be distinct. In terms of etiology, 
about 30-35% of preterm births are medically indicated while most of those are 
spontaneous (40-45% follow spontaneous preterm labour and 25-30% follow preterm 
premature rupture of the membranes) [21, 38]. Until now, some pathological 
processes have already been demonstrated to be implicated in the preterm birth 
syndrome, including uterine overdistension, intrauterine infection, endocrine 
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disorders, uterine ischaemia, abnormal allogenic recognition, allergic-like reaction 
and cervical disease [35, 39].  
1.2. Management strategies for the prevention of preterm labour 
There are many barriers to the prevention of preterm labour including our inability to 
identify those women who are at increased risk of preterm birth and the failure of 
current treatments to stop preterm labour once it has started [40]. Current prediction 
of risk of preterm labour relies on the individual’s obstetric history, cervical length 
and biochemical markers such as fetal fibronectin in cervico-vaginal secretions [41]. 
However, the progress of developing effective prophylactic treatment for women 
considered to be at risk for preterm birth is still unsatisfactory. Many strategies, such 
as antibiotic therapy, bed rest and routine hospitalization have been proved to be 
ineffective. However, progesterone supplementation appears promising based on the 
hypothesis that progesterone induces uterine quiescence despite little progress being 
made in understanding the molecular mechanisms of how it works [42-46].  
Progesterone has been used for the prevention of spontaneous abortions for more than 
40 years [47]. In most of clinical trials, either natural progesterone or synthetic 
progestagens have been used. The latter is derived from progesterone or 
nortestosterone and is similar in structure to progesterone. For instance, 17-alpha-
hydroxyprogesterone caproate (17P) is most commonly used, and it significantly 
decreased the rate of recurrent preterm birth but has no effect on multiple 
pregnancies-induced preterm labour [48-51]. Moreover, two recent studies indicated 
the potential maternal side-effects that 17P may cause, such as an increased risk of 
gestational diabetes [52, 53]. Although 17P may not be the best progestational agents 
to prevent preterm birth, it is very important to understand and determine the potential 
mechanisms by which progestational agents prevent preterm birth.  
A better understanding of the molecular mechanisms of progesterone action and its 
interaction with the pathological processes suggests ways in which we can design 
more effective therapies and preventative approaches in the future, ultimately 
reducing the risks of preterm labour. 
1.3. Uterine distension 
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1.3.1. The role of stretch in normal pregnancy 
During normal pregnancy, the action of estrogen regulates the growth of the uterus, 
which provides enough space for the fetus to grow. Despite the fact that the fetus and 
placenta increase in size during gestation, the intra-amniotic pressure stays relatively 
constant throughout this period [54, 55] due to the effect of progesterone and some 
endogenous myometrial relaxants such as nitric oxide [56] and cAMP [57], which 
promotes myometrial hyperplasia and hypertrophy and prevent the uterus from the 
influence of stretch-induced CAP gene expressions [58-60]. Toward the end of 
pregnancy, uterine growth halts leading to the loss of coordination between the 
growth of uterus and fetus and increasing tension of the uterine wall. Therefore, the 
effect of stretch enhances in late gestation, associating with augmented production of 
placental CRH and increased amniotic fluid surfactant proteins and lipids, which can 
lead to the onset of labour [58, 61-64]. 
1.3.2. Uterine overdistension causes preterm labour 
The rate of preterm labour increases in women with multiple pregnancy [65], 
polyhydramnios [66-68], and mullerian duct abnormalities [69, 70], which are 
associated with uterine overdistension.  
Multiple pregnancy is defined as any pregnancy that carries more than one fetus. In 
every 80 live births, there is approximately one twins born spontaneously while 
triplets occurs one in every 1600 [71]. In the US, 51% of twins and 91% of triplets are 
born preterm, which is 6-9 times higher than that of singletons. 14% of twins and 41% 
of triplets are even born very preterm, whereas only 1.7% in singletons [72]. Another 
study based in Scotland showed that 52.2% of multiple births are preterm and 10.7% 
of them delivered before 32 weeks. In the UK, the neonatal mortality rate of twins is 
1.8%, which is 6-7 times that of singleton pregnancies while the rate in higher order 
multiple pregnancies goes to 39.6%. With the development of in vitro fertilisation 
(IVF), it contributes over 20% of all multiple births in the UK, although only 1.3% of 
all births are IVF births. There is some evidence to indicate that the incidence of 
preterm birth is higher in IVF twins than the spontaneous ones [73].  
1.3.3. Mechanisms of preterm labour in multiple pregnancy 
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Clinically, progesterone administration reduces preterm labour rates in singleton but 
not in multiple pregnancies [49, 51, 74]. This suggests that different processes are 
involved in singleton and multiple preterm labour. Since multiple pregnancies have 
more fetuses and a larger placental mass, it is likely that the physiological stimuli, 
such as CRH, surfactant protein-A (SP-A), and platelet-activating factor (PAF), are 
greater [64, 75, 76], increasing the possibility of early delivery (Figure 1-3) [77]. 
TambyRaja et al. supported part of this hypothesis and found that levels of placental 
CRH were higher in twin pregnancies than in singleton pregnancies, but there is no 
difference in the CRH levels in those twins that did and did not deliver early [75]. 
However, it is still unknown whether the levels of SP-A and PAF are also higher in 
multiple pregnancy.  
Some groups have tried to investigate the difference in the basic functional properties 
of myometrium from both singleton and multiple pregnancies. Although there was no 
statistically significant difference in the number of proliferating cells, the uteri from 
multiple pregnancies contracted more frequently than singleton controls [78, 79]. 
However, there was no threshold of contraction frequency could be established for the 
purpose of prediction. In terms of the myometrial thickness, although ultrasound 
evaluations showed that the lower uterine segment of twin pregnancies became 
thinner with increasing gestation, there was no difference comparing with singleton 
groups. The stretch-induced protein expression in twin pregnancies may increase the 
length of the uterine wall rather than the myometrial thickness [80]. These data are 
also consistent with an earlier study which showed myometrial thickness of the upper 
uterine segment in singletons remained relatively constant throughout gestation, 
whereas that of the lower uterine segment decreased with  advancing gestational age  
[81].   
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Figure 1-3 Potential mechanisms leading to preterm birth in multiple pregnancies. 
The increased fetal and placental mass of multiple pregnancy is like to induce the levels of stimuli including 
stretch, placental CRH production and lung maturity factors and causes increased myometrial and fetal membrane 
activation. Similar or greater proportions of multiple pregnancies compared with singleton pregnancies will be 
seen in pathological processes such as infection, cervical insufficiency, placental dysfunction and stress. A higher 
incidence of iatrogenic preterm birth occurs in twins due to more frequent medical indications for delivery. 
Adapted from Stock, S. and J. Norman, Semin Fetal Neonatal Med, 2010. 15(6): p. 336-41 [77]. 
Many investigations are focused on the effect of stretch as it is considered to be one of 
the most important factors leading to preterm labour in multiple pregnancies. Animal 
studies have shown that stretch increases myometrial expression of the oxytocin 
receptor (OTR), cyclooxygenase-2 (COX-2), connexin-43 and activator protein-1 
(AP-1) family members [58, 60, 82]. Uterine stretch not only occurs on the 
myometrium but also affects the fetal membranes, which adhere to the inner surface 
of the uterus. The in vitro studies on human myometrial and amnion epithelial cells 
revealed that labour-associated proteins are also up-regulated by mechanical stretch 
via one or more transcription factors, such as AP-1 and nuclear factor-kappa B (NF-
κB) [83-87]. These transcription factors are also found to be involved in stretch-
induced genes expression in other cell types including airway smooth muscle cells 
and endothelial cells [88, 89]. By comparison between myometrium of singleton and 
multiple pregnancies, another in vitro study tested the expression of gap junction 
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proteins, prostaglandin E receptors, and G-protein subunit Gsα and found that their 
expression levels were not altered by stretch [78].  
The mechanisms leading to preterm birth in multiple pregnancy are still unclear, 
although many hypotheses have been proposed. Therefore, we still cannot fully 
explain why therapies that prevent preterm labour in singletons are ineffective in 
multiple pregnancy or may even be harmful.   
1.4. Intrauterine infection/inflammation 
1.4.1. Inflammation and pregnancy 
Inflammation is part of the innate immune response and regarded as a process by 
which tissues of body respond to insults in order to recruit cells and molecules to 
suppress the infection, limit the degree of damage, and induce regeneration of affected 
tissues. It is characterized by elevated production of chemokines, cytokines and 
pattern recognition receptors. Clinically, inflammation is defined by the presence of 
five classical signs: heat, pain, redness, swelling and loss of function [90]. However, 
an excessive inflammatory reaction or disruption of inflammation regulation is 
causally associated with the development of a large variety of human diseases [91]. In 
the reproductive process, inflammation plays a critical role because ovulation, 
implantation and parturition are all inflammatory phenomena. Adverse pregnancy 
outcomes, such as spontaneous abortion, preeclampsia, intrauterine growth restriction 
and preterm labour, are usually caused by the disorder of cytokine networks [92]. 
Cytokines are divided into four families depending on their structure: the four-α-helix 
bundle family including Interleukin (IL)-2, Interferon (IFN)-γ, and IL-10; IL-1 
family; IL-17 family; and small cytokines (chemokines) family such as IL-8, 
monocyte chemotactic protein-1 (MCP-1), and chemokine (C-C motif) ligand 5 
(CCL5). Functionally, they can be grouped into those involved in cell-mediated 
immunity and those involved in humoral immune response. The former is regulated 
by T helper (Th) 1 cells where IL-1, IL-2, IL-6, IL-12, IL-15, IL-18, TNF-α and IFN-
γ are mainly produced. The latter is modulated by Th2 cells, which are the source of 
IL-4, IL-5, IL-10, IL-13, and granulocyte-macrophage colony-stimulating factor 
(GM-CSF). Although the cytokines are produced by local T cells, the main sources of 
Th2 cytokines are non-lymphoid tissues, such as the placental/decidual tissues and 
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trophoblast [93]. During normal human pregnancy, Th2 initially plays the 
predominant role to protect the feto-maternal relationship, followed by a shift toward 
Th1 in the late of gestation. The balance of Th1 and Th2 cytokines can be altered 
abnormally by inflammation/infection processes which make Th1 predominance and 
initiate the production of inflammatory cytokines seen in spontaneous abortion, 
preeclampsia and preterm delivery (Figure 1-4) [94].  
 
Figure 1-4 Th1-Th2 balance in physiological pregnancy and in gestational diseases. 
Adapted from Challis, J.R., et al., Reprod Sci, 2009. 16(2): p. 206-15  [94]. 
1.4.2. The role of inflammation/infection in preterm labour 
Although preterm labour can be initiated by several pathological processes as 
mentioned before, inflammation is a common component associating with many of 
these mechanisms. Since infection is a major cause of inflammation, intrauterine 
infection is one of the most frequent conditions leading to premature labour and 
delivery [95-98]. So far, it is the only pathological process which has been established 
a firm causal link with preterm birth [37]. To support this causal relationship, there is 
some evidence from both humans and animals that have been demonstrated and 
summarized by Romero et al. [35, 90, 91]: (1) intrauterine infection or administration 
of microbial products to pregnant animals can cause preterm labour [99-101]; (2) 
extrauterine maternal infections, such as pyelonephritis, pneumonia and malaria, are 
associated with preterm birth [102-104]; (3) pregnant women who have intra-amniotic 
infection or intrauterine inflammation in the mid-trimester are likely to delivery 
prematurely [105-107]; (4) antibiotic treatment of ascending intrauterine infections is 
able to prevent prematurity [108].  
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In the most common pathway of intrauterine infection, leukocytes (neutrophils and 
macrophages) are first stimulated locally as microorganisms reach the decidua. 
Microorganisms may then cross intact membranes into the amniotic cavity to 
stimulate resident macrophages and other host cells. Finally, they gain access to the 
fetus and a systemic fetal inflammatory response is triggered. The invasion of 
microorganisms is normally associated with the microbial proliferation and bacterial 
products, such as lipopolysaccharides (LPS) (from cell wall of Gram-negative 
bacteria), peptidoglycans or lipoteichoic (from cell wall of Gram-positive bacteria), 
and endotoxin. These products, which mediate the effects of microorganisms, can be 
recognized by Toll-like receptors (TLR-4 recognises products from Gram-negative 
bacteria; TLR-2 recognises products from Gram-positive bacteria) and other pattern-
recognition receptors and then stimulate the release of inflammatory cytokines and 
chemokines, leading to increased production of prostaglandins and matrix-degrading 
enzymes. These molecules can activate the processes of cervix remodeling, fetal 
membranes weakening and rupture, and myometrial contractility [109-111].   
Although bacteria are considered to be the main cause of intrauterine inflammation 
leading to infection-associated preterm labour, viral infections are also found to be 
involved. The most common viruses in the amniotic fluid include adenovirus, 
cytomegalovirus, enterovirus and respiratory syncytial virus [112].  
1.4.3. Uterine cytokine and chemokine networks 
Due to the crucial role of uterine pro-inflammatory cytokines and chemokines in both 
term and preterm parturition, several studies have focused on their individual 
function, such as IL-1β, tumor necrosis factor-α (TNF-α), IL-8 and IL-6. 
IL-1 is the first cytokine found to be involved in the onset of infection-associated 
preterm labour. More evidence in support of the importance of IL-1 was subsequently 
revealed. Romero et al. found that human decidua produced IL-1 in response to 
bacterial products and IL-1 stimulated prostaglandin biosynthesis in human amnion 
[113, 114]. In the amniotic fluid of women with preterm labour and infection, an 
increase in the concentration and activity of IL-1 was found [115]. Sadowsky and 
colleagues reported that IL-1β could stimulate uterine activity and cause preterm 
labour in nonhuman primates [116-118]. Another study in mice showed that systemic 
administration of IL-1 induced preterm labour whereas the administration of an IL-1 
Chapter 1: Introduction 
- 31 - 
receptor antagonist blocked this induction [119, 120]. Although IL-1 administration 
was sufficient, it was not necessary for the onset of infection-induced preterm labour 
as was suggested by a study using IL-1 receptor knockout mice, which showed that 
preterm labour still occurred after bacterial exposure [121]. However, in a follow-up 
study, this group used another mice model lacking the type I receptors for both IL-1 
and TNF and found that the rates of preterm delivery were significantly lower in 
double-knockout mice compared with the wild type controls suggesting the 
combination of both signalling pathways are crucial in this context [122].  
TNF-α is a 17kDa soluble protein, which can also stimulate prostaglandin synthesis in 
amnion, decidua and myometrium, is increased in the amniotic fluid of women with 
preterm labour and intra-amniotic infection [96, 123, 124]. A number of animal 
studies have also supported its importance in the mechanisms of preterm parturition 
associated with infection [125-127].  
IL-8, which is one of the major mediators of the inflammatory response, belongs to 
the chemokine family. As a chemokine, IL-8 is responsible for the induction of 
chemotaxis, which directs the migration of cells, particularly neutrophil granulocytes, 
to the inflammation sites. It is produced by macrophages and other cell types such as 
epithelial cells and present in uterine tissues, including choriodecidua, placenta, cervix 
and myometrium [128-131].  Its expression increases in the uterus with advancing 
gestational age and can be induced by many stimuli, such as IL-1β, TNF-α and stretch 
[130, 132, 133]. A leukocyte influx caused by IL-8 is associated with cervical 
ripening and also occurs in the myometrium and lower uterine segment with labour 
[126, 134].  
Other cytokines have also been implicated in this cytokine network, such as IL-6 and 
IL-10. The concentrations of IL-6 in amniotic fluid are considered as a bio-marker, 
which is highly sensitive for prediction of intrauterine infection, but the assays for this 
marker has not been standardized to test amniotic fluid [135-137]. Unlike other pro-
inflammatory cytokines, IL-10 plays anti-inflammatory role to maintain pregnancy. 
This is supported by the evidence that IL-10 expression is significantly decreased in 
the placental tissues at both term and preterm labour [138, 139]; COX-2 mRNA 
expression is inhibited by IL-10 in cultured placental explants from preterm labour 
deliveries [139]; IL-1β-induced uterine contractility is reduced by IL-10 and 
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dexamethasone treatment [116]; and the administration of IL-10 prevents endotoxin-
induced preterm birth in pregnant rats [140].  
1.4.4. Prostaglandins and oxytocin in human parturition 
1.4.4.1. Prostaglandins, prostaglandin biosynthesis and metabolism 
In human parturition, stimulatory prostaglandins such as prostaglandin (PG) E2 and 
PGF2α play a central role by inducing cervical and fetal membrane remodeling and 
uterine contractility [1, 141, 142]. The evidence supporting their roles in the initiation 
and progression of labour includes: (1) the concentrations of prostaglandins and their 
metabolites elevate in amniotic fluid, intrauterine tissues, and maternal blood prior to 
and with labour [1, 143-147]; (2) administration of prostaglandins induces 
transformation of the uterus and cervix leading to pregnancy termination and labour 
[148-151]; (3) inhibition of prostaglandin biosynthesis by both non-selective and 
selective COX-2 inhibitors prolongs pregnancy and delays labour, although there are 
considerable maternal and fetal side effects [152-155]; (4) Calcium released from 
intracellular and extracellular stores by prostaglandins was suggested to be a trigger 
leading to myometrial contractions [156-158]. Therefore, the regulation of 
prostaglandin biosynthesis in uterine tissues is crucial for human parturition.  
The biosynthetic pathway of prostaglandin can be divided into three main stages 
(Figure 1-5): (1) hydrolysis of membrane phospholipids by phospholipase (PL) 
enzymes, such as PLA2, PLC and PLD, to produce free arachidonic acid (AA); (2) 
COX enzymes catalyse a reaction where molecular oxygen is inserted into free AA to 
form an unstable intermediate (PGG2), which is rapidly converted to PGH2; (3) 
conversion of PGH2 to PGE2, PGF2α, PGD2, PGI2 and thromboxane by specific 
synthase enzymes, which determines the cell-type-specific prostaglandin profile 
[159].  
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Figure 1-5 Prostaglandin synthesis and actions. 
After the cells are activated by a host of factors such as mechanical trauma, cytokines, growth factors, or various 
inflammatory stimuli, arachidonic acid (AA) is released from membrane lipids by cytosolic phospholipase 
(cPLA2) and metabolised by COX enzymes to the intermediate PGH2. These factors can also induce de novo 
COX-2 enzyme synthesis, which reinforces prostaglandin (PG) formation. In a cell-type restricted fashion, a 
heterogeneous family of PGH2 metabolizing enzymes can form PGE2, PGD2, PGF2α, PGI2 (prostacyclin) and TxA2 
(thromboxane). After transportation from the cell through a known prostaglandin transporter (PGT) or other 
carriers, these prostaglandins exert autocrine or paracrine actions on a family of prostaglandin receptors EP1, EP2, 
EP3, EP4, DP1, DP2, FP, IP, TPα, and TPβ depending on the cell types. Adapted from Funk, C.D., Science, 2001. 
294(5548): p. 1871-5 [159]. 
Although a number of studies have been focusing on the function and regulation of 
the PLA2 enzymes and noted that two groups of PLA2 (secretory PLA2 and cytosolic 
PLA2) are differentially expressed and regulated in intrauterine tissues before and 
during labour [160-163], COX enzymes may play more important roles in the 
pathway of prostaglandin production as they mediate the rate-limiting step where AA 
is irreversibly converted to PGH2 [145]. Three isoforms are known so far in this COX 
enzyme family: COX-1, COX-2, and COX-3 [also referred as prostaglandin G/H 
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synthase (PGHS) -1, -2, and -3 respectively]. They are generated from separate genes 
and controlled by different mechanisms, except that COX-3 is an mRNA-splicing 
isoforms from COX-1 gene. COX-1 is a constitutive enzyme expressed in most cell 
types while COX-2 is almost undetectable under normal physiological condition but 
can be induced and controlled by cytokines and growth factors in a cell and tissue 
specific manner [164-166]. A solid body of evidence indicates the importance of 
COX-2 in the onset of human parturition: (1) COX-2 mRNA and protein levels, but 
not COX-1, increase in intrauterine tissues at term before and during labour [167-
170]; (2) The increase of PGE2 in human amnion with the onset of labour is 
associated with selective induction of COX-2 gene [171, 172]; (3) a series of in vitro 
studies show that COX-2 expression can be induced in primary cultured cells of 
different gestational tissues [173-175]; (4) as mentioned before, selective COX-2 
inhibitors prolong pregnancy and delay labour by suppression of prostaglandin 
synthesis. Therefore, the mechanisms involved in the transcriptional regulation of 
COX-2 gene and posttranslational modification of COX-2 protein have been focused 
on by researchers [176-179]. Although COX-2 promoter has already been very well 
characterised, which contains several pro-inflammatory transcription factor binding 
sites such as NF-κB, CCAAT-enhancer-binding protein (C/EBP), and AP-1 [180], the 
molecular mechanisms have still not been fully understood due to the multifactorial 
regulation system and the cell type-dependent manner [181-185].  
The enzyme that controls prostaglandin metabolism is prostaglandin dehydrogenase 
(PGDH), which catalyses the irreversible conversion of PGE2 and PGF2α to their 
biological inactive forms (15-keto-derivatives). The amnion is the major source of 
prostaglandins, not surprisingly it contains very low or no PGDH enzyme, which has 
been predominantly localized to trophoblast cells of chorion [186]. The chorion 
therefore becomes an important site for prostaglandin metabolism and interposes the 
transfer of prostaglandins from the amnion to the maternal tissues of the uterus, such 
as decidua and myometrium, in order to control the myometrium contraction. This 
suggests that the contractility of myometrium driven by exposure to PGs depends on 
the balance of COX-2 and PGDH in the chorion. Several studies have shown that 
progesterone may prevent myometrial exposure to prostaglandins by stimulating 
PGDH and inhibiting COX-2 whereas estrogen, CRH, cortisol and some immune 
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cytokines play opposing roles by increasing active prostaglandins in the myometrium 
[18, 187-190].  
After prostaglandin biosynthesis and metabolism, prostaglandins are finally 
transported to the target cells and exert their effects through specific G-protein 
coupled receptors. There are currently ten known prostaglandin receptors on various 
cell types. For examples, four PGE2 receptors have been identified: EP1, EP2, EP3 and 
EP4 while only one receptor, named FP, has been found for PGF2α. Among them, the 
EP1 and FP cause contraction by increasing intracellular calcium whereas EP2 and EP4 
are associated with relaxation by stimulating intracellular cAMP formation [191, 
192]. The EP3, however, can either mediate contraction or relaxation depending on the 
cohort of receptor isoforms expressed, which are generated by multiple alternatively 
spliced transcript variants [193]. Therefore, to fully understand the mechanisms of 
prostaglandin function and regulation in human parturition, a thorough 
characterisation of the prostaglandin population in each gestational tissue is required.  
1.4.4.2. Oxytocin and oxytocin receptor 
Oxytocin is known to play an important role in human parturition due to its function 
of increasing uterine smooth muscle contractility and remain the most widely used 
method of inducing labour at term. The myometrium becomes increasingly sensitive 
to oxytocin as term approaches due to increased OTR expression [194-198]. Although 
this up-regulation of myometrial OTR in the early stages of labour is a general 
phenomenon that exists not only in human but also in several other animal species, 
such as rat, rabbit, guinea pig, cow and pig [198-204], the amount and character of 
elevation is different between human and other animals. In rats and rabbits, a sudden 
increase occurs just before the onset of labour whereas only about 2-fold rise of OTR 
concentration was found in human myometrium [198, 202, 204-206]. It has been 
reported that the decline of circulating progesterone and elevation of estrogen levels 
contribute, at least in part, to the up-regulation of OTR in the rat myometrium [198, 
207]. In women, however, progesterone levels do not fall at the end of pregnancy, 
which suggests that the regulation of OTR expression is different in the rat and 
human. Recent studies by our group found that inflammatory stimuli may be involved 
in triggering OTR expression as several putative transcription factor-binding sites 
were located in the OTR promoter region, including AP-1, C/EBP and NF-κB which 
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are frequently associated with pro-inflammatory cytokines, such as IL-1β and IL-6 
[208-210]. However, the effects of cytokines on OTR activity are still controversial 
and the regulation of OTR expression in human pregnancy remains unclear. 
Collectively, the biochemical events involved in parturition resemble an inflammatory 
reaction, which affects the common pathway of parturition including uterine 
contractility, cervical ripening, and activation of the membranes/decidua (Figure 1-6). 
 
Figure 1-6 Inflammation and parturition. 
Adapted from Challis, J.R., et al., Reprod Sci, 2009. 16(2): p. 206-15  [94]. 
1.5. Endocrine disorders 
It has been suggested that there is a parturition cascade, in which the steroid hormones 
and paracrine and autocrine factors are responsible for uterine contractions at term 
(Figure 1-7). Among these steroid hormones, progesterone and estrogen play central 
roles in the regulation of human parturition. In normal pregnancy, the interaction 
between these two steroids is in a dynamic balance which controls all of the 
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components of the common pathway of parturition. Generally, maternal plasma 
progesterone maintains pregnancy by promoting uterine quiescence, inhibiting 
cervical ripening, and suppressing decidual/membranes activation. In contrast, 
estrogen acts in an opposite manner, inducing the transformation of the uterus and 
cervix to favour parturition [211]. Thus, this progesterone-estrogen balance has to be 
very well controlled and any disorders disrupting it will lead to an imbalance in the 
process of parturition.  
 
Figure 1-7 Proposed mechanism of labour induction at term. 
The parturition cascade including the major hormones and paracrine and autocrine factors responsible for the 
uterine contractions at term. Adapted from Norwitz, E.R., J.N. Robinson, and J.R. Challis, N Engl J Med, 1999. 
341(9): p. 660-6 [17]. 
1.5.1. Progesterone withdrawal 
Progesterone is a steroid hormone and plays essential roles in normal human 
physiology, not only in non-reproductive tissues such as bone, cardiovascular systems 
and the central nervous system, but more importantly in reproductive tissues such as 
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uterus and ovary [212-215]. In the parturition, as its name implies (progestational 
steroid hormone), progesterone is crucial for establishing and maintaining pregnancy. 
In 1956, Csapo proposed a hypothesis about “progesterone block” which suggested 
that parturition was initiated by the withdrawal of the progesterone block [216]. This 
hypothesis was confirmed in most laboratory animals such as rats, mice, rabbits, 
goats, cows and sheep, in which peripheral progesterone levels dramatically decrease 
before the onset of labour. The phenomenon is called “the systemic withdrawal of 
progesterone”, accompanied by a concurrent increase in estrogen concentration. By 
contrast, in humans, non-human primates, and guinea pigs, maternal, fetal and 
amniotic progesterone levels remain elevated throughout pregnancy (Table 1-1) until 
the placenta is expelled suggesting that systemic progesterone withdrawal is not a 
prerequisite for labour at term [217-221]. 
Table 1-1 Source of steroids and mechanisms for progesterone withdrawal before parturition in several 
species. 
 
Adapted from Romero, R., et al., BJOG, 2006. 113 Suppl 3: p. 17-42 [35]. 
Such difference is, at least in part, due to the different place of progesterone 
production. In most of those animal species, progesterone is produced principally by 
the corpus luteum and the onset of parturition is caused by the regression of the 
corpus luteum mediated by PGF2α. As shown in the FP knockout mouse, it has no 
corpus luteum lysis and consequently no progesterone withdrawal and fails to deliver 
at term [222]. Conversely, lutectomy or oophorectomy leads to abortion or the 
initiation of parturition. In other animal species like sheep and cow, rather than the 
corpus luteum, the placenta becomes the dominant source of progesterone in late 
pregnancy; therefore the mechanisms responsible for the switch in the progesterone to 
estrogen ratio are different. In sheep, for example, there is a remarkable increase in 
fetal adrenal cortisol production at term due to the activation of the fetal 
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hypothalamic-pituitary-adrenal axis, which not only stimulates the maturation of key 
fetal organs such as lungs and liver but also induces 17α-hydroxylase activity in the 
ovine placenta. Consequently, progesterone is converted to androstenedione rapidly 
causing progesterone withdrawal while estrogen biosynthesis rises (Figure 1-8).  
  
Figure 1-8 Early steps of sex steroid biosynthesis. 
Pregnenolone and progesterone are converted to their 17-hydroxy forms by 17α-hydroxylase. It also converts 17-
hydroxypregnenolone and 17-hydroxyprogesterone to DHEA and androstenedione, respectively. Adapted from 
Pandey, A.V., S.H. Mellon, and W.L. Miller, J Biol Chem, 2003. 278(5): p. 2837-44 [223]. 
In the human, progesterone is also mainly generated by corpus luteum until between 7 
and 8 weeks of gestation. In this period, either lutectomy or administration of 
progesterone receptor antagonist (RU486) is able to induce abortion [224, 225]. This 
suggests that in the early human pregnancy progesterone action is similar to that of 
those laboratory animals. In later pregnancy, progesterone production is taken over by 
placenta. However, the human placenta does not express 17α-hydroxylase, which 
excludes this as a potential mechanism for a systemic progesterone withdrawal. As 
mentioned above, although progesterone withdrawal has already been proved in many 
animal species, it is still unclear how it occurs in human parturition, but it seems 
likely that this is achieved through a functional progesterone withdrawal. 
The effect of progesterone is mediated through its receptors (PRs), which act via 
genomic and non-genomic pathways (Figure 1-9).  
Chapter 1: Introduction 
- 40 - 
 
Figure 1-9 Schematic model of the genomic and non-genomic pathways by which steroid hormones affect 
contractility of the human pregnancy myometrium. 
Adapted from Mesiano, S. and T.N. Welsh, Semin Cell Dev Biol, 2007. 18(3): p. 321-31 [226]. 
In the genomic pathway, several putative mechanisms have been proposed and will be 
discussed in the following sections including quantitative changes in PR isoforms, 
post-translational modifications on PR isoforms and their co-factors, alterations of PR 
co-regulators and co-chaperones in the steroid receptor complex, and interaction with 
other transcription factors. Other potential mechanisms have also been suggested: (1) 
reduction of the amount of free active progesterone by binding to a high affinity 
protein [227, 228]; (2) conversion of progesterone to an inactive form [229, 230]; (3) 
competition between progesterone and cortisol for binding to GR in the late 
pregnancy [231]. For the non-genomic progesterone actions, progesterone and its 
metabolites exert more rapid and direct effects and interact with a family of 
membrane PRs (mPRs), progesterone receptor membrane components (PGRMCs), 
nuclear PRs, OTR and gamma-aminobutyric acid (GABA) type A receptor to 
modulate myometrial cells contractility by controlling intracellular signalling 
pathways  [226, 232, 233].  
1.5.2. Genomic progesterone actions in functional progesterone withdrawal 
1.5.2.1. Changes in the expression of PR isoforms 
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In humans, genomic progesterone actions are mediated by the classic nuclear PRs, 
which are activated as transcriptional factors upon ligand binding. PR exists as two 
major isoforms, PR-A (~94 kDa) and PR-B (~116kDa), both of which are encoded by 
a single gene but independently regulated by two distinct promoters [234, 235]. PR-A 
is a truncated form of PR-B lacking the first 164 N-terminal amino acids, where the 
activator element 3 (AF3) is located [236]. As a result, PR-B is the principal 
transcriptional activator of progesterone responsive genes whereas PR-A is 
predominantly a transcriptional repressor [237-239]. Besides these two main isoforms, 
the existence and function of other truncated forms of PR, such as PR-C, have been 
proposed [240-245]. Thus, the subtype and the expression level of these PR isoforms 
may lead to different progesterone responsiveness. To address this hypothesis, a 
number of groups have investigated the levels of PR in non-pregnant and pregnant 
myometrium at different gestational age and indicated that there was an increase in 
the myometrial PR-A/PR-B expression ratio at the onset of labour [246-251]. 
However, the mechanisms of triggering this change are not very clear except that 
certain factors such as PGE2, PGF2α, and TNF-α may be involved [247, 250-252]. 
1.5.2.2. PR transcriptional activity is regulated by post-translational 
modifications 
There is increasing evidence suggesting that in order to control the activation of PR, 
some post-translational modifications play an essential role in either ligand-dependent 
or ligand-independent manner (Figure 1-10). These modifications include 
phosphorylation, sumoylation, ubiquitination, methylation and acetylation [253-258]. 
These covalent modifications can act individually or in a particular combination, 
which leads to functionally distinct activities. 14 serine residues in PR-B are known to 
be phosphorylated: 1 Casein kinase II site, 3 mitogen-activated protein kinases 
(MAKP) consensus sites, 8 cyclin-dependent kinase 2 (CDK2) sites and 2 unknown 
kinases sites [259]. Differential phosphorylation of PR-B alters its transcriptional 
activity [260-263], protein complex formation and target-gene specificity [254, 255, 
263-268]. Some of the phosphorylation sites have been well-characterized in breast 
cancer cells, particularly Serine 294, 345 and 400 [269]. 
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Figure 1-10 Post-translational modification of PR results in the regulation of specific subpopulations of PR 
genes. 
Different modifications of PR differentially regulate gene expressions. Upon ligand binding, three different post-
translationally modified populations of PR can be generated. Besides the classical ligand-bound PR which 
recognizes PRE in the gene promoter region (PR-1), sumoylated PR at Lys388 and phosphorylated PR at Ser345 
can also activate gene transcription at selected promoters (PR-2 and PR-4).  In response to growth factors, such as 
EGF, activated MAPK signaling induces PR phosphorylation at Ser294 and desumoylation at Lys388 (PR-3). 
Phosphorylated PR by CDK2 results in increased liganded and unliganded PR activity on unknown PR target-gene 
promoters (PR-5). Adapted from Dressing, G.E., et al., Endocr Relat Cancer, 2009. 16(2): p. 351-61 [270]. 
1.5.2.3. Alterations of PR co-chaperones and co-regulators 
In the absence of ligand, the receptor is transcriptionally inactive, sequestered in a 
large complex with heat shock proteins and other chaperone proteins; these are 
responsible for maintaining unliganded PR in such a state as to allow ligand binding 
and nuclear transport. Various in vitro studies have investigated which components of 
the cytoplasmic complex are essential for PR function. Minimal requirement of 
chaperones and co-chaperones in the PR complex are heat shock proteins Hsp40, 
Hsp70, Hsp90, Hsc70/Hsp90-organizing protein (Hop) and p23, which also requires 
adenosine triphosphate (ATP) as an energy resource [271-273]. Assembly of steroid 
receptor with chaperones occurs in an ordered, step-wise fashion. But this minimal 
five-protein system lacks the dynamics of the complete PR complexes. Therefore, 
other possible co-chaperones known to exist in native receptor complexes including 
FK506 binding protein (FKBP)51, FKBP52, BCL2-associated athanogene (Bag1), 
protein phosphatase 5, Hsc/Hsp70-interacting protein (Hip) and cyclophilin 40 are 
also required for optimal PR activity in different situations. Animal studies have 
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revealed the physiological importance of FKBP52 in reproductive processes. Female 
FKBP52 knockout mice with normal PR expression and circulating progesterone 
levels display infertility as a result of uterine progesterone resistance [274, 275]. 
However, progesterone supplementation is able to rescue implantation and even 
achieve full-term pregnancy with a higher dose depending on the genetic background 
of the mouse [275]. On the other hand, there are no similar reproductive abnormalities 
in FKBP51-null mice. However, FKBP51 shows its importance by inhibiting 
glucocorticoid receptor (GR) hormone-binding affinity and glucocorticoid resistance 
[276, 277]. Its expression is highly inducible by glucocorticoid, progestin, and 
androgen [278, 279], suggesting a feedback mechanism for preventing tissue from 
secondary hormone exposures. Given the close relationship but opposing effect of 
FKBP51 and FKBP52, understanding the mechanisms by which FKBP co-chaperones 
selectively elevate or inhibit hormone binding affinity may lead to novel insights into 
steroid signaling pathways [280]. 
Upon ligand binding, the receptor undergoes a distinct conformational change, 
resulting in the dissociation of a monomeric receptor from the heat shock protein 
complex. Ligand-bound receptors then dimerise and translocate into the nucleus 
where they bind to specific response elements in the promoter region of target genes 
to modulate transcription. The DNA-bound receptor can then either positively or 
negatively drive target gene transcription depending on the co-regulatory proteins 
involved in the receptor multiprotein complexes. These co-regulators can be divided 
into two families: co-activators or co-repressors, depending on whether they act to 
enhance or suppress transcriptional activity [237]. In some conditions, co-regulators 
such as steroid receptor coactivator-2 (SRC-2) [also called glucocorticoid receptor 
interacting protein 1 (GRIP-1)] can transform their roles from one to the other 
according to the different intracellular conditions [237, 281-283]. Some other co-
regulatory proteins can also remodel chromatin by catalyzing histones acetylation 
which opens the chromatin in order to increase access of the transcription complex 
into DNA [240, 244]. Thus, genomic responsiveness of myometrial cells to 
progesterone will be determined partially by the amount of PR expression and the 
cohort of co-regulators. 
1.5.2.4. PR interacts with other transcription factors 
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Another possible mechanism of progesterone “functional withdrawal” is the 
interaction between PR and other transcription factors such as NF-κB, AP-1 and 
C/EBP. These transcription factors function to up-regulate inflammatory response 
pathways and might impair PR activity. There is increasing evidence to suggest that 
both term and preterm labour are associated with an inflammatory response within the 
maternal uterus and cervix and that uterine quiescence during most of pregnancy is 
maintained by the anti-inflammatory actions of progesterone acting via PR. In other 
words, the balance between PR and pro-inflammatory transcription factors will, at 
least in part, determine the balance between uterine quiescence and contractility. Once 
initiated, the inflammatory response can be amplified by the release of further 
chemokines either in response to the inflammatory cytokines or mechanical stretch 
[87, 284] resulting in further infiltration of the myometrium, cervix, and fetal 
membranes by neutrophils and macrophages [64, 109, 134]. This process leads to 
local activation of NF-κB, which promotes the expression of labour-associated genes, 
including the FP [285], the gap junction protein connexin 43 [61], matrix 
metalloproteinase (MMPs) [286], the OTR [200], and COX-2 [176, 287]. Moreover, a 
negative interaction between the RelA (p65) subunit of NF-κB and PR was found in 
HeLa 229 and COS-1 cells, which suggests that the attenuation of PR function leading 
to labour may be due to their direct interaction [288]. Another possibility suggested 
by Condon et al. is that NF-κB contributes to a functional progesterone withdrawal by 
increasing PR-C expression [289].  Coversely, PR has also been shown to block NF-
κB activation in human fundal myometrial cells and breast cancer (T47D) cells [290].  
AP-1 activity was stimulated by unliganded PR, which cannot translocate into the 
nucleus by itself, suggesting a potential interaction between PR and the Jun/Fos 
complex in endometrial adenocarcinoma cells [291]. The C/EBP family of 
transcription factors is composed of six functionally related basic leucine zipper 
binding proteins (C/EBP, , , , ε and ). C/EBPβ contains two isforms: the full-
length activator liver-enriched activatory protein (LAP) and the truncated inhibitor 
liver-enriched inhibitory protein (LIP), which can form heterodimers with PR-B as 
well as PR-A in vitro and either modulate expression of C/EBPβ-depended genes or 
activate progesterone response element (PRE)-driven promoters [292]. C/EBPδ was 
found to be up-regulated by PR-B only in human breast cancer cells [293]. In our 
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previous study, we found that stretch of myometrial cells reduced the expression of 
PR-B, which is associated with activation of both C/EBPβ and AP-1 [85, 279].  
1.5.3. Non-genomic progesterone actions in functional progesterone 
withdrawal 
It has been known for many years that progesterone can act via the non-genomic 
pathway. Recently, a new family of membrane-bound PRs has been identified [294]. 
They are unrelated to nuclear PRs but related to G-protein coupled receptors, which 
have seven transmembrane regions. Three members (mPRα, -β, and γ) have been 
mainly studied and found to be expressed in human gestational tissues, such as 
myometrium, amnion, placenta and chorion [295]. However, the regulation of their 
expression and function in the uterus are still controversial as the results from several 
research groups are inconsistent [295-298]. Another group of progesterone 
transmembrane receptors whose structures are different from both nuclear PRs and 
mPRs contain two members: PGRMC-1 and -2. Animal studies suggest that their 
expression appears to be under the control of ovarian steroids. In granulosa cells, it 
has been found that the interaction of PGRMC-1 and serpine1 mRNA binding protein 
1 (SERBP1) is required for the cell surface translocation of PGRMC-1 and this 
protein complex activates protein kinase G and decreases intracellular Ca
2+
 level upon 
progesterone binding [299]. The information regarding the biological function of 
PGRMC-2 is much less compared with PGRMC-1 and its ability to bind progesterone 
has not been assessed yet. Interestingly, nuclear PRs may also mediate some of non-
genomic progesterone actions suggested by the fact that both PR-A and PR-B contain 
proline-rich SH3 binding region in their N terminus. This region is able to activate the 
Ras/Raf-1/MAPK pathway upon ligand binding [300]. Collectively, although none of 
the reported non-genomic PRs have been characterized in-depth and they seems to 
make the progesterone actions more complicated, it meanwhile increases the 
possibilities of understanding the progesterone regulation in pregnancy. 
1.5.4. Cross-talk between steroid receptors and NF-κB 
A number of studies have shown that liganded steroid receptors, especially 
progesterone receptor and glucocorticoid receptor, are able to inhibit the activity of 
NF-κB, which plays an essential role of controlling genes involved in inflammation, 
cell proliferation and apoptosis. This suggests the involvement of steroid receptors 
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and NF-κB in human parturition, which is resembles an inflammatory process. As we 
discussed in the previous sections, the cross-talk between PR and NF-κB may have a 
biological significance in maintaining the uterus quiescence during pregnancy and 
initiating “functional” progesterone withdrawal before the onset of labour.  
Given that progesterone not only activates PR, but also binds GR, although the 
affinity of progesterone for GR is much less than that of cortisol, some of 
progesterone actions might be mediated via GR. Generally, cortisol is the most 
important human glucocorticoid, which is the specific ligand for GR and plays anti-
inflammatory effects. Unlike progesterone, cortisol does not bind to PR at physiologic 
concentrations [301]. In primary cultured trophoblast cells from full-gestation 
placentas obtained at selective cesarean section, the expression of PR is hardly 
detected and the inhibitory effect of progesterone on CRH is suggested to be mediated 
through GR [231]. This may provide an explanation for the elevated CRH level at the 
end of human gestation as increased cortisol in the late pregnancy can compete with 
progesterone for binding to GR in order to up-regulate CRH expression. Thus, there is 
a possibility that the cross-talk between GR and NF-κB may be also involved in 
human pregnancy. 
The mechanisms of this cross-talk have been extensively explored due to its clinical 
relevance in inflammation. Many potential mechanisms have been proposed as 
researchers realised that studies cannot be limited to these two proteins. Beyond a 
simple physical interaction between GR and NF-κB, more complex intracellular 
processes are involved, these can be grouped into two categories: nuclear models and 
cytoplasmic models [302]. 
1.5.4.1. Nuclear models 
The physical interaction between GRα and NF-κB was first demonstrated in vivo in a 
lung epithelial cell line [303], which was thought to be an explanation for their mutual 
effects as the interaction could block each other’s DNA-binding functions. However, 
the subsequent studies showed that their binding could also occur in the cytoplasm 
[304] and GR-mediated repression on NF-κB did not disrupt its binding to the 
response element in the promoter region [305].  Rather, the recruitment of the 
polymerase II Ser2 C-terminal domain phosphorylating kinase pTEFb might be a 
prerequisite for GR repression mechanism [306]. As an important part of steroid 
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hormone receptor complex, some co-modulators can also bind with NF-κB, such as 
CREB-binding protein (CBP)/p300, nuclear receptor co-repressor (NCoR), and 
silencing mediator for retinoid and thyroid-hormone (SMRT), suggesting that they 
may have a role in the GR-NF-κB cross-talk. Based on this, Sheppard et al. 
hypothesize that the competition between GR and NF-κB for limited amounts of 
CBP/p300 could be one of the GR repression mechanisms [307]. Recently, another 
study showed that GRIP-1, which can bind with GR, was also recruited to the GR-p65 
complex facilitating the trans-repression effect of GR on NF-κB-driven COX-2 
expression [308]. In another study, histone acetylation played a role in the regulation 
of inflammatory genes, because histone deacetylase 2 (HDAC2) was recruited by 
activated GR to switch off NF-κB-driven gene expression [309].  
1.5.4.2. Cytoplasmic models 
At least three intracellular signalling pathways have been demonstrated to be involved 
in this model: nuclear factor-kappa B inhibitor α (IκBα), MAPK phophatase-1 (MKP-
1) and protein kinase A (PKA). Although there is no classical glucocorticoid response 
element in the promoter of IκBα, glucocorticoid could induce IκBα expression, which 
down-regulates NF-κB-driven genes by blocking NF-κB’s nuclear translocation. But 
this is not a universal mechanism as the induced up-regulation of IκBα is strictly cell 
type-dependent. MAPK pathways are also affected by glucocorticoid because in 
certain cell types including myometrium cells, MKP-1 can be up-regulated by 
glucocorticoid via GR [310, 311]. MKP-1 inactivates MAPK-dependent NF-κB trans-
activation by dephosphorylating and inhibiting extracellular-signal-regulated kinases 
(ERKs) and p38 MAPK activities [310, 312]. Besides the influence on NF-κB-driven 
genes transcription, the stabilization of pro-inflammatory gene mRNAs (such as 
COX-2, IL-6 and IL-8) is also impaired by MKP-1 [312]. Another signalling pathway 
implicated in the GR-NF-κB cross-talk is PKA pathway, which is responsible for the 
phosphorylation of p65 at Ser-276. This phosphorylation has been found be to 
required for p65-mediated repression of GR-dependent transcription [313].  
Collectively, although several mechanisms have been proposed, none of them seems 
to be universal and they occur in a cell/tissue- and promoter-specific manner. 
Moreover, in the natural condition, since GR and NF-κB are shuttling between 
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nucleus and cytoplasm, both models may exist dynamically and more than one 
mechanism may be employed in their cross-talk [308].  
1.6. Summary and hypotheses 
Prematurity in human parturition is still a puzzle, although many factors have been 
discovered as causes of preterm birth (Figure 1-11). It is important to understand and 
elucidate the molecular mechanisms hidden behind parturition despite the requirement 
of intense research. By manipulating key regulators in the labour processes, we may 
have a better chance of preventing or substantially reducing the rates of preterm birth.  
 
Figure 1-11 Molecular signaling in parturition. 
The normal timing of parturition is regulated by coordinated signaling through progesterone and estrogen. Stretch 
signaling affects the endocrine stimulation and the balance of progesterone and estrogen, especially multiple 
pregnancy increases the effect of mechanical stimulation. Prematurely preterm labor occurs if the normal 
programming is disrupted by pathological conditions, such as premature uterine stretch, inflammation or cervical 
aberration, or some combination of these factors. Adapted from Hirota, Y., J. Cha, and S.K. Dey, Nat Med, 2010. 
16(5): p. 529-31 [314]. 
In this study, progesterone action was mainly investigated in two contexts: 
i. Clinically, progesterone administration only reduces the preterm labour rate in 
singleton pregnancies but is insufficient in multiple pregnancies. Our stretch model 
will be employed to study the mutual effects between progesterone and mechanical 
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stretch in uterine smooth muscle cells (USMCs). I hypothesise that progesterone does 
not affect stretch-induced cell signalling and gene expression, while stretch impairs 
progesterone action which may contribute to the progesterone functional withdrawal. 
ii. In humans, the onset of preterm labour is often associated with increased 
inflammatory and immune responses and altered prostaglandin synthesis driven by 
COX-2. It has been suggested that progesterone exerts its anti-inflammatory effects 
partially by down-regulating COX-2 expression. Therefore, it is important to 
understand how IL-1β impairs progesterone action and how progesterone reduce the 
IL-1β-induced COX-2 expression. I hypothesise that their mutual negative effects are 
mediated by the interaction between progesterone receptor and NF-κBp65.  
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2. Materials and Methods 
2.1. Materials 
2.1.1. Chemicals, Reagents and Solvents 
Absolute Ethanol:      Fisher Scientific 
Acrylamide:        Roche 
Agarose:        Invitrogen 
Ammonium Persulphate (APS):     BDH 
Ampicillin:        Sigma-Aldrich 
β-Mercaptoethanol:       Sigma-Aldrich 
Bench top protein marker:      Invitrogen 
Blot Qualified BSA:      Promega 
Bovine Serum Albumin (BSA):     Sigma-Aldrich 
Bromophenol Blue:       Bio-Rad 
Coelenterazine:       CalBiochem 
CaCl2:        Sigma-Aldrich 
Coomassie Brilliant Blue R250:     Bio-Rad 
Deoxynucleotide triphosphate (dNTP):    Invitrogen 
Dimethyl Sulfoxide (DMSO):     Sigma-Aldrich 
Dithiothreitol (DTT):       Bio-Rad 
DNA Ladders:       Invitrogen 
DNA loading dye:       Invitrogen 
Ethidium Bromide:       Bio-Rad 
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Ethylenediaminetetraacetic Acid (EDTA):    Sigma-Aldrich 
FuGENE 6 Transfection Reagent:     Roche 
Genejuice Transfection Reagent:    Novagen 
Glycerol:        BDH 
HEPES:        Sigma-Aldrich 
IPTG:         Sigma-Aldrich 
Isopropanol:        Fisher Scientific 
Kanamycin:        Sigma-Aldrich 
KCl:         Sigma-Aldrich 
LB-Agar:        VWR 
LB-Broth:        VWR 
Methanol:        Fisher Scientific 
MgCl2:        Sigma-Aldrich 
NaCl:         Sigma-Aldrich 
NaOH:        Sigma-Aldrich 
Oligo-dT random primers:     Applied Biosystems 
Oligonucleotides and primers:     Invitrogen 
Peptone:        Sigma-Aldrich 
RNaseZap:       Ambion 
Skimmed Milk Powder:      Marvel 
S.O.C. media:       Invitrogen 
SYBR Green Reagents:      Applied Biosystems 
SYBR Safe:        Invitrogen 
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TEMED:        Sigma-Aldrich 
Tris Base:        Sigma-Aldrich 
Triton X-100:        Sigma-Aldrich 
Tween 20:        Sigma-Aldrich 
2.1.2. Antibodies 
2.1.2.1. Primary antibodies 
AP-1 c-Fos:     Cell Signaling, 4384 
AP-1 c-Jun:      Cell Signaling, 9165 
α-tubulin:      Santa Cruz Biochemicals, SC-8035 
β-actin:      Abcam, Ab6276 
C/EBPβ:      Cell Signaling, 3087 
C/EBPδ:      Santa Cruz Biochemicals, SC-636 
COX-2:     Santa Cruz Biochemicals, SC-1745 
GR:      Santa Cruz Biochemicals, SC-1003 
GR (NR3C1 mAb):    Abnova, MAB0119 
GRIP-1:     Millipore, 07-1799 
Halo Tag:     Promega, G9281 
HSD11β1:     Abcam, ab83522 
PR:      Leica, NCL-PGR-312 
NF-κB p65:      Santa Cruz Biochemicals, SC-8008 
NF-kB p65- CHIP Grade:   Abcam, ab7970 
Phospho-NF-kB p65 (Ser536):  Cell Signaling, 3031 
Strep Tag:      Qiagen, 34850 
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TATA binding protein:   Abcam, ab818 
2.1.2.2. Secondary antibodies 
Donkey anti-Goat:     Santa Cruz Biochemicals, SC-2020 
Anti-mouse IgG, HRP-linked Antibody: Cell Signaling, 7076 
Anti-rabbit IgG, HRP-linked Antibody: Cell Signaling, 7074 
2.1.3. Buffers, Solutions and Gels 
TE buffer 
100mM Tris-HCl, pH8.0 
1mM EDTA, pH8.0 
Cytosolic Buffer A 
10 mM HEPES 
10 mM KCl 
0.1 mM EDTA 
0.1 mM EGTA 
2 mM DTT 
1 % (v/v) NP-40 
Complete protease inhibitor tablets (Roche) 
Nuclear Buffer B 
10 mM HEPES 
10 mM KCl 
0.1 mM EDTA 
0.1 mM EGTA 
2 mM DTT 
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400 mM NaCl 
1 % NP-40 (v/v) 
Complete protease inhibitor tablets (Roche) 
Polyacrylamide stacking gels 
125mM Tris-HCl, pH6.8 
5% Acrylamide/Bis 
1% SDS 
1% Ammonium persulfate 
0.1% TEMED 
Phosphate Buffered Saline (PBS) 
140mM NaCl 
2.5mM KCl 
1.5mM KH2PO4, pH 7.2 
10mM Na2HPO4, pH7.2 
Tris Buffered Saline (TBS) 
130mM NaCl 
20mM Tris-HCl, pH7.6 
Adjusted to pH7.4 with HCl 
TBS-Tween 20 (TBS-T) 
0.1% Tween 20 in TBS 
Western Blocking Buffer 
5% (w/v) non-fat milk in TBS-T 
Western Antibody Incubation Buffer 
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1% (w/v) non-fat milk in TBS-T 
co-IP Lysis buffer 
5 ml 10% Triton X100 (or NP40) or 500 ul neat (final concentration 1%) 
1.5 ml NaCl (final concentration 150 mM) 
2.5 ml 1M Tris-HCl, pH 7.4 (Final concentration 50mM) 
100 ul 0.5M EDTA (final concentration 1mM)  
10% Glycerol 
Make up to 50ml with water 
Add standard protease (1 tablet into 10 ml) and phosphatise (1:100) inhibitors 
immediately before use 
co-IP IP buffer 
Lysis buffer without Glycerol 
CHIP Szak RIPA buffer 
150mM NaCl 
1%v/v Nonidet P-40 
0.5% w/v deoxycholate 
0.1% w/v SDS 
50mM Tris-HCl, pH 8.0 
5mM EDTA 
Add standard protease (1 tablet into 10 ml), phosphotase (1:100) inhibitors, and 0.5 
mM PMSF immediately before use (can also supplement with HDAC inhibitors) 
CHIP Low-salt buffer 
150mM NaCl 
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0.5% Na deoxycholate 
0.1% SDS 
1% Nonidet P-40 
1 mM EDTA, pH 8.0 
50mM Tris-HCl, pH 8.0 
CHIP High-salt buffer 
500mM NaCl 
0.5% Na deoxycholate 
0.1% SDS 
1% Nonidet P-40 
1 mM EDTA, pH 8.0 
50mM Tris-HCl, pH 8.0 
CHIP Elution buffer 
1% SDS 
100 mM NaHCO3 
2.1.4. Cell culture materials and media 
Cell strainer (2 mm):      Falcon 
Collagenase XI or 1A:     Sigma-Aldrich 
Dulbecco’s Modified Eagles’ Medium:   Sigma-Aldrich 
Fetal Bovine Serum:      Sigma-Aldrich 
Filter Unit (0.20 μM):     Sartorius 
L-glutamine:       Sigma-Aldrich 
Nutrient Mixture F-12 Ham:    Sigma-Aldrich 
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Penicillin/Streptomycin:     Sigma-Aldrich 
Tissue Culture Plastic-ware:     Corning, Falcon, Orange 
Trypsin/EDTA:      Sigma-Aldrich 
6-well flexible-bottom plates:    Flexcell International Corp. 
2.1.5. Competent cells 
Escherichia coli DH5α:     Invitrogen 
Escherichia coli TOP10:     Invitrogen 
2.1.6. Enzymes 
Ampli-Taq Gold DNA Polymerase:  Applied Biosystems 
DNase I (RNase-free):    Qiagen 
MuLV reverse transcriptase:   Applied Biosystems 
Pfu DNA Polymerase:   Promega 
Restriction enzymes:     New England Biolabs and Promega 
T4 DNA Ligase:     Promega 
2.1.7. Inhibitors and Treatments 
CDK Inhibitor roscovitine:    CalBiochem 
CDK2 Inhibitor II:     CalBiochem 
Complete Protease Inhibitors:    Roche 
ERK Inhibitor U0126:    Sigma-Aldrich 
JNK Inhibitor SP600125:    Sigma-Aldrich 
p38 Inhibitor SB203580:    Sigma-Aldrich 
Halt Phosphatase Inhibitor Single-Use Cocktail Thermo 
Interleukin 1β (IL-1β):     Sigma-Aldrich 
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Medroxyprogesterone Acetate (MPA):  Sigma-Aldrich 
Org31710:      N.V. Organon 
Progesterone:      Sigma-Aldrich 
RU486:      Sigma-Aldrich 
Trichostatin A (TSA):     Sigma-Aldrich 
2.1.8. Kits 
Amaxa Nucleofector Kit:    Lonza 
cDNA synthesis and SYBR Green for qPCR:  Applied Biosystems 
DNA Maxiprep/Miniprep Kit:    Qiagen 
Endofree Plasmid Kits:    Qiagen 
GenElut Gel Extraction Kit:     Qiagen 
MinElute Reaction Clean-up kit:    Qiagen 
NucBuste Protein Extraction Kit:   Novagen 
QIA quick PCR purification kit:    Qiagen 
RNeasy mini Kit:      Qiagen 
SteadyLite Plus Kit:      PerkinElmer 
Wizard SV Gel and PCR Clean-Up System:  Promega 
2.1.9. Plasmids 
pcDNA AP-1 c-Jun:    Dr B. Gellersen, Hamburg, Germany 
pcDNA AP-1 c-Fos:    Dr B. Gellersen, Hamburg, Germany 
pCS2:     Prof. C. Lange, Minneapolis, USA 
pCS2-CDK2-TY:   Prof. C. Lange, Minneapolis, USA 
pFC14A:    Promega 
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pFC14A-PR-A:   self-cloned 
pFC14A-PR-B:   self-cloned 
pFN21A:    Promega 
pFN21A-PR-A:   self-cloned 
pFN21A-PR-B:   self-cloned 
pFN22K:     Promega 
pFN22K-PR-A:   self-cloned 
pFN22K-PR-B:   self-cloned 
pGL4:      Promega 
pGL4-C/EBP:    Dr S. Khanjani, Imperial College London, UK 
pHT2:     Dr M. Christian, Imperial College London, UK 
pTAL-Luc:    Clontech 
pAP-1-Luc:    Clontech 
pNF-κB-Luc:    Clontech 
pPRE-Luc:    Dr B. Gellersen, Hamburg, Germany 
pQE-p65:    Dr S. Khanjani, Imperial College London, UK 
pRL-CMV:    Promega 
pRL-SV40:    Promega 
pSG5:      Dr J.White, Imperial College London, UK 
pSG5-PR-A:     Dr P. Chambon, Strasbourg, France 
pSG5-PR-B:     Dr P. Chambon, Strasbourg, France 
pSG5-PR-B(S294A):    Prof. C. Lange, Minneapolis, USA 
pSG5-PR-B(S345A):    Prof. C. Lange, Minneapolis, USA 
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pSG5-PR-B(S400A):    Prof. C. Lange, Minneapolis, USA 
pSG5-PR-C301:    Dr Y. Lee, Imperial College London, UK 
pSG5 C/EBPβ LAP:    Dr B. Gellersen, Hamburg, Germany 
pSG5 NF-κB p65:    Dr J J.White, Imperial College London, UK 
2.1.10. SDS-PAGE electrophoresis and Western blotting materials 
Cell Lysis buffer:      Cell Signaling 
ECL Plus Western Blotting Detection System:   GE Healthcare 
ECL hperfilm:       Amersham Biosciences 
Hybond ECL Nitrocellulose membrane:    Amersham Biosciences 
Novex Sharp Pre-stained Protein Standard:    Invitrogen 
NuPAGE LDS Samples buffer:    Invitrogen 
NuPAGE MOPS SDS running buffer:   Invitrogen 
SDS PAGE pre-cast gels:      Invitrogen 
SuperSignal West Pico Chemiluminescent Substrate: Pierce 
Transfer buffer:      Bio-Rad 
2.1.11. siRNA and shRNA 
DHARMAFECT 2 transfection reagent:   Dharmacon, T-2002-0 
ON-TARGET plus Non-Targeting siRNA:   Dharmacon, D-001810-01-05 
ON-TARGETplus SMARTpool for C/EBPβ:  Dharmacon, L-006423-00-0005 
ON-TARGETplus SMARTpool for C/EBPδ:  Dharmacon, L-010453-00-0005 
ON-TARGETplus SMARTpool for c-Fos:   Dharmacon, L-003265-00-0005 
ON-TARGETplus SMARTpool for c-Jun:   Dharmacon, L-003268-00-0005 
ON-TARGETplus SMARTpool for RelA:   Dharmacon, L-003533-00-0005 
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ON-TARGETplus SMARTpool for AR:   Dharmacon, L-003400-00-0005 
ON-TARGETplus SMARTpool for GR:   Dharmacon, L-003424-00-0005 
ON-TARGETplus SMARTpool for PR:   Dharmacon, L-003433-00-0005 
ON-TARGETplus SMARTpool for GRIP-1:  Dharmacon, L-020159-00-0005 
ON-TARGETplus SMARTpool for HSD11β1:  Dharmacon, L-009910-00-0005 
HuSH shRNA Cloning Vector (pRS Vector): OriGene, TR20003 
Non-effective 29-mer scrambled shRNA cassette: OriGene, TR30012 
HuSH 29mer shRNA Constructs against PGR: OriGene, TR320455 
HuSH 29mer shRNA Constructs against PGR-B: OriGene, custom designed 
2.2. Methods 
2.2.1. Tissue specimens 
Biopsies (0.5×0.5×0.5 cm
3
) of term human myometrium were collected from the 
upper margin of uterine incision at the time of caesarean section in Dulbecco’s 
modified Eagle’s Medium (DMEM, Invitrogen) medium containing 100 mU/ml 
penicillin and 100 µg/ml streptomycin. Samples were stored at 4˚C for no more than 3 
h prior to cell preparation for culture. All specimens were obtained after fully 
informed, written patient consent. 
2.2.2. Primary cell culture 
Myometrial tissue was washed in phosphate-buffered saline (PBS) and finely 
dissected. Tissue samples were then digested for 1 h at 37˚C in a collagenase solution 
which contains 1 mg/ml collagenase 1A (Sigma) and 1 mg/ml collagenase XI (Sigma) 
in a mixed medium (50% DMEM and 50% Dulbecco’s Modified Eagle’s 
Medium/Nutrient Mixture F-12 Ham, Invitrogen). Tissue pieces were suspended 
using a pasteur pipette and passed through a cell strainer (70 µm nylon cell strainer). 
Myocytes were then collected by centrifugation at 3000 rpm for 5 min and 
resuspended with DMEM medium containing 7.5% fetal calf serum, L-glutamine and 
100 mU/ml penicillin and 100 g/ml streptomycin. After that cells were cultured in 
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T25 in an atmosphere of 5% CO2:95% air at 37˚C.Myometrial cells grown in this 
manner have previously been characterized [87]. Myometrial cells from passage 3-4 
were trypsinised in 0.25% trypsin containing 0.02% EDTA in PBS and cultured in 24-
well, 6-well plates or flasks depending on the requirement. In some cases, at the end 
of the specified time, medium was removed and cells were frozen at -80˚C for the 
extraction of RNA, protein or the luciferase assay. In other cases, such as co-
immunoprecipitation (co-IP), nuclear protein extraction and chromatin 
immunoprecipitation (CHIP), cells were harvested and processed directly after 
treatment.  
Before treating the cells with different stimuli, old medium was removed and replaced 
with 2mL of fresh stripped medium (1% Charcoal and Dextran-stripped fetal calf 
serum, supplemented with L-glutamine, 100 mU/ml penicillin and 100 g/ml 
streptomycin) overnight. In some cases, cells were pre-incubated with 1µM RU486 
(GR/PR antagonist, Sigma-Aldrich Company Ltd., Dorset, SP8 4XT), 1µM Org31710 
(PR selective antagonist, N.V. Organ) for 2h or with 0.5µM Trichostatin A (HDAC 
inhibitor, Sigma-Aldrich Company Ltd., Dorset, SP8 4XT), 0.5µM sanguinarine 
(MKP-1 inhibitor, Tocris Cookson Ltd., Northpoint, Fourth Way, Avonmouth, 
Bristol, BS11 8TA) for 1h prior to other stimuli, such as IL-1β (5ng/mL), MPA 
(1µM), P4 (10µM) and Dex (1µM), either alone or in combination.  
2.2.3. The stretch model 
For mechanical stretch, cells were subjected to a static stretch of 11% for different 
periods using 6-well flexible-bottom plates which pre-coated with collagen type I (for 
more details, please see http://www.flexcellint.com/; Flexcell International Corp., 
McKeesport, PA). Unstretched cells grown and treated similarly were used as 
controls. In some cases, cells were pre-incubated with treatment like MAPK and CDK 
inhibitors for 1 h prior to stretch. Although this model is unable to directly reflect the 
difference of stretch strength between singleton and multiple pregnancies, it has been 
using for many years and shown to be a good method to study stretch-induced cell 
signaling and gene expression. 
2.2.4. Whole-cell protein extraction 
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Protein samples were prepared from monolayer myometrial cells by being lysed in 
Cell Lysis Buffer (Cell Signaling). The supernatant was separated from cell debris by 
centrifugation at 13,000×g for 20 min at 4˚C. Protein concentrations were determined 
by protein assay (Bio-Rad Laboratories, USA) and bovine serum albumin (BSA) 
reference standards. Samples were then aliquot and stored at -80˚C. 
2.2.5. Cytosolic/nuclear protein extraction 
Cells were harvested by trypsinization using a standard method as described before. 
The cell pellet was resuspended with buffer A and incubated on ice for 5-20 min. 
Lysates were vortexed for 10 sec at a high speed followed by centrifugation at 
16,000×g for 30 sec at 4˚C. The supernatants were retained as the cytosolic protein 
extracts. The pellets were resuspended in buffer B, incubated for 15 min on ice with 
shaking (~200 rpm), and then centrifuged for 5 min at 16,000×g for at 4˚C. After the 
last centrifugation, the supernatant (nuclear extract) was transferred to a separate tube. 
It can be used immediately or stored in aliquots at -80˚C. 
2.2.6. Western blot analysis 
Electrophoresis was carried out on aliquots of protein samples that were denatured by 
adding NuPAGE LDS samples Buffer (Invitrogen) and heating for 10 min at 70˚C. 
Western blotting was performed following an electrophoretic transfer (126V for 95 
min at 4˚C) onto a Hybond ECL nitrocellulose membrane (Amersham Pharmacia 
Biotech). Membranes were blocked in blocking buffer (1×TBST and 5% milk) for 1 h 
at room temperature, washed in 1×TBST and hybridized with the primary antibody 
over night at 4˚C. Membranes were washed again and then incubated with secondary 
antibody at a dilution of 1:2000 for 2 h at room temperature. SuperSignal West Pico 
Chemiluminescent Substrate (Pierce, USA) or ECL Plus was used for detection. 
Protein band size was determined using Novex Sharp Pre-stained Protein Standard 
(Invitrogen). 
2.2.7. RNA extraction and qPCR 
Total RNA was extracted and purified from myometrial cells grown in 6-well plates 
using RNeasy mini kit (Qiagen Ltd, UK). After quantification, 1.0 µg was reverse 
transcribed with oligo dT random primers using MuLV reverse transcriptase (Applied 
Biosystems Ltd, UK). Primer sets for PR and its co-modulators were designed and 
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obtained from Amersham Pharmacia Biotech. These primer sets produced amplicons 
of the expected size. Assays were validated for all primer sets by confirming that 
single amplicons of appropriate size and sequence were generated according to 
predictions. Quantitative PCR was performed in the presence of SYBR Green (Roche 
Diagnostics Ltd, UK), and amplicon yield was monitored by Rotor Gene R-G 3000 
(Corbett Research, Australia) that continually measures fluorescence caused by the 
binding of the dye to double-stranded DNA. Pre-PCR cycle was 7 min at 95˚C 
followed by 35 cycles of 95˚C for 10 s and 72˚C for 10 s followed by final extension 
at 72˚C for 1 min. The cycle in which fluorescence reached a preset threshold (cycle 
threshold) was used for quantitative analyses. The cycle threshold in each assay was 
set at a level where the exponential increase in amplicon abundance was 
approximately parallel between all samples. For each set of primers, a standard curve 
was derived from a ten-fold dilution series of the concentrated DNA template. All 
mRNA abundance data were expressed relative to the amount of constitutively 
expressed GAPDH. 
Table 2-1 Primer pair sequences with gene accession numbers 
Name Forward (F) and Reverse (R) primer sequence (5’-3’) 
Genebank/EMBL 
Accession no. 
Product 
size (bp) 
COX-2 F: tgtgcaacacttgagtggct AY151286 297 
 
R: actttctgtactgcgggtgg 
 
 
FKBP5 F: tccctcgaatgcaactctct NM_001145775 194 
 
R: gccacatctctgcagtcaaa 
 
 
GAPDH F: tgatgacatcaagaaggtggtgaag BC014085 240 
 
R: tccttggaggccatgtaggccat 
 
 
HSD11β1 F: accttcgcagagcaatttgt NM_005525 226 
 
R: gccagagaggagacgacaac 
 
 
IL-8 F: gccttcctgattttgcagc NM_000584 150 
 
R: cgcagtgtggtccactctca 
 
 
MMP10 F: caaaatctgttccttcggga NM_002425 84 
 
R: tctcccctcagagtgctgat 
 
 
OTR F: agaagcactcgcgcctctt NM_000916 102 
 
R: aggtgatgtcccacagcaact 
 
 
PR-B F: aactcagcgagggactgaga X51730 151 
 
R: gaggactggagacgcagagt 
 
 
PR-total F: agcccacaatacagcttcgag NM_000926 253 
 
R: tttcgacctccaaggaccat 
 
 
ERRFI1 F: agccctctctctggatgaca NM_018948 238 
 
R: tggaggaggatttggatctg 
 
 
DUSP1 F: cagctgctgcagtttgagtc NM_004417 161 
 
R: aggtagctcagcgcactgtt 
 
 
ABCA1 F: taaatgcccagcacaattca NM_005502 213 
 
R: catgacacatggctctttgg 
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HSPA7 F: gaggtggagaggatggttca NR_024151 160 
 
R: tgtcctcttcgggaatcttg 
 
 
IL33 F: acattgggcaaagttgcttc NM_033439 196 
 
R: gcatccagaggtcaggtgat 
 
 
TNFRSF11B F: ggcaacacagctcacaagaa NM_002546 241 
 
R: ctgggtttgcatgcctttat 
 
 
IL17A F: tccggctggagaagatactg NM_002190 152 
 
R: ttgaaggatgagggttcctg 
 
 
IL1β F: gctgaggaagatgctggttc NM_000576 240 
 
R: tccatatcctgtccctggag 
 
 
KCNE4 F: gctccaagttctgtgcttcc NM_080671 225 
 
R: gttcagactaaccggccaaa 
 
 
UBQLN4 F: gagatcagccacatgctcaa NM_020131 218 
 
R: aagggattgttgccaaactg 
 
 
AHSA2 F: tcaacgagttgaagcaggtg NM_152392 243 
 
R: acagtcaattcctgggttgc 
 
 
HSD3β1 F: ccatgaagaagagcctctgg NM_000862 202 
 
R: gttgttcagggcctcgttta 
 
 
EDA2R F: ccacatttgacactgctgct NM_021783 200 
 
R: cacctccaattgctgaacct 
 
 
PPP1R8 F: aagaagcccacaccttcctt NM_014110 163 
 
R: ggttaggatgccaggagaca 
 
 
KCNE2 F: cttgtgtgcaacccagaaga NM_172201 150 
 
R: gtcttccagcgtctgtgtga  
 
 
2.2.8. Transient transfections and luciferase assays 
Cells were cultured in 24-well plates to about 80% confluence and then transfected by 
using Gene-Juice transfection reagent (Novagen) for DNA and DharmaFECT 2 
(Dharmacon) for siRNA according to the manufacturer’s instructions. Expression 
constructs and reporter vectors were co-transfected at concentrations of 300 ng/well 
and SV40-Renilla vector (pRL-SV40, Promega) was used as an inner control for 
transfection efficiency at concentrations of 100 ng/well. The empty expression vector 
pSG5, pGL4 and pTAL-Luc were included as filler constructs so that the total amount 
of transfected DNA per well was constant. For knockdown experiments, siRNAs 
targeting C/EBPβ, C/EBPδ, c-Jun, c-Fos and p65 respectively were transfected. Non-
targeting siRNA was used as control. Cells were treated 24 h post transfection with 
the specific stimulus or vehicle for another 24 h. Firefly luciferase activity was 
measured by using a dual firefly/renilla luciferase assay (Luclite, Packard Bell and 
Coelentrerazin CN Biosciences). All transfections were performed in triplicates. 
Results of luciferase activity was first normalized to the level of Renilla luciferase 
activity and then calculated as fold induction relative to either expression of vehicle-
treated group, or the control empty expression vector. 
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In order to transfect the USMCs with some expression vectors, shRNA or siRNA 
more efficiently, the Amaxa Nucleofector technology (Amaxa, Cologne, Germany) 
was used. Cells were harvested by trypsinization as described above. Approximately 
1×10
6
 cells were resuspended in 100 µl Nucleofector solution and mixed with 2 µg 
DNA or 30 pmol siRNA at room temperature. The cell/DNA or siRNA suspension 
was then transferred into certified cuvette and electroporated in the Nucleofector 
Cuvette Holder with the Nucleofector Program A-033. Immediately after 
electroporation, cells were suspended with 500 µl pre-warmed culture medium and 
gently transferred into 6-well plates or 10 cm petri dishes. The cells were incubated in 
a humidified 37˚C/5% CO2 incubator until analysis and change medium 16-18 h post 
Nucleofection.  
2.2.9. Amplification of long PCR products 
Polymerase chain reactions (PCR) were performed using DNA polymerase. A 50 μl 
reaction included 200 μM of each dNTP (dATP, dCTP, dGTP, dTTP), 50 nM (for the 
50 μl reaction) of each sense and antisense primer, 20 ng template DNA, 1×PCR 
buffer containing 1-2 mM Mg
2+
 as supplied by the manufacturer, and 0.5 μl of 
Promega pfu Taq. DNA templates were initially denatured by heating the reaction to 
95˚C for 2 min, the reaction mixture was then subjected to 35 thermo-cycles of 95˚C 
for 30 sec, primer annealing at between 60˚C for 30 sec, and primer extension at 72˚C 
for 5 min. This was followed by a final extension of 72˚C for 10 min. Final products 
were analysed by gel electrophoresis. 
2.2.10. Agarose gel electrophoresis 
Agarose gels of 1.5-2 % (w/v) were prepared by dissolving agarose in fresh 1×TBE 
and heating the suspension in a microwave oven until boiling. The solution was 
allowed to cool to approximately 50˚C, and poured into an appropriate gel mould after 
adding SYBR safe. Once set, the gel was submerged in 1×TBE buffer in a gel tank, 
and DNA samples containing 1×DNA loading buffer were loaded into the wells. 
Electrophoresis was carried out at 120V for a variable time which depending on the 
size of DNA and previous experience. The size of the DNA fragments was estimated 
by comparing their relative mobility to that of restriction fragments of known size, 
typically 100 bp and 1 Kb markers. If the DNA was going to be purified, the gel was 
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visualized on a dark reader (Dark Reader transilluminator, Clare Chemical Research) 
and the band cut out using a scalpel. 
2.2.11. DNA purification from agarose gel and concentration determination 
DNA fragments were purified from agarose gels using the GenElute™ Gel Extraction 
Kit based on the manufacturer’s protocol. Briefly, the excised gel band was weighed 
and Gel Solubilisation Solution was added accordingly. The mixture was then 
incubated at 50-65˚C for 10 min, or until the gel slice was completely dissolved. 100 
μl of isopropanol was added to the gel mixture per 100 mg of gel when the size of the 
target DNA fragment is less than 200 bp. After several washing steps, the column was 
placed in a fresh microcentrifuge tube and 50 μl ddH2O was applied to the column. 
The column was incubated at room temperature for 1-3 min and centrifuged for 1 min. 
All centrifugations were performed at 17000×g at room temperature. 
DNA concentration was determined using a NanoDrop Nd-1000 spectrophotometer. 2 
μl of sample was applied onto the hole of the measurement pedestal. Absorbance 
readings were taken at 230, 260 and 280nm. The A260:A280 ratio was expected to be 
in the region of 1.8 for DNA and 2.0 for RNA. If the ratio is much lower it may 
indicate protein contamination. The A260:A230 ratio of 2.0-2.2 was expected. If the 
ratio was lower it indicated possible contamination with substances, which absorb at 
230 such as carbohydrates, EDTA and phenol.  
2.2.12. Restriction enzyme digestion and ligation reaction 
20 μl of DNA (50 ng/μl) was used for digestion, 5 μl of 10×restriction enzyme buffer, 
1 μl of restriction enzyme (10 U/μl) and nuclease-free H2O to a total volume of 50 μl 
and incubated at 37˚C for 1-4 h. After the digestion, the reaction can be either run on 
an agrose gel to check the positive cloned constructs or purified by PCR purification 
Kit for further experiment, such as ligation. 
Ligations were performed with 30-50 ng of purified DNA fragments and typically a 
5:1 molar ratio of parental vector was used. A final volume of 10 μl containing 1×T4 
DNA ligase buffer and 1 μl T4 DNA ligase (6 units). All reactions were incubated for 
2 h at room temperature or overnight at 16˚C. 
2.2.13. Colony PCR 
Chapter 2: Material and Methods 
- 69 - 
To rapidly find out the positive clone after ligation and transformation, colony PCR 
was performed. 20 μl of H2O was used to resuspend a colony picked from an agar 
plate. 5 μl was saved, so that if it is positive, it could be used to inoculate LB for the 
growth of minicultures, and the remaining 15 μl was heated for 5-10 minutes at 95˚C 
to lyse the cells. The samples were then centrifuged for 2 min at 16,000×g to remove 
any debris. 1 μl of the supernatant was used as template in a PCR reaction. Primers 
used in the cloning step were added into this reaction. 
2.2.14. DNA sequencing and analysis 
After the positive clone was selected, the plasmid was then sent off for sequencing, 
which is provided by MRC clinical sciences service, Imperial College London. The 
results were reported in the form of a consensus sequence and its associated 
chromatograms, and they were analyzed using DNAMAN software. 
2.2.15. Co-immunoprecipitation (Co-IP) 
All immunoprecipitation procedures were performed at 4˚C. Cells were harvested and 
washed twice with ice-cold PBS before lysis. Cells were lysed in lysis buffer. The 
lysate was pre-cleared by protein G-Agarose beads before the incubation with the 
antibody against the protein of interest or pre-immune IgG of the same species 1-2 h 
with rotation, 2% of the lysate was kept as input. This lysate/antibody mixture was 
subsequently incubated with protein G-Agarose beads for 1 h with rotation. The beads 
were pelleted by centrifugation at 1000×g for 30 sec and washed four times in IP 
buffer. The protein–antibody complexes that were released from beads by adding the 
loading buffer and heating at 70˚C for 10 min were subjected to Western blot analysis 
after separation by SDS–PAGE.  
2.2.16. Chromatin immunoprecipitation 
Cell monolayers in 10 cm dishes were treated with different stimuli after serum 
starvation overnight. Cells were washed with PBS, and cross-linked with 1% 
formaldehyde for 10 min at room temperature. 125 mM of Glycine was added and 
incubated for 5 min at room temperature to stop the cross-link reaction. Cells were 
washed twice with ice-cold PBS, scraped and pelleted at 200×g for 10 min at 4˚C. 
The cell pellets were resuspended with Szak RIPA buffer and incubated for at least 20 
min on ice with occasional mix. While this cell lysates were sonicated, the antibody-
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coupling dynabeads were prepared. 4 µg antibody against the protein of interest and 
preimmune rabbit polyclonal IgG were incubated with dynabeads for 2 h at 4˚C, 
respectively. The sonicated cell supernatant was diluted to 1 ml aliquots and incubated 
with dynabeads for 1 h at 4˚C to pre-clear. After pre-clear, 10% of cell lysates were 
kept as “input” positive control for the later qPCR analysis. The rest of pre-cleared 
cell lysates were incubated with antibody-coupling dynabeads for 2 h at 4˚C with 
rotation. The beads were collected with the tube on the magnet and the supernatant 
was discarded. The beads were washed with different buffer in the following order: 
1× in Szak RIPA buffer, 2× in Low-salt buffer, 2× in High-salt buffer, and 2× in TE 
buffer. Each wash step was carried out with 1 ml buffer for 5 min at 4˚C with rotation. 
After the last wash, beads were finally incubated with Elution buffer for 15 min at 
room temperature to elute DNA-antibody complexes, and then collect the supernatant 
with the tube on the magnet. To each 120 µl eluants, 2 µl of 0.5 mg/ml RNase A and 
6 µl of 5 M NaCl were added. These eluants were then incubated overnight at 65˚C 
with shaking to reverse the cross-links. The DNA was finally purified using QIA 
quick PCR purification kit according to manufacturer’s instructions, and the target 
sequences was amplified by qPCR with the following specific oligonucleotide 
primers: 
Proximal NF-κB site (NF-κB 1) on COX-2 promoter (-223 to -214): 
Forward primer: 5’-AGGAGAGGGAGGGATCAGAC-3’ 
Reverse primer: 5’- GACTGTTTCTTTCCGCCTTT-3’ 
Distal NF-κB site (NF-κB 2) on COX-2 promoter (-446 to -437): 
Forward primer: 5’- GTCCCGACGTGACTTCCTC-3’ 
Reverse primer: 5’- AGCCAGTTCTGGACTGATCG-3’ 
2.2.17. Statistical analysis 
All data were initially tested for normality using a Kolmogorov-Smirnoff test. 
Normally distributed data were analysed using a Student t test for two groups and an 
ANOVA followed by a Dunnett post hoc test for three groups or more. Data that were 
not normally distributed were analysed using a Mann–Whitney U test for non-paired 
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data and a Wilcoxon matched pairs test for paired data (two groups) and when 
comparing three groups or more we used a Friedman’s Test, with a Dunn's Multiple 
Comparisons post hoc test. p<0.05 was considered statistically significant.  
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3. Uterine Stretch and Progesterone Action 
3.1. Introduction 
Progesterone plays an essential role in maintaining pregnancy in both humans and 
animals. In lower order animals, such as rats, mice, rabbits, goats and pigs, a systemic 
progesterone withdrawal can lead to the onset of parturition [7]. In contrast, in 
primates and humans, maternal, fetal and amniotic progesterone levels remain 
elevated throughout pregnancy suggesting that systemic progesterone withdrawal is 
not a prerequisite for labour at term. However, tissues of the reproductive tract 
become resistant to progesterone action suggesting that a functional progesterone 
withdrawal occurs [7]. The facts that mifepristone, which inhibits genomic 
progesterone action, can increase myometrial sensitivity to exogenous prostaglandins 
[315] and induce labour [316] and that progesterone administration reduces preterm 
labour rates in high-risk women [48], support the concept that in the human 
progesterone plays an important role in determining the onset of labour. Clinically, 
however, progesterone administration only reduces preterm labour rates in singleton 
pregnancies and has no effect in women with multiple pregnancies [49, 51, 74]. This 
suggests that different processes are involved in singleton and multiple preterm labour 
such that the risk of preterm labour in singleton pregnancies can be modulated by 
progesterone administration whereas the risk in multiple pregnancies cannot.  
There is increasing evidence suggesting that progesterone promotes uterine relaxation, 
at least in part, by blocking the myometrial response to oxytocin and prostaglandins 
[225, 317, 318]. In human myometrium, three progesterone receptor isoforms A, B 
and C (PR-A, -B, -C) have been identified and all belong to the nuclear receptor 
family. PR-B represents the full-length functional receptor and is thought to mediate 
most of the progesterone effects; PR-A and PR-C are truncated versions that 
predominantly repress transcription; however, recent studies suggest that PR-A may 
also mediate some of progesterone’s effects [232]. Thus, the subtype and the 
expression level of these PR isoforms may lead to different progesterone 
responsiveness. A fall in the ratio of PR-B to PR-A/C has been proposed as one of 
potential mechanisms responsible for repressing the genomic actions of progesterone, 
leading to a functional withdrawal of progesterone action [319]. This hypothesis has 
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drawn support from both primate and human data [246, 249, 319, 320].  On the other 
hand, the non-genomic actions of progesterone and its metabolites may also 
contribute to myometrial relaxation [321, 322]. With advancing gestation, the uterus 
is subject to increasing stretch as the pregnancy grows. Animal studies suggest that 
progesterone is responsible for maintaining uterine quiescence and promoting 
myometrial hyperplasia and hypertrophy to prevent any increase in uterine wall 
tension [58-60, 323]. Clinically, a relative increase in uterine volume, as seen in a 
unicornuate uterus, or an absolute increase, as seen in multiple pregnancy or 
polyhydramnios is associated with excessive uterine stretch and results in an increased 
risk of preterm labour [65, 66, 69]. As mentioned above, progesterone administration 
does not reduce this risk and despite the fact that circulating progesterone levels are 
high, uterine stretch, achieved by the insertion and inflation of a balloon into the 
uterine cavity can be used clinically to induce abortion during the second trimester of 
pregnancy and labour at term [324, 325]. In contrast, pregnant rats seem to be tolerant 
of uterine stretch when progesterone levels are maintained [59]. These data suggest 
that the human uterus becomes refractory to the effects of both endogenous and 
exogenous progesterone due to uterine stretch, implying that uterine stretch might 
contribute to the progesterone functional withdrawal before the onset of labour. 
In previous studies by our group, the in vitro model of pregnancy-induced uterine 
stretch has been characterized. The stretch of USMCs increases the expression of 
COX-2 and IL-8 via MAPK activation and induces the expression of OTR in a 
MAPK-independent manner [85, 87, 133, 326, 327]. These data are consistent with 
earlier human and rabbit studies which found that uterine distension was associated 
with a prostaglandin-driven increase in uterine activity [325, 328, 329] and in vitro 
studies of rat myometrial strips, in which ERK1/2 was activated by stretch [330]. 
In this chapter, I have investigated whether progesterone is able to inhibit stretch-
induced MAPK activation and gene expressions and/or whether stretch in turn affects 
progesterone actions in USMCs. 
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3.2. Results 
3.2.1. Does progesterone affect stretch-induced ERK1/2 activation and gene 
expression? 
USMCs were exposed to 11% mechanical stretch for 5, 15, 30, and 60 min. The 
phosphorylation of ERK1/p44 was significantly increased at all last three time points 
compared with baseline (ANOVA=0.02, baseline vs. 15, 30 and 60 min, p<0.01, 0.05 
and 0.05 respectively). For ERK2/p42, the significant increases occurred at 15 and 30 
min (ANOVA=0.034, baseline vs. 15 and 30 min, p<0.05 and 0.01 respectively). 
There was no difference in the stretch-induced ERK1/2 activation in cells pre-
incubated with MPA (Figure 3-1). Similarly, pre-incubation with MPA (0.5 and 5 μM 
for 48 h) did not significantly reduce the stretch-induced increases in COX-2, IL-8, 
and OTR (Figure 3-2). However, if the endogenous progesterone tone was high, this 
may have masked any repressive effect of MPA. To address this, USMCs were pre-
exposed to RU486 (1 μM for 48 h) before stretch. However, the stretch-induced 
increases in COX-2, IL-8, and OTR mRNA expression were not enhanced by RU486; 
rather the trend showed attenuation in gene expression of COX-2 (p=0.0625) and 
OTR (p=0.09; Figure 3-3). To confirm this result, I stretched the cells after silencing 
PR expression by siRNA, which was delivered by optimized electroporation method 
(Figure 3-4), and the data indicated that the ability of stretch to increase COX-2 
mRNA expression was unchanged (Figure 3-5). 
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Figure 3-1 The failure of progesterone to significantly reduce stretch-induced activation of ERK1/2. 
USMCs were isolated from myometrium of non-labouring women and were pre-incubated with MPA (1 μM) for 
48 h before being exposed to 11% stretch for between 0 and 60 min. Protein was extracted and the western blots 
performed as described in Materials and Methods. A typical example of the western analysis is shown at the top of 
the figure with the densitometry below. The data are expressed as median, the 25th and 75th percentiles and the 
range and compared using an ANOVA and Dunnett’s post test for longitudinal data and a paired t test for matched 
data. * indicates a significant difference of p<0.05; and **, p<0.01, compared with baseline (n=6). This 
experiment was done by Ben Cryar. 
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Figure 3-2 The failure of progesterone to significantly reduce stretch-induced gene expression. 
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USMCs were isolated as described above and pre-incubated with MPA (0.5 and 5.0 μM) for 48 h before being 
exposed to 11% stretch for 60 min. mRNA was extracted and the levels of COX-2, IL-8, and OTR mRNA were 
measured using qPCR. Data are shown as the median, the 25th and 75th percentiles and the range and were 
compared using Wilcoxon matched pairs test. ** indicates a significant difference of p<0.01 (n=10). 
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Figure 3-3 RU468 does not accentuate the stretch-induced gene expression. 
USMCs were isolated as described above and pre-incubated with RU486 (1 µM) for 48 h before being exposed to 
11% stretch for 60 minutes. mRNA was extracted and the levels of COX-2, IL-8 and OTR mRNA were measured 
using qPCR. Data are shown as the median, the 25th and 75th percentiles and the range and were compared using 
Wilcoxon matched pairs test. * indicates a significant difference of p<0.05 vs. control (n=6). 
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Figure 3-4 The comparison of transfecion efficiency between Amaxa (nucleofection) and Gene Juice in 
USMCs. USMCs were transiently transfected with a green fluorescent protein (GFP) expressing plasmid, 
pmaxGFP using Amaxa (nucleofection) or Gene Juice. Cells were examined by fluorescence microscopy from 2 
day post-transfection to day 5. BF, bright field. 
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Figure 3-5 PR knockdown does not affect the stretch-induced COX-2 expression. 
USMCs were isolated as described above, and total PR was knocked down using siRNA before being exposed to 
11% stretch for 60 minutes. mRNA was extracted and the levels of COX-2 mRNA were measured using qPCR. 
Data are shown as the median and the range (n=3). 
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3.2.2. Does stretch change progesterone-responsive gene expression? 
In the literature, several genes have been identified as progesterone-responsive, 
including secretory leukocyte peptidase inhibitor (SLPI), calcitonin gene related 
peptide (CGRP), nitric oxide synthase 3 (eNOS), relaxin receptor 1 (LGR7), 
uteroglobin, inhibitor of kappa B (IκB), and nuclear factor kappa-light-chain-enhancer 
of activated B cells (NFκB). So I investigated whether progesterone affected their 
expression in USMCs. However, none of them were modulated by MPA treatment 
(Figure 3-6). Consequently, a microarray analysis was performed comparing PR 
knockdown group with control group and four genes were found to be strongly 
regulated, matrix metallopeptidase 10 (MMP10), carbonic anhydrase XII (CA12), 
fibronectin leucine rich transmembrane protein 3 (FLRT3), potassium inwardly-
rectifying channel, subfamily J, member 2 (KCNJ2), but only MMP10 showed a 
consistent decrease in response to MPA. Furthermore, when I performed another 
microarray on USMCs comparing MPA-treated cells (exposure to MPA for 48 h) and 
vehicle, several genes were identified to be progesterone-responsive (Table 3-1, Table 
3-2). However, after I used the more stringent Benjamini-Hochberg Correction on 
these data, only three genes were shown to be significantly modulated by MPA [Six-
transmembrane epithelial antigen of prostate 4 (STEAP4), 11β-Hydroxysteroid 
dehydrogenase (HSD11β1), and FK506 binding protein 5 (FKBP5)]. Use qPCR to 
confirm these results and found that only FKBP5 and HSD11β1 responded 
consistently to MPA. So after combining two sets of microarray data, three 
progesterone-responsive genes were identified in USMCs; amongst these, MMP10 
was down-regulated whereas both FKBP5 and HSD11β1 were up-regulated by MPA. 
Stretch was found not to alter either the basal or the MPA-induced change in the 
expression of these 3 genes (Figure 3-7). 
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Figure 3-6 Progesterone-responsive genes in the literature are not modulated by progesterone in USMCs. 
USMCs were isolated from myometrial biopsies obtained from women at the time of pre-labour lower segment 
cesarian section (LSCS). Cells were pre-incubated with MPA (1 µM) for 48 h. mRNA was then extracted and the 
mRNA levels of various progesterone-responsive genes were measured using qPCR. Data are shown as the 
median, the 25th and 75th percentiles and the range, and were compared using Wilcoxon matched pairs test (n=6). 
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Table 3-1 Top 50 up-regulated genes by MPA with gene symbol, gene name, GeneBank accession number 
and fold change 
Gene symbol Gene name GeneBank  accession no. Fold  change  
STEAP4 STEAP family member 4 NM_024636 -5.327 
FKBP5 FK506 binding protein 5 NM_001145775 -4.30804 
ADH1B alcohol dehydrogenase 1B (class I), beta polypeptide NM_000668 -4.15886 
HSD11B1 hydroxysteroid (11-beta) dehydrogenase 1 NM_005525 -4.14498 
CORIN corin, serine peptidase NM_006587 -3.99429 
GRIA1 glutamate receptor, ionotropic, AMPA 1 NM_000827 -3.56978 
MAOA monoamine oxidase A NM_000240 -3.16342 
OMD osteomodulin NM_005014 -3.13773 
CRISPLD2 cysteine-rich secretory protein LCCL domain containing  NM_031476 -2.91513 
MAOB monoamine oxidase B NM_000898 -2.87449 
RORB RAR-related orphan receptor B NM_006914 -2.87273 
C7 complement component 7 NM_000587 -2.81362 
ENPP1 ectonucleotide pyrophosphatase/phosphodiesterase 1 NM_006208 -2.58711 
AOX1 aldehyde oxidase 1 NM_001159 -2.30587 
CCDC68 coiled-coil domain containing 68 NM_025214 -2.28405 
FMO2 flavin containing monooxygenase 2 (non-functional) NM_001460 -2.28082 
LMO3 LIM domain only 3 (rhombotin-like 2) NM_018640 -2.17594 
SYNPO2 synaptopodin 2 NM_133477 -2.15819 
GCNT1 glucosaminyl (N-acetyl) transferase 1 NM_001490 -2.09552 
IMPA2 inositol(myo)-1(or 4)-monophosphatase 2 NM_014214 -2.01049 
P2RY14 purinergic receptor P2Y, G-protein coupled, 14 NM_014879 -1.94793 
SYTL4 synaptotagmin-like 4 NM_080737 -1.94427 
RNF182 ring finger protein 182 NM_152737 -1.93839 
ERRFI1 ERBB receptor feedback inhibitor 1 NM_018948 -1.92055 
CYP7B1 cytochrome P450, family 7, subfamily B, polypeptide 1 NM_004820 -1.91402 
FAM19A2 family with sequence similarity 19 NM_178539 -1.90505 
SORBS1 sorbin and SH3 domain containing 1 NM_001034954 -1.884 
CD226 CD226 molecule NM_006566 -1.8602 
PRUNE2 prune homolog 2 NM_015225 -1.84631 
DKFZP564O0823 DKFZP564O0823 protein NM_015393 -1.82917 
ADH1C alcohol dehydrogenase 1C NM_000669 -1.8003 
TSC22D3 TSC22 domain family, member 3 NM_198057 -1.78509 
FAM105A family with sequence similarity 105, member A NM_019018 -1.76203 
MATN2 MATN2 NM_002380 -1.75105 
C5orf23 chromosome 5 open reading frame 23 BC022250 -1.73304 
SLC24A3 solute carrier family 24 NM_020689 -1.68371 
PHF17 PHD finger protein 17 NM_199320 -1.65895 
GLUL glutamate-ammonia ligase NM_002065 -1.65882 
GPM6B glycoprotein M6B NM_001001995 -1.64214 
ADH1A alcohol dehydrogenase 1A NM_000667 -1.64047 
RASL11A RAS-like, family 11, member A NM_206827 -1.62452 
DUSP1 dual specificity phosphatase 1 NM_004417 -1.61945 
ACSL1 acyl-CoA synthetase long-chain family member 1 NM_001995 -1.61094 
GFPT2 glutamine-fructose-6-phosphate transaminase 2 NM_005110 -1.60649 
MOBKL2B MOB1, Mps One Binder kinase activator-like 2B NM_024761 -1.60496 
ADRA2C adrenergic, alpha-2C NM_000683 -1.59029 
SLCO4C1 solute carrier organic anion transporter family NM_180991 -1.57083 
ODZ3 ten-m homolog 3 NM_001080477 -1.56596 
RPL7A ribosomal protein L7a NR_000017 -1.55156 
CA8 carbonic anhydrase VIII NM_004056 -1.55022 
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Table 3-2 Top 50 down-regulated genes by MPA with gene symbol, gene name, GeneBank accession number 
and fold change 
Gene symbol Gene name GeneBank Accession no. Fold Change  
MMP10 matrix metallopeptidase 10 NM_002425 3.9034 
DIO2 deiodinase, iodothyronine, type II NM_013989 3.57657 
SYTL5 synaptotagmin-like 5 NM_138780 3.3714 
ITGA8 integrin, alpha 8 NM_003638 2.6605 
CD24 CD24 molecule NM_013230 2.61073 
SERPINB7 serpin peptidase inhibitor, clade B NM_003784 2.48935 
MMP11 matrix metallopeptidase 11 NM_005940 2.42556 
KCNMB2 potassium large conductance calcium-activated channel NM_005832 2.38572 
ZNF711 zinc finger protein 711 NM_021998 2.11108 
EGR2 early growth response 2 NM_000399 2.04323 
GRIA4 glutamate receptor, ionotrophic, AMPA 4 NM_000829 2.04202 
SLC14A1 solute carrier family 14 (urea transporter), member 1 NM_001128588 2.02716 
ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 NM_152565 1.93544 
H19 H19, imprinted maternally expressed transcript NR_002196 1.93198 
CYYR1 cysteine/tyrosine-rich 1 NM_052954 1.91243 
WNT2 wingless-type MMTV integration site family member 2 NM_003391 1.9121 
KLHL4 kelch-like 4 NM_019117 1.84201 
DACH1 dachshund homolog 1 NM_080759 1.82225 
LOC401097 Similar to LOC166075 ENST00000326474 1.81298 
HMCN1 hemicentin 1 NM_031935 1.79146 
AFAP1L2 actin filament associated protein 1-like 2 NM_001001936 1.78916 
FGF9 fibroblast growth factor 9 NM_002010 1.78754 
TNNT2 troponin T type 2 NM_000364 1.78262 
CLSTN2 calsyntenin 2 NM_022131 1.78205 
C5orf13 chromosome 5 open reading frame 13 NM_004772 1.77996 
FAM46C family with sequence similarity 46, member C NM_017709 1.7651 
RARRES2 retinoic acid receptor responder (tazarotene induced) 2  NM_002889 1.75464 
IGF1 insulin-like growth factor 1 NM_001111283 1.73159 
GPR39 G protein-coupled receptor 39 NM_001508 1.72622 
LAMP3 lysosomal-associated membrane protein 3 NM_014398 1.72367 
ZNF704 zinc finger protein 704 NM_001033723 1.70278 
CPA4 carboxypeptidase A4 NM_016352 1.70155 
UNQ565 UNQ565 BC040288 1.69181 
IGFBP3 insulin-like growth factor binding protein 3 NM_001013398 1.68453 
KRT18 keratin 18 NM_000224 1.68018 
IL6 interleukin 6 NM_000600 1.67977 
B3GALT1 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase NM_020981 1.67742 
PLA2G4A phospholipase A2, group IVA NM_024420 1.66087 
RASSF9 Ras association (RalGDS/AF-6) domain family NM_005447 1.64334 
BMP6 bone morphogenetic protein 6 NM_001718 1.64126 
DGKB diacylglycerol kinase NM_004080 1.63946 
TMEM130 transmembrane protein 130 NM_001134450 1.62963 
IGJ immunoglobulin J polypeptide NM_144646 1.6187 
DKK2 dickkopf homolog 2 NM_014421 1.61117 
C6orf141 chromosome 6 open reading frame 141 NM_001145652 1.60936 
SLC44A5 solute carrier family 44, member 5 NM_152697 1.60717 
MYLIP myosin regulatory light chain interacting protein NM_013262 1.60701 
OR2J1 olfactory receptor, family 2, subfamily J, member 1  ENST00000377171 1.6019 
CCL11 chemokine (C-C motif) ligand 11 NM_002986 1.60141 
TPD52L1 tumor protein D52-like 1 NM_001003395 1.5991 
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Figure 3-7 Stretch of human USMCs does not inhibit the ability of progesterone to modulate gene 
expression.  
USMCs were isolated from myometrial biopsies obtained from women at the time of pre-labour LSCS. Cells were 
pre-incubated with MPA (1 µM) for 24 h before being exposed to 11% stretch for 60 min. mRNA was then 
extracted and the mRNA levels of various progesterone-sensitive genes measured using qPCR. Data are shown as 
the median, the 25th and 75th percentiles and the range; and were compared using Wilcoxon matched pairs test. * 
indicates a significant difference of p<0.05, and **, of p<0.01 (n=6).  
Chapter 3: Uterine stretch and progesterone action 
- 87 - 
3.2.3. Stretch does not change liganded PR-B-driven PRE activation or 
progesterone repression of IL-1β-induced COX-2 expression 
Mechanical stretch did not affect PR-B-driven progesterone response element (PRE) 
activation in the presence of MPA (Figure 3-8). MPA not only reduced the basal level 
of COX-2 expression also reduced the IL-1β-induced increase in COX-2 mRNA 
expression and protein synthesis. In the cells that were pre-stretched for 24 h, the 
ability of MPA to repress IL-1β-induced increase in COX-2 mRNA expression and 
protein synthesis was unchanged (Figure 3-9).  To further clarify the statement that 
MPA reduces the IL-1β-driven COX-2 expression and also to detect a possibility that 
MPA may simply have reduced the baseline level of COX-2 such that the total COX-
2 after combined treatment was less than that in the experiment using IL-1β alone, I 
carried out an analysis to see whether the IL-1β-induced COX-2 increase is different 
between in the presence and absence of MPA. As shown in Figure 3-10, A and B, the 
ability of IL-1β inducing COX-2 expression is attenuated in the presence of MPA 
compared with in the absence of MPA (n=16, p<0.0001 at mRNA level and n=6, 
p=0.0117 at protein level). However, MPA shows no effect on stretch-induced COX-2 
expression (Figure 3-10, C) and stretch does not affect MPA to repress the basal level 
of COX-2 expression (Figure 3-10, D), which are consistent with my previous results. 
 
Figure 3-8 Stretch of human USMCs does not inhibit the ability of progesterone to activate a progesterone 
response element. 
USMCs were transiently co-transfected with a PRE, with or without progesterone receptor (PR-B). SG5 was used 
as control. MPA was added 24 h post transfection and the cells were either stretched or not for another 24 h before 
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luciferase assay. Data are expressed as median, 25th and 75th percentiles and range and were analyzed using a 
Wilcoxon matched pairs test. * indicates a significant difference of p<0.05 (n=6). 
 
Figure 3-9 Stretch of human USMCs does not inhibit the ability of progesterone to repress IL-1β-driven 
COX-2 expression. 
USMCs were stretched for 30 h; in the last 6 h, the cells were exposed to different stimuli, IL-1β or MPA, alone or 
in combination. mRNA was then extracted and the COX-2 mRNA levels were measured using qPCR. Protein was 
extracted and the western blotting performed as described in Materials and Methods. Data are expressed as 
median, 25th and 75th percentiles and range and compared using ANOVA and Dunnett’s post test and paired t test 
for other comparisons. NS, non-stretched cells; S, stretch-cells. * indicates a significant difference of p<0.05, and 
***, p<0.001 vs. baseline; §, p<0.05, and §§, p<0.01 between samples exposed to IL-1β alone or with stretch 
incubated with or without MPA; ##, p<0.01 vs. samples exposed to IL-1β alone or with stretch (n=5-6). 
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Figure 3-10 MPA represses IL-1β-driven COX-2 expression but has no effect on stretch-induced COX-2 
expression. 
Data were analyzed by using delta value of (vehicle and IL-1β) and (non-stretch and stretch) in the presence or 
absence of MPA. NS, non-stretched cells; S, stretch-cells. Data are expressed as median, 25th and 75th percentiles 
and range and were analyzed using a Wilcoxon matched pairs test. * indicates a significant difference of p<0.05 
(n=6), and ***, p<0.001 (n=16). 
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3.2.4. The effect of mechanical stretch on PR expression 
Although stretch did not affect progesterone action, stretch down-regulated PR-B and 
PR-total mRNA expression (p<0.05 and p<0.01 respectively) as well as PR-B protein 
level (Figure 3-11). To further investigate how stretch represses PR expression, 
inhibitors of MAPK and IKK signaling pathways were employed. After UMSCs were 
pre-incubated with these inhibitors, basal level of PR-total was significantly reduced 
by all three MAPK inhibitors whereas basal expression of PR-B was unaffected 
(Friedman’s test, p=0.027, Dunn’s multiple comparison for each inhibitor, p<0.05). 
Only the IKK inhibitor resulted in a significant reversal of the stretch-induced 
inhibition of PR-B and PR-total mRNA expression (Figure 3-12; Friedman’s test, 
p=0.02, Dunn’s multiple comparison for IKK inhibitor p<0.01). The addition of 
anisomycin (0.2 µM for 2 h), a MAPK activator, increased the PR-B expression in an 
ERK- and p38 dependent manner (paired t test, p<0.05, ANOVA=0.0099, ERK and 
p38 inhibitors <0.05) and a trend of increasing PR-total (p=0.08) in an ERK-
dependent manner (Figure 3-13; ANOVA=0.036, ERK inhibitor <0.05). In the 
literature, PKC and PLC have been reported to be involved in the stretch-induced 
changes in gene expression [331, 332]. However, activators of PKC and PLC did not 
affect the basal mRNA levels of PR, and their inhibitors had no effect on the stretch-
induced reduction in PR mRNA expression (Figure 3-14).  
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Figure 3-11 Stretch of USMCs results in a reduction in PR-B, PR-total mRNA and PR-B protein expression. 
USMCs were isolated from myometrial biopsies obtained from women at the time of pre-labour LSCS. Cells were 
exposed to 11% stretch for 60 min. mRNA was then extracted and the levels of PR-B and PR-total mRNA were 
measured using qPCR. In an independent experiment, USMCs were exposed to stretch for 30 hours, protein was 
extracted and the western blots were performed as described in Materials and Methods. Data are shown as median, 
the 25th and 75th percentiles and the range and were compared using Wilcoxon matched pairs test. * indicates a 
significant difference of p<0.05, and ** of p<0.01 compared with paired sample (n=24 for mRNA data; n=6 for 
protein data). 
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Figure 3-12 Stretch reduces PR-B, PR-total mRNA and PR-B protein via NF-κB activation. 
USMCs were isolated from myometrial biopsies obtained from women at the time of pre-labour LSCS. Cells were 
pre-incubated with specific inhibitors of MAPK and IKK, the cells were then either processed or exposed to 11% 
stretch for 60 min. mRNA was extracted and the levels of PR-B and PR-total mRNA were measured using qPCR. 
Data are shown as median, 25th and 75th percentiles and range and were compared using Wilcoxon matched pairs 
test for control vs. stretch. * indicates a significant difference of p<0.05 vs. control. Friedman’s Test, with a Dunn's 
Multiple Comparisons post hoc test was used to compare the stretched sample with those pre-incubated with 
specific inhibitors before stretch, §, Significant difference of p<0.05, and §§, of p<0.01 (n=6-7). This part of work 
was collaborated with Renyi Hua. 
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Figure 3-13 MAPK activator increases PR mRNA expression. 
USMCs were isolated from myometrial biopsies obtained from women at the time of pre-labour LSCS. Cells were 
incubated with the MAPK activator, anisomycin 0.2µM for 2 h in the presence or absence of specific MAPK 
inhibitors. Cells were then processed, mRNA was extracted and the levels of PR-B and PR-total mRNA were 
measured using qPCR. Data are shown as median, 25th and 75th percentiles and range; and were compared using 
paired t test for control vs. anisomycin. * indicates a significant difference of p<0.05. An ANOVA, with a 
Dunnett’s post test, was used to compare the sample exposed to anisomycin alone with those pre-incubated with 
specific inhibitors before anisomycin exposure. #, Significant difference of p<0.05, and ##, of p<0.01 (n=6). 
 
Figure 3-14 The effect of PKC and PLC activators and inhibitors on basal PR expression and stretch-
repressed PR expression. 
USMCs were isolated from myometrial biopsies obtained from women at the time of pre-labour LSCS. Cells were 
pre-incubated with specific activators, SC10 and 3M3FBS, of PKC and PLC respectively. Other cells were pre-
incubated with the inhibitors, GF109203x and U73122, of PKC and PLC, respectively, before exposure to 11% 
stretch for 60 min. mRNA was extracted and the levels of PR-B and PR-total mRNA were measured using qPCR. 
Data are shown as median, 25th and 75th percentiles and range; and were compared using Wilcoxon matched pairs 
test for control vs. stretch. * indicates a significant difference of p<0.05. Friedman’s Test, with a Dunn's Multiple 
Comparisons post hoc test, was used to compare the control sample and those exposed to SC10 and 3M3FBS and 
to compare the stretched cells alone with those pre-incubated with specific inhibitors GF109203x and U73122 
(n=6). 
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3.2.5. Stretch induces unliganded PR-B-driven PRE activation via CDK2  
As mentioned above, mechanical stretch had no effect on the PR-B-driven PRE 
activation in the presence of MPA (Figure 3-8). Surprisingly, stretch significantly 
increased the activity of unliganded PR-B (Figure 3-15). In our previous study, stretch 
was found to increase gene expression through activation of different components of 
the MAPK cascade in USMCs [326]. Moreover, phosphorylation by kinases is one of 
the important PR post-translational modifications, which regulates PR activity. To 
examine whether the MAPK pathway was also implicated in stretch-induced 
unliganded PR-B activation, specific MAPK inhibitors (ERK 1/2, U0126; JNK 1/2/3, 
SP600125; p38, SB203580) were used and stretch-induced activation of unliganded 
PR-B was assessed. As shown in Figure 3-16, none of the three inhibitors blocked 
PR-B activation in the absence of MPA suggesting that stretch-induced PR-B 
activation was not mediated via MAPK, although it is possible that there is crossover 
in the different MAPK subtype activities such that a combination or all 3 would have 
to be inhibited in order to block the effect of stretch on PR-B activity. Since CDK2 is 
also known to be involved in PR-B phosphorylation, the CDK inhibitor (roscovatine) 
and CDK2 selective inhibitor were tested. The result showed that both inhibitors 
abolished the significant increase in unliganded PR-B activity in response to stretch, 
suggesting that phosphorylation by CDK2 was essential for PR-B activation in the 
absence of ligand (Figure 3-17). To further determine the influence of CDK2 on PR-B 
transcriptional activity, a construct encoding an active CDK2 double mutant (CDK2-
TY), in which Thr14 and Tyr15 had been mutated to Ala and Phe respectively, was 
used to generate constitutively active CDK2. However, the activity of PR-B was not 
increased by CDK2-TY in the absence of MPA (Figure 3-18) even with increasing 
concentrations (Figure 3-19), suggesting that either CDK2 alone is not sufficient to 
induce PR-B activity or there might be some other factors blocking CDK2 function in 
vivo.  
The regulation of human PR transcriptional activity in a ligand-independent manner is 
rarely reported. Although there are 8 out 14 CDK2 phosphorylation sites on PR-B, 
only Ser400 site was characterized to be the target of ligand-independent PR-B 
activation in human breast cancer cells [261]. Since I have already determined that 
CDK2 was involved in the activation of unliganded PR-B by stretch, to identify 
whether Ser400 was also the target, either wild type (W) or mutant PR-B (S400A) 
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were transfected into USMCs along with PRE. As shown in Figure 3-20, Ser400 
mutant PR-B did not block the stretch-induced increase in PR-B activity, suggesting 
that Ser400 site was not the essential phosphorylation site in this context. 
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Figure 3-15 Stretch increases unliganded PR-B activity. 
USMCs were transiently co-transfected with a PRE, with or without progesterone receptor (PR-B). SG5 was used 
as control. One day after transfection, cells were either stretched or not for another 24 h before luciferase assay. 
Data are expressed as median, 25th and 75th percentiles and range and were analyzed using a Wilcoxon matched 
pairs test. *** indicates a significant difference of p<0.001 (n=19). 
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Figure 3-16 MAPK inhibitors have no effect on stretch-induced unliganded PR-B activation. 
USMCs were transiently co-transfected with PR-B and PRE. SG5 was empty expression vector used as control. 
Cells were pre-incubated with specific inhibitors of ERK, JNK and p38 respectively for 1 hour at 24 h post 
transfection and then stretch was performed for another 24 h before luciferase assay. Data are expressed as median, 
25th and 75th percentiles and range and were analyzed using a Wilcoxon matched pairs test. * indicates a 
significant difference of p<0.05 (n=5). 
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Figure 3-17 Stretch of USMCs results in an increase of unliganded PR-B activation mediated through 
CDK2. 
USMCs were transiently co-transfected with PR-B and PRE. SG5 was empty expression vector used as control. 
Cells were pre-incubated with CDK inhibitor or selective CDK2 inhibitor for 1 hour at 24 h post transfection and 
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then stretch was performed for another 24 h before luciferase assay. Data are expressed as median, 25th and 75th 
percentiles and range and were analyzed using a Wilcoxon matched pairs test. ** indicates a significant difference 
of p<0.01 (n=6). 
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Figure 3-18 Constitutively active CDK2 (CDK2-TY) does not increase unliganded PR-B activity. 
USMCs were transiently co-transfected with PR-B, PRE and mutant CDK2-TY. SG5 and pCS2 were empty 
expression vectors used as control. MPA was added 24 h post transfection and cells were incubated for another 24 
h before luciferase assay. Data are expressed as median, 25th and 75th percentiles and range and were analyzed 
using a Wilcoxon matched pairs test, (n=4). 
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Figure 3-19 Increasing dose of CDK2-TY has no effect on unliganded PR-B activity. 
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USMCs were transiently co-transfected with PR-B and PRE, along with increasing amounts of mutant CDK2-TY 
(0.5 μg, 1.0 μg, 1.5 μg). pCS2 were parental vector of CDK2-TY used as control (1.5μg) or filler so that the total 
amount of transfected DNA per well was constant. Cells were performed luciferase assay at 48 h post-transfection. 
Data are expressed as median, 25th and 75th percentiles and range and were analyzed using a Wilcoxon matched 
pairs test, (n=4). 
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Figure 3-20 Mutation of PR-B on Ser400 fails to block stretch-induced unliganded PR-B activation. 
USMCs were transiently co-transfected with either wild type (W) PR-B or mutant PR-Bs (S400A, S294A and 
S345A) and PRE. SG5 was empty expression vector used as control. Cells were incubated for 24 h after 
transfection and then stretch was performed for another 24 h before luciferase assay. Data are expressed as means 
± SD, n=2. 
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3.3. Summary and Discussion 
In this chapter, I investigated the relationship between progesterone action and 
mechanical stretch in USMCs and found that progesterone did not inhibit stretch-
induced MAPK activation or gene expression and that although stretch reduced PR 
expression in a NF-κB-dependent manner and increased unliganded PR-B-driven PRE 
activity, it did not appear to affect progesterone action. These results provide an 
explanation for the ineffectiveness of progesterone to prevent preterm labour in 
multiple pregnancy, but also suggest that uterine stretch is not responsible for the 
process of functional progesterone withdrawal seen with the onset of human labour.  
3.3.1. Progesterone does not affect stretch-induced ERK1/2 activation and 
gene expression 
Clinically, progesterone administration is the only way to reduce the preterm labour 
rates in singleton pregnancy but has no effect in multiple pregnancy [49, 51, 74]. This 
is consistent with our finding that MPA did not inhibit stretch-induced ERK1/2 
activation and labour-associated gene expression. To exclude the possibility that these 
data are due to the presence of a high basal level of endogenous progesterone activity 
masking the effect of exogenous progesterone, I treated the cells with RU486. 
However, no significant change was found in stretch-induced increases in gene 
expression. Rather than accentuating the effect of stretch, interestingly, the trend of 
the effect of RU486 was to reduce stretch-induced COX-2, IL-8, and OTR, which 
might be due to its partial agonist activity in the absence of ligand [333, 334]. In 
singleton pregnancy, the ability of progesterone to reduce the risk of preterm labour is 
at least partially due to its anti-inflammatory effect, best illustrated by its ability to 
block IL-1β-induced up-regulation in COX-2 mRNA expression by reducing NF-κB 
binding to the COX-2 promoter in hTERT myometrial cell line [290]. More recently, 
our group found that NF-κB can be activated by stretch in USMCs and inhibiting NF-
κB activation by blocking IKK represses the stretch-induced increase in COX-2 
mRNA and protein expression. Given that progesterone has been shown to inhibit IL-
1β-induced NF-κB activation and COX-2 expression [290, 335], it might have been 
expected a similar effect in the context of stretch. However, this effect is clearly not 
seen which suggests that progesterone does not impair stretch-induced gene 
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expression and the mechanisms involved in singleton and multiple pregnancies are 
different.  
3.3.2. Stretch does not affect progesterone action 
I then assessed whether stretch could alter progesterone action in terms of 
progesterone-regulated gene expression, liganded PR-B-driven PRE activity and the 
ability of progesterone to repress IL-1β-induced COX-2 mRNA expression and 
protein synthesis. Firstly, I identified some putative progesterone-responsive genes 
from the literature. However, none of them showed any consistent response to MPA 
in USMCs. I then detected some genes which were identified to be PR sensitive from 
a microarray study done by one of my colleague comparing PR knockdown group 
with control. Although this experiment was done in human USMCs, I found that of 
the four most strongly modulated genes by MPA only MMP10 expression was 
consistently regulated. These data indicate that PR and progesterone-regulated genes 
are different from each other despite some overlap. Simply silencing PR may have 
other effects, including the altering the availability of co-regulators or releasing 
transcription factors that may otherwise have been bound to PR. In my microarray 
study, I identified three genes which were highly modulated by MPA according to 
stringent statistical analysis. In completely independent experiments, two genes 
(FKBP5 and HSD11β1) were validated to be up-regulated by MPA. Finally, I used 
these three genes (FKBP5, HSD11β1, and MMP10) as candidates to assess the 
hypothesis that stretch alters the ability of progesterone to drive gene expression. The 
results demonstrated that mechanical stretch did not change the ability of MPA to 
induce the expression of FKBP5 and HSD11β1 or to repress the expression of 
MMP10.  
Similarly, when I used a luciferase reporter assay, I found that stretch did not alter the 
ability of liganded PR-B-driven PRE activation. Also stretch had no effect on the 
ability of MPA to repress IL-1β-driven COX-2 expression, which is primarily 
mediated through NF-κB [176]. All these data suggest that the genomic activity of 
progesterone is not affected by mechanical stretch; therefore, stretch may not be 
responsible for the progesterone functional withdrawal before the onset of human 
labour. However, it is known that progesterone can also maintain uterine quiescence 
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through a non-genomic mechanism where stretch might have a negative effect on 
progesterone action.  
Despite the fact that prolonged stretch increased COX-2 mRNA expression from the 
basal level, it had no further enhancement on the IL-1β-driven COX-2 mRNA 
expression. Interestingly, however, it enhanced the IL-1β-driven COX-2 protein 
synthesis, which might be mediated through more efficient post-transcriptional 
translation of COX-2 mRNA as has been recently described for COX-2 protein 
synthesis in cardiac muscle via a p38-dependent mechanism [336, 337].  
3.3.3. Stretch decreases PR-total mRNA expression and PR-B protein 
synthesis 
There are several putative mechanisms of progesterone functional withdrawal that 
have been proposed in the literature and the ratio change of different PR isoforms is 
one of them [338]. To support this hypothesis, Mesiano et al. found that both PR-A 
and PR-B mRNA expression increased in the samples obtained at the time of active 
labour compared with non-labouring myometrial samples, but that the increase in PR-
A was much greater, resulting in an increase in the ratio of PR-A/PR-B [249], 
although the primers for PR-B and the methodology of deriving the PR-A can be 
disputed, these data were supported by changes in protein levels of two PR isoforms 
[246, 319]. Condon et al. have also demonstrated that PR-B and PR-C mRNA 
expression increased, but that the increase in PR-C was relatively more marked [289]. 
Both studies implied that increases in the truncated PR-B isoforms would cause a 
functional withdrawal of progesterone action. In my work, I assessed the effects of 
stretch on PR mRNA expression and found that stretch-induced a decline in both PR-
B and PR-total (PR-A, -B, and -C) mRNA expression and these changes were 
reflected in a reduction in PR protein levels. The different pattern of change in PR 
mRNA and protein suggests that stretch is not responsible for the labour-induced 
changes proposed by both authors [249, 289]. Furthermore, I found that NF-κB 
mediated the stretch-induced changes in both PR-B and PR-total. Interestingly, basal 
PR-total mRNA expression decreased in the presence of MAPK inhibitors, whereas 
the MAPK activator, anisomycin, increased PR expression, suggesting that MAPK is 
involved in the up-regulation of basal PR expression. Previously, we showed that the 
up-regulation of labour-associated genes by stretch and IL-1β required both MAPK 
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and NF-κB activation [85], but my data suggest that they have opposing effects in the 
case of PR expression.  
3.3.4. Stretch increases PR-B activity in the absence of progesterone 
These data indicate a novel link between mechanical stretch and unliganded PR-B 
transcriptional activity in a cell cycle mediator-dependent fashion. Up to now, despite 
the increasing importance of the unliganded PR, there are very few studies of 
hormone-independent activation of human PR and its downstream targets. AP-1 
activity was first reported to be stimulated by unliganded PR in human endometrial 
adenocarcinoma cells while the addition of MPA impaired the unliganded PR-induced 
AP-1 activation [291]. More recently, a study by Carol Lange et al. not only 
demonstrated that the activation of CDK2 can increase PR-B transcriptional activity 
by phosphorylation, but also identified that phosphorylation of the serine 400 site 
mediated this effect. Interestingly, they found that two out of three cell lines displayed 
a CDK2-induced increased in PR-B activity. However, the last cell line showed 
completely no response to increasing concentrations of constitutively active CDK2. 
This cell line expresses a high level of p27 (a natural CDK inhibitor), which 
physically interacts with cyclin A/CDK2 [339]. This might explain the failure of 
constitutively active CDK2 to increase PR-B activity. My study indicates that 
mechanical stretch can induce PR-B activation through CDK2-driven PR 
phosphorylation in USMCs. However, overexpression of CDK2 failed to elevate the 
PR-B transcriptional activity even with increasing concentrations, suggesting that 
USMCs might also express relatively high basal levels of CDK inhibitors, such as p27 
and p21. In this case, stretch might induce a decline in p27 and/or p21, which may 
then liberate CKD2 to activate unliganded PR-B. Additionally, a PR-B construct with 
a mutation at Serine 400 site showed similar effects as wild-type PR-B, indicating that 
the PR-B serine 400 site is not a key point in this stretch-induced PR-B activation. 
This suggests that the ability of CDK2 to increase PR activity may occur at other PR-
B phosphorylation sites or may even be independent of PR-B phosphorylation, for 
example mediated through a PR co-activator SRC-1, alternatively, linker histones 
have also been reported to be the targets of CDK2 [259, 267, 340-342]. 
To conclude, these data show that progesterone does not inhibit stretch-induced 
changes in intracellular signalling and gene expression and that stretch does not affect 
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the ability of progesterone to regulate gene expression, to bind to its response element, 
or to repress IL-1β-induced gene expression, although stretch does reduce PR 
expression and induce unliganded PR-B activation. These results may help us 
understand clinically why progesterone is ineffective in the prevention of stretch-
induced preterm labour but also suggest that stretch is probably not responsible for the 
functional progesterone withdrawal seen with the onset of human labour. 
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Chapter Four: Glucocorticoid Receptor is A Key 
Player that Mediates Progesterone Action 
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4. Glucocorticoid Receptor is a Key Player that Mediates 
Progesterone Action 
4.1. Introduction 
Progesterone is widely used in several different formulations to reduce the risk of 
preterm labour in high-risk singleton pregnancies [48, 343, 344]. However, the 
mechanisms underpinning this effect are unclear. The precipitous fall in systemic 
progesterone levels that occurs before the onset of labour in virtually all non-primates 
does not occur in the human. Nevertheless, the seminal work of Csapo [317], who 
showed that progesterone was essential for the maintenance of early pregnancy, and 
the observation of Frydman et al, that mifepristone, the progesterone antagonist, can 
be used to induce labour [316], suggest that progesterone does play an important role 
in the maintenance of pregnancy in the human too. Animal studies suggest that 
progesterone acts predominantly to allow the uterus to tolerate stretch; in its absence 
uterine distension (with a pregnancy or artificially) up-regulates the expression of 
prolabour factors such as oxytocin receptor [59] and connexin-43 [58], stimulating the 
onset of labour. Progesterone does not seem to have a similar role in the human since 
randomised studies of progesterone administration in multiple pregnancies failed to 
show any prolongation of pregnancy [49, 74] and in vitro studies failed to show any 
effects on stretch-induced gene expression [279]. This suggests that in the human 
progesterone acts through different pathways to delay the onset of labour.  
A mutual repression is thought to exist between NF-κB and PR in reproductive 
tissues, which determines the timing of the onset of labour [13]. Initial work by 
Kalkhoven et al reported that the trans-repression between PR and NF-κB occurred 
independently of PR isoform, reporter construct or cell type and, since PR and RelA 
interacted in vitro, suggested that the mutual repression was due to a direct interaction 
between the proteins [288]. This work was performed in Hela, Cos and the human 
breast cancer, T47D, cell lines, with overexpression of PR-B, PR-A and RelA and 
using PRE, MMTV and NF-κB reporter constructs [288]. Later studies by our group, 
in amnion cells, showed that IL-1β was able to repress progesterone-activation of a 
PRE and that overexpression of PR repressed the activity of an NF-κB reporter 
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construct [176]. More recently Mendelson’s group using immortalized human fundal 
myometrial cells found that progesterone suppressed the IL-1β-induced expression of 
COX-2 mRNA, and that this effect was blocked by RU486 [290]. Using chromatin 
immunoprecipitation, they showed that the IL-1β-induced an increase in p65 binding 
to both proximal and distal NF-κB binding elements of the COX-2 promoter was 
reduced by progesterone [290]. They also found that progesterone induced the 
expression of IκB, which binds to p65 in the cytoplasm, and concluded that this was 
the mechanism likely to be responsible for progesterone repression of IL-1β activity 
[290]. These and our earlier data are weakened by the use of overexpression of PR 
and/or p65 and by the use of cell lines, making it uncertain whether these data can be 
extrapolated to the in vivo situation. Consequently, uncertainty remains as to the true 
nature of the relationship between progesterone, its receptors and NF-κB. 
In this chapter, I have re-examined the evidence in support of the existence of a 
mutual repression between PR and NF-κB and investigated potential alternative 
explanations for the inhibition of inflammatory cytokine-driven COX-2 expression by 
progesterone. Key differences in this work in comparison to previous work is the use 
of progesterone and NF-κB-responsive genes to assess the degree of mutual 
repression and TF:TF arrays, complimented by knockdown studies as well as studies 
using reporter constructs and the overexpression of PR and NF-κB. 
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4.2. Results 
4.2.1. The mutual repression of NF-κB and progesterone receptor activity 
4.2.1.1. IL-1β represses progesterone action via NF-κB 
Firstly, the concentration of MPA and progesterone (P4) was optimized and 1 µM of 
MPA and 10 µM of P4 were chosen in my following experiments (Figure 4-1). Using 
primary USMCs transfected with a PRE, the overexpression of PR-B in the presence 
of MPA increased PRE activation and this was repressed by IL-1β (p<0.05; Figure 
4-2, A). Overexpression of p65 alone repressed MPA/PR-B-driven PRE activity and 
this effect was more marked in the presence of IL-1β (both p<0.05; Figure 4-2, A). 
Knockdown of p65 inhibited the ability of IL-1β to repress MPA/PR-B activation of 
the PRE (Figure 4-2, B). This repression was evident in the similar increase seen in 
FKBP5 mRNA expression in response to MPA and P4 in IL-1β treated cells (Figure 
4-2, C). 
 
Figure 4-1 The opitimizition of the concentration of MPA and P4. 
USMCs were exposed to different stimuli, IL-1β (5 ng/µl), MPA (1 µM, 10 µM and 100 µM) and P4 (1 µM, 10 
µM and 100 µM), either alone or in combination. mRNA was then extracted, and the COX-2 mRNA levels were 
measured using qPCR. Data are expressed as mean ± SEM (n=3). 
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Figure 4-2 IL-1β represses MPa and P4 action via NF-κB.  
A, USMCs were transiently co-transfected with a progesterone response element (PRE), with or without 
progesterone receptor B (PR-B) and p65. SG5 was used as control. MPA and IL-1β were added 24 h after 
transfection and the cells were incubated for another 24 h before luciferase assay. B, USMCs were transfected with 
either siRNA for p65 (sip65) or a non-targeting siRNA (siNT) as control. After 72 h, cells were co-transfected with 
PR-B and PRE. MPA and IL-1β were added at day 4 post-transfection and cells were then incubated for another 24 
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h before luciferase assay. C, USMCs were exposed to different stimuli, IL-1β, MPA and P4, either alone or in 
combination. mRNA was then extracted, and the FKBP5 mRNA levels were measured using qPCR. Data are 
expressed as median, 25th and 75th percentiles and range, and were analysed using Wilcoxon matched pairs test. * 
indicates a significant difference of p<0.05, **, of P<0.01, and ***, of P<0.001; NS indicates no statistic 
significant difference (n=6-12). 
4.2.1.2. PR-B inhibits NF-κB activity 
Conversely, overexpression of PR-B alone inhibited p65-driven activation of an NF-
κB reporter construct (p<0.01) and this effect was enhanced by MPA (p<0.01; Figure 
4-3, A). Similarly, MPA and P4 repressed IL-1β-driven COX-2 mRNA expression 
(Figure 4-4, C-E). The mutual repression was possibly explained by the ability of PR-
B and p65 to bind to each other as shown by the immunoprecipitation of C-terminal 
Halo-tagged PR-B and Strep-tagged p65 (Figure 4-3, B) and the increased binding of 
activated p65 to PR-B in IL-1β-stimulated cells in a TF:TF array (Figure 4-3, C). 
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Figure 4-3 PR-B inhibits NF-κB activity.  
A, USMCs were transiently co-transfected with a NF-κB luciferase construct (NF-κB-Luc) and p65, with or 
without PR-B. SG5 was used as control. MPA were added 24 h after transfection and the cells were incubated for 
another 24 h before luciferase assay. Data are expressed as median, 25th and 75th percentiles and range, and were 
analysed using paired t test. * indicates a significant difference of p<0.05 and **, of P<0.01 (n=6). B, Strep-tagged 
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p65 (Strep-p65) and Halo-tagged PR-A (with Halo tag linked on the C terminus, HcA) or PR-B (with Halo tag 
linked on the N terminus, HnB; with Halo tag linked on the C terminus, HcB) were transfected into USMCs as 
indicated. Parental halo-tag construct (HT2) was used as control. Cell lysates were then immunoprecipitated using 
anti-Strep antibody. The immunoprecipitates were examined by Western blotting using anti-Halo antibody. Input 
represented 10% of cell lysates used in the co-IP experiment. C, TF:TF array. The nuclear extracts were isolated 
from USMCs that were untreated and treated with IL-1β for 6 h. Each transcription factor (TF) is represented in 
four spots on the blot in a 2*2 grouping of two rows and two columns. The first row consists of DNA spotted 
normally, and the second row consists of DNA diluted 1:10. Array analysis of TFs binding to p65 in IL-1β 
simulated USMCs was carried out using a Panomics TransSignal TF-TF array system. Both the left and right panel 
show hybridization signals of TFs binding to p65 using anti-p65 antibody, and normal IgG was used as control. 
The table show the identities of TFs in the array that bind to p65 after treatment. The most prominent NF-κB 
binding TFs detected in the array are underlined. The TF:TF array was done by Shirin Khanjani. 
4.2.1.3. Effect of PR modulation on progesterone inhibition of IL-1β-driven 
COX-2 expression 
Neither overexpressed PR-B or PR-A enhanced the ability of MPA to repress IL-1β-
driven COX-2 mRNA expression (Figure 4-4, A and B). The progesterone antagonist, 
Org31710, also failed to block this effect, whereas RU486, which inhibits both P4 and 
glucocorticoid activity, was able to reverse the MPA and P4 inhibition of IL-1β-
driven COX-2 mRNA expression (Figure 4-4, C). Similarly when PR and AR were 
silenced, it had no effect on either MPA or P4 inhibition of IL-1β, only GR 
knockdown reversed their ability to block IL-1β-driven COX-2 mRNA expression 
(Figure 4-4, D). To exclude the possibility that the action of P4 was mediated though 
increased HSD11β1 expression and the consequent increased conversion of cortisone 
to cortisol, the knockdown of HSD11β1 was performed, but again this had no effect 
on MPA/P4 inhibition of IL-1β activity (Figure 4-4, E). I then confirmed that 
glucocorticoid (dexamethasone, Dex) acted exclusively via GR but not PR to repress 
IL-1β-driven COX-2 expression (Figure 4-4, F).  
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Figure 4-4 The effect of PR modulation on P4 inhibition of IL-1β-driven COX-2 expression.  
A and B, USMCs were transfected with PR-B or PR-A. SG5 was used as control. MPA and IL-1β, either alone or 
in combination were added 48 h after transfection and the cells were incubated for another 6 h. mRNA was then 
extracted, and the COX-2 mRNA levels were measured using qPCR. Data are expressed as median, 25th and 75th 
percentiles and range, and were analysed using Wilcoxon matched pairs test. * indicates a significant difference of 
p<0.05 and **, of P<0.01; NS indicates no statistic significant difference (n=6). C, USMCs were pre-incubated 
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with Org31710 (1 μM) or RU486 (1 μM) for 2 h before being exposed to different stimuli, IL-1β, MPA and P4, 
either alone or in combination. mRNA was then extracted, and the COX-2 mRNA levels were measured using 
qPCR. Data are expressed as median, 25th and 75th percentiles and range, and were analysed using paired t test. * 
indicates a significant difference of p<0.05; NS indicates no statistic significant difference (n=6). D, USMCs were 
transfected with different siRNAs against PR (siPR), GR (siGR) and AR (siAR), respectively. Non-targeting 
siRNA (siNT) was used as control. After transfection, cells were incubated for 96 h before being exposed to 
different stimuli, IL-1β, MPA and P4, either alone or in combination. mRNA was then extracted, and the COX-2 
mRNA levels were measured using qPCR. Data are expressed as median, 25th and 75th percentiles and range, and 
were analysed using paired t test. ** indicates a significant difference of p<0.01 and ***, of P<0.001; NS indicates 
no statistic significant difference (n=6). E, USMCs were transfected with siRNA against HSD11β1 (siHSD11β1). 
siNT was used as control. After transfection, cells were incubated for 96 h before being exposed to different 
stimuli, IL-1β, MPA, P4 and Dex, either alone or in combination. mRNA was then extracted, and the COX-2 
mRNA levels were measured using qPCR. Data are expressed as mean ± SEM (n=3). F, USMCs were transfected 
with different siRNAs against PR and GR. siNT was used as control. After transfection, cells were incubated for 
96 h before being exposed to different stimuli, IL-1β and Dex, either alone or in combination. mRNA was then 
extracted, and the COX-2 mRNA levels were measured using qPCR. Data are expressed as median, 25th and 75th 
percentiles and range, and were analysed using Wilcoxon matched pairs test. * indicates a significant difference of 
p<0.05 and # of P<0.05 between samples exposed to both IL-1β and Dex with or without GR knockdown (n=6). 
4.2.2. P4 acts via both PR and GR to drive gene expression 
P4 increased FKBP5 mRNA expression via a combination of PR and GR, but the 
increase of HSD11β1 mRNA is via PR alone (Figure 4-5, A and B). In contrast, MPA 
acted via GR exclusively to increase both FKBP5 and HSD11β1 mRNA (Figure 4-5, 
C and D). 
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Figure 4-5 The effect of PR modulation on P4-responsive genes expression.  
A-D, USMCs were transfected with different siRNAs against PR (siPR), GR (siGR) and AR (siAR), respectively. 
Non-targeting siRNA (siNT) was used as control. After transfection, cells were incubated for 96 h before being 
exposed to MPA or P4. mRNA was then extracted, and the mRNA levels of FKBP5 and HSD11β1 were measured 
using qPCR. Data are expressed as median, 25th and 75th percentiles and range, and were analysed using Wilcoxon 
matched pairs test. * indicates a significant difference of p<0.05, **, of P<0.01, and ***, of P<0.001 (n=6-12). 
4.2.3. The mechanism of P4 and MPA actions on IL-1β inhibition 
It was confirmed that GR could bind p65 in USMCs using immunoprecipitation 
(Figure 4-6, A). To assess whether activation of GR and p65 mutually changed their 
nuclear translocation, nuclear and cytosolic protein were extracted and showed that 
neither MPA nor P4 repressed IL-1β-induced p65 phosphorylation and nuclear 
translocation and similarly, nor did IL-1β repress MPA/P4 induced nuclear 
translocation of GR (Figure 4-6, B and C).  
I then assessed whether MPA/P4 altered p65 binding to both proximal and distal NF-
κB binding elements of the COX-2 promoter and no change was found, however, GR 
knockdown enhanced p65 binding to both elements (Figure 4-6, D), but this was not 
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associated with an increase in COX-2 mRNA expression (Figure 4-4, D). HDAC 
inhibitors have been shown to partially reverse glucocorticoid inhibition of IL-1β-
induced expression of GM-CSF [309], however, TSA did not change the MPA 
inhibition of IL-1β-driven COX-2 expression and actually tended to enhance the 
effect of P4 (Figure 4-6, E). The ability of GR to inhibit LPS-induced COX-2 
expression was found to be associated with increased GR/GRIP-1 recruitment to the 
p65 DNA complex and increased MKP-1 activity, which reduced AP-1 activity [308]. 
Therefore, to address the importance of GRIP-1 in this context, GRIP-1 knockdown 
was carried out in USMCs, but the result showed that this did not alter the MPA/P4 
inhibition of IL-1β-driven COX-2 expression (Figure 4-6, F). However, when the 
MKP-1 activity was inhibited, the ability of MPA/P4 to inhibit IL-1β activity was 
significantly reduced (Figure 4-6, G); interestingly, both P4 and MPA increased 
MKP-1 expression, which was mediated by GR (Figure 4-6, H). 
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Figure 4-6 The mechanism of action of P4 and MPA on IL-1β inhibition.  
A, In vivo co-IP experiment was carried out in USMCs cells. Cell lysates from cells treated with or without IL-1β 
and MPA for 30 min, 1 h, and 2 h, respectively, were incubated with anti-GR antibody. For Western blotting of 
immunoprecipitates, anti-p65 antibody was used. Input represented 10% of cell lysates used in the co-IP 
experiment. B and C, USMCs were exposed to different stimuli, IL-1β, MPA or P4, either alone or in combination 
for 0 min, 30 min, 1 h, 2 h and 6 h. Cytosolic and nuclear extracts were prepared as described in the Materials and 
Methods and analysed by Western blotting using antibodies directed against total p65, phosphor-p65 (Ser536) and 
GR. TATA-bind protein (TBP) and α-tubulin were used as the internal controls for cytosolic and nuclear fraction, 
respectively. D, USMCs were transfected with siGR. siNT was used as control. After transfection, cells were 
incubated for 96 h before being exposed to different stimuli, IL-1β, MPA and P4, either alone or in combination 
for 1 h. The cells were then treated with 1% formaldehyde to cross-link chromatin, which was sonicated and 
immunoprecipitated using anti-p65 antibody. DNA was isolated and two NF-κB binding sites were measured by 
qPCR. Data are expressed as mean ± SEM (n=3). E, USMCs were pre-incubated with Trichostatin A (TSA, 0.5 
μM) for 1 h before being exposed to different stimuli, IL-1β, MPA and P4, either alone or in combination. mRNA 
was then extracted, and the COX-2 mRNA levels were measured using qPCR. Data are expressed as median, 25th 
and 75th percentiles and range, and were analysed using paired t test. * indicates a significant difference of p<0.05 
and **, of P<0.05; #, of p<0.05 vs. baseline (n=6). F, USMCs were transfected with siRNA against GRIP-1 
(siGRIP-1). siNT was used as control. After transfection, cells were incubated for 96 h before being exposed to 
different stimuli, IL-1β, MPA and P4, either alone or in combination. mRNA was then extracted, and the COX-2 
mRNA levels were measured using qPCR. Data are expressed as median, 25th and 75th percentiles and range, and 
were analysed using paired t test. * indicates a significant difference of p<0.05 and **, of P<0.01 (n=6). G, 
USMCs were pre-incubated with sanguinarine (Sang, 0.5 μM) for 30 min before being exposed to different stimuli, 
IL-1β, MPA and P4, either alone or in combination. mRNA was then extracted, and the COX-2 mRNA levels were 
measured using qPCR. Data are expressed as median, 25th and 75th percentiles and range, and were analysed using 
paired t test. ** indicates a significant difference of p<0.01 and ***, of P<0.001; #, of p<0.05 and ##, of p<0.01 
between samples exposed to the same stimuli but with or without Sang (n=6). H, USMCs were transfected with 
siPR or siGR. Non-targeting siRNA (siNT) was used as control. After transfection, cells were incubated for 96 h 
before being exposed to MPA or P4. mRNA was then extracted, and the MKP-1 mRNA levels were measured 
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using qPCR. Data are expressed as median, 25th and 75th percentiles and range, and were analysed using paired t 
test. ** indicates a significant difference of p<0.01 and ***, of P<0.001; ##, of p<0.01 and ###, of P<0.001 vs. 
baseline (n=12). 
 
Figure 4-7 A schematic diagram of the inhibitory effect of P4 on IL-1β-driven COX-2 expression in USMCs. 
Progesterone inhibits IL-1β-induced COX-2 expression via GR-mediated MKP-1 activation, whereas the 
phosphorylation, nuclear translocation and DNA binding activity of p65, the HDAC activation and the recruitment 
of GRIP-1 on GR-p65 protein complex are not involved. 
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4.3. Summary and Discussion 
These data suggest that P4 inhibition of IL-1-driven COX-2 expression in USMC is 
independent of any inhibition of p65 activity, but rather is mediated via a GR-induced 
activation of MKP-1. However, the ability of IL-1 to inhibit MPA/PR-B-driven PRE 
activation and gene expression is probably mediated through an inhibition of PR 
action by p65. 
In the first study to identify a mutual inhibition between PR and NF-κB, Kalkhoven et 
al found that this effect was independent of PR isoform, reporter construct, or cell 
type used and demonstrated a direct interaction between PR and p65 in vitro [288]. In 
addition, they found that TNFα treatment repressed PR activity, and that conversely 
PR repressed TNFα-induced NF-κB activation [288]. These findings were replicated 
in primary amnion cells [176] and in my current study, a similar response was found 
in primary USMCs and the effect of IL-1β on PR-B activity was mediated via p65. 
The interaction of p65 and PR-B was also confirmed by immunoprecipitation with 
over expressed Halo-tagged PR-B, but p65 did not bind to Halo-tagged PR-A. It was 
also shown that activated p65 bound to PR in non-transfected primary USMCs, 
indicating that this interaction occurs endogenously. These data were consistent with 
the mutual inhibition identified by Kalkhoven et al [288] and consequently, I expected 
that the increased PR-B levels by transient transfection might lead to an enhanced 
inhibition of IL-1β-driven COX-2 expression. However, overexpression of PR-B (or 
of PR-A) had no effect on either P4 or MPA inhibition of IL-1β activity. Then I used 
the specific P4 antagonist Org31710 to block the effects of P4, but this agent had no 
effect, in contrast to the PR/GR antagonist RU486, which reduced the inhibitory 
effect of both MPA and P4. Org31710 has a similar affinity for PR as RU486, but a 
30-fold lower affinity for GR [345], suggesting that neither P4 nor MPA were acting 
via PR, rather the effect of RU486 suggested that their actions were mediated via GR. 
Indeed, the knockdown study confirmed that both P4 and MPA were acting via GR. 
Since it has been previously observed that progesterone enhanced the expression of 
HSD11β1 in USMCs [279], it was possible that P4’s GR dependency was mediated 
via enhanced expression of HSD11β1 and the consequent increased conversion of 
cortisone to cortisol. However, knockdown of HSD11β1 had no effect on the ability 
of P4 or MPA to repress IL-1β-induced COX-2 expression, making it more likely that 
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P4 and MPA are acting directly via GR to mediate their effects on IL-1β-driven COX-
2 expression. Indeed, P4 has been suggested to act via GR to inhibit placental CRH 
synthesis [231] and 20α-hydroxysteroid dehydrogenase expression in the rat corpus 
luteum [346] and to down-regulate the TLR4-mediated activation of macrophages 
[347]. However, the evidence in these papers was based on the absence of detectable 
PR and the ability of RU486 to block the P4 effects [231, 346] and the inability of a 
specific PR agonist to down-regulate TLR4 actions [347]. In contrast, my results from 
the antagonist study are supported by knockdown of PR and GR, which proved that 
P4 acted via GR to inhibit IL-1β-driven COX-2 expression. It also showed that P4 
acted via both PR and GR to up-regulate FKBP5 and only via PR to up-regulate 
HSD11β1 mRNA expression in USMCs, whereas the effects of MPA were mediated 
exclusively via GR. 
Activated GR has been shown to inhibit NF-κB activity through a variety of 
mechanisms including delaying the nuclear translocation of activated p65 [304], 
HDAC activation [309], the incorporation of GR and GRIP-1 into the transcriptional 
complex [308] and the inhibition of MKP-1 activation [308, 348, 349]. Interestingly, 
although GR was confirmed to interact with p65 in USMCs, there was relatively little 
delay in the nuclear translocation of either of them, suggesting that this does not 
account either for the P4/GR repression of IL-1β activity or the p65 repression of GR 
action in USMCs. The IL-1β-induced p65 binding to COX-2 promoter was also 
unaffected by P4.  
HDAC inhibitors in their own right have been shown to be potent anti-inflammatory 
agents, inhibiting both LPS-induced TNFα expression and TNFα-induced expression 
of inflammatory genes [350]. The anti-inflammatory effects of glucocorticoid have 
been related to GR-regulated inhibition of histone acetylation by repressing CBP-
associated HAT activity and also by recruiting HDAC2 to the p65-CBP HAT 
complex [309].  However, I found that HDAC inhibition did not alter the ability of 
MPA and tended to enhance the ability of P4 to inhibit IL-1β suggesting that P4/GR 
repression of IL-1β is not mediated via HDAC activation in USMCs. These 
observations are consistent with those of Condon et al, who found that histone 
acetylation decreased in myometrial samples with advancing gestation in the mouse 
and human and that the administration of the HDAC inhibitor, TSA, prolonged mouse 
gestation [351]. 
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GRIP-1 can function as both a co-repressor and a co-activator by binding to nuclear 
receptors. In a recent paper, GR bound GRIP-1 was recruited to the p65 DNA 
complex and repressed the LPS-induced COX-2 expression, confirmed by the fact 
that GRIP1 knockdown reduced the glucocorticoid inhibition of LPS-induced COX-2 
expression [308]. However, the knockdown of GRIP1 had no effect on P4/GR 
inhibition of IL-1β activity in my study. Finally, since GR has been shown to act via 
MKP-1 to repress AP-1 activity in a variety of tissues [308, 348, 349], I inhibited 
MKP-1 activity and found that the ability of P4/GR to repress IL-1β activity was 
attenuated, suggesting that this maybe the mechanism through which P4 inhibits IL-
1-induced COX-2 expression in USMCs.  
These data show that while p65 does repress PR activity, P4 acts via GR-induced 
MKP-1 activation to repress p65 induced gene expression. Thus, only half of the 
proposed mutual inhibition between PR and NF-κB appears to be active in USMCs. 
Nevertheless, the ability of NF-κB to repress PR may be sufficient to explain the 
withdrawal of P4 action with the onset of human labour. 
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Chapter Five: Gene Networks and Cellular Functions 
that Regulated by Progesterone and Glucocorticoid 
Receptors in USMCs 
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5. Gene networks and cellular functions that regulated 
by progesterone and glucocorticoid Receptors in 
USMCs 
5.1. Introduction 
The progesterone receptor, glucocorticoid receptor, androgen receptor, and 
mineralocorticoid receptor are classic type I receptors in nuclear receptor superfamily. 
They are structurally conserved, ligand-dependent intracellular transcription factors, 
regulating the transcription of target genes upon ligand binding [352, 353]. 
Physiologically, they play crucial roles in a variety of fundamental biological 
processes such as metabolism, immune function, development, homeostasis, and 
reproduction. As the ligands of these steroid receptors, progesterone, glucocorticoid, 
androgen, and mineralocorticoid can freely across the plasma membrane without the 
help from membrane receptors due to their lipophilic nature [302]. The classic 
genomic mechanism of these steroid receptors to regulate gene expression has already 
been characterized [255]. Upon binding to their hormonal ligand, the receptors release 
chaperone proteins, such as heat shock proteins and immunophilins, translocate from 
the cytoplasm into the nucleus, directly regulate their responsive gene by contacting 
promoters/enhancers at sequence-specific DNA response elements. However, there is 
growing evidence that steroid receptors can also regulate gene expression via protein-
protein interactions with other transcription factor such as NF-κB (through interaction 
with p65 subunit), AP-1 (fos/jun), C/EBPβ, and Stat5 [288, 291, 292, 354, 355]. Both 
mechanisms require ligand activation and exchange of chaperone proteins and co-
regulators [356-360].  
Inflammation plays a central role in many human diseases. Several nuclear receptors 
have been found as key regulators in response to inflammatory processes. Human 
parturition resembles an inflammatory reaction, where progesterone and progesterone 
receptors have already been demonstrated to suppress contraction-associated gene 
expression [232]. In my study, GR also showed the ability to mediate progesterone’s 
anti-inflammatory effect. In fact, there are many similarities between PR and GR in 
hormone-regulated events. For instance, both of them recognize the same DNA 
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binding sequence; they rely on HATs and several common co-regulators for its 
activity [361-363]. Despite these similarities, clear differences have been observed in 
their binding to the HRE region of MMTV promoter [364], suggesting that the DNA 
binding of these two receptors not only depends on the specific DNA sequence, but is 
also influenced by other factors such as sets of co-regulators, chromatin state, cell 
type-specific transcription factors, and signaling pathways [365, 366]. Their functions, 
biologic activities, structural properties, and ligands are summarized in Table 5-1 and 
Table 5-2, respectively. 
Table 5-1 Summary of the functions, biologic activities, structural properties, and ligands for PR. 
Receptor nomenclature NR3C3 
Other names PGR, progesterone receptor 
Molecular information Hs: 933aa, P06401;  
Rn: 923aa, Q63449;  
Mm: 923aa, Q00175. 
DNA binding Homodimer;  
HRE core sequence: GGTACANNNTGTTCT 
Partners HSP90: cellular localization; 
HMGB: DNA binding; 
Src family kinases: activation of rapid signalling cascades, independent of PR DNA binding. 
Agonists Progesterone (P4), Levonorgestrel, medroxyprogesterone, promegestone (R5020), dydrogesterone, 
norethisterone 
Antagonists Asoprisnil, mifepristone (RU486), Org31710 
Biologically important isoform PR-A (Hs, Mm, Rn): N-terminally truncated isoform that is a weak transcriptional activator of specific 
target genes in a cell type-dependent manner and a strong repressor of transactivation by PR-B and other 
steroid receptors; 
PRB (Hs): full-length protein that strongly activates target genes. 
Tissue distribution Mammary gland, uterus, brain, muscle, testis, ovary (Hs, Mm, Rn) 
Functional assay Inhibition of proliferation in endometrial cells caused by treatment of ovariectomized (estrogen-treated) 
mice with progesterone (Mm);  
Proliferation in PR-positive breast cancer cells and normal breast epithelial cells (Hs);  
Mammary gland ductal tree branching and lobuloalveolar development in ovariectomized (estrogen-
treated) mice treated with progesterone (Mm). 
Main target genes Activated: FSHβ, multidrug resistance 1B (Mm), Stat5A (Hs), 11β-hydroxysteroid dehydrogenase (Hs), 
Indian hedgehog (Mm) 
Mutant phenotype Disruption of both PR-A and PR-B isoforms results in impaired sexual behavior, anovulation, uterine 
dysfunction, and reduced ductal branching and lobuloalveolar development in the mammary gland (Mm) 
[knockout];  
Targeted overexpression of PR-A in the mammary gland results in reduced induction of apoptosis (Mm) 
[overexpression]. 
Human disease Pseudocorpus luteum insufficiency: due to decreased PR expression;  
Breast cancer: higher PR-A/PR-B ratio correlates with increased tumor grade;  
Endometriosis: due to reduced expression of PR-B (not PR-A) in diseased tissue;  
Endometrial cancer: increased risk caused by polymorphisms in the PR promoter favoring expression of 
PR-B. 
Adapted from Challis Lu, N.Z., et al., Pharmacol Rev, 2006. 58(4): p. 782-97 [367]. 
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Table 5-2 Summary of the functions, biologic activities, structural properties, and ligands for GR. 
Receptor nomenclature NR3C1 
Other names PGR, progesterone receptor 
Molecular information Hs: 777aa, P04150;  
Rn: 795aa, P06536;  
Mm: 783aa, P06537. 
DNA binding Homodimer;  
HRE core sequence: GGTACANNNTGTTCT 
Partners HSP90: cellular localization; 
HMGB: DNA binding; 
AP-1, NF-κB: transactivation; 
14-3-3ζ: cellular localization, transactivation. 
Agonists Dexamethasone, triamcinolone acetonide, prednisolone, triamcinolone, cortisol, corticosterone 
Antagonists RU-486 
Biologically important isoform GRα (Hs, Mm, Rn): main isoform1;  
GRβ (Hs): widely expressed alternative splicing variant lacking ligand binding, associated with several 
diseases; 
GR-A, B, C, D (Hs, Mm, Rn): alternative translation initiation isoforms with distinct transcriptional 
activities and tissue distribution patterns. 
Tissue distribution Ubiquitous (Hs, Mm, Rn) 
Functional assay Suppression of endogenous cortisol level by exogenous dexamethasone (Hs);  
Apoptosis of thymocytes in the thymus (Rn);  
Elevated blood glucose level by intravenous injection of glucocorticoids (Hs). 
Main target genes Activated: MKP-1 (Mm), lipocortin-1 (Hs);  
Repressed: IL-8 (Hs), TNF-α (Hs). 
Mutant phenotype GR-/- mice die within hours because of respiratory failure. They have atelectatic lungs, impaired liver 
function, impaired HPA axis, increased plasma levels of ACTH and corticosterone and enlarged adrenal 
glands that produce no adrenaline (Mm) [knockout]; 
Mice expressing type II GR antisense RNA exhibit impaired T-cell function, disrupted HPA axis, 
increased plasma levels of ACTH and corticosterone, reduced GR binding, and alterations in thymocyte 
migration (Mm) [antisense oligonucleotide]. 
Human disease Glucocorticoid resistance: due to various SNPs;  
Glucocorticoid hypersensitivity: due to an N363 polymorphism;  
Asthma and acute childhood lymphoblastic leukemia: due to a receptor mutation. 
Adapted from Challis Lu, N.Z., et al., Pharmacol Rev, 2006. 58(4): p. 782-97 [367]. 
Results from the last chapter indicate that the progesterone actions, including 
progesterone-induced gene expression and progesterone’s anti-inflammatory effect, 
are mediated by PR, GR or both. Consequently, I performed microarray studies in 
USMCs to identify more genes that are regulated by P4/MPA through PR and/or GR 
and that are simply regulated by PR or GR, whereby it is possible to gain a broader 
view and help us understand the role of PR and GR in human parturition.  
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5.2. Results 
5.2.1. Samples preparation 
Six term non-labouring human myometrium biopsies were collected at the time of 
caesarean section. Cells were cultured and transfected with siRNA as described in the 
Materials and Methods. Four days after transfection, cells were exposed to different 
stimuli (Table 5-3) for 6 h, and then total RNA and protein were extracted from each 
culture. The concentration and purity of RNA were determined by value of 
OD260:280. The effectiveness and selectiveness of PR and GR knockdown were 
assessed by western blot (Figure 5-1). Three samples (B, D, and F) were chosen as 
representatives for Affymetrix Human Genome U133 plus 2.0 Array. Among them, 
Sample D has the lowest endogenous PR level, whereas their GR levels are similar. 
Table 5-3 Experiment design for microarray analysis. 
7. siNT (vehicle) 9. siNT (MPA) 10. siNT (P4) 
13. siPR (vehicle) 15. siPR (MPA) 16. siPR (P4) 
19. siGR (vehicle) 21. siGR (MPA) 22. siGR (P4) 
 
 
Figure 5-1 Western blot analysis of PR and GR knockdown. 
USMCs were isolated from myometrium of non-labouring women. PR and GR were knocked down using siRNA 
before being exposed to MPA, P4 or vehicle. Protein was extracted and the western blotting performed as 
described in Materials and Methods. siNT, non-target siRNA; siNR, siRNA for PR (upper panel) and GR (middle 
panel); A-F, the sample ID (n=6). 
5.2.2. Analysis methods and gene lists 
After general array Quality Control (QC) and data export, the data were normalized 
using Robust Multichip Average (RMA) and imported into Partek. Array data were 
then checked for any outliers and overall grouping/separation using Principal 
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Component Analysis (PCA). The PCA was plotted (Figure 5-2) depending on cell 
samples (B, D, and F) and also for the 9 different conditions (these are described as 7, 
9, 10, 13, 15, 16, 19, 21, and 22). The plot shows that the Sample D is differentiating 
from the other two groups, which is also distinct according to the endogenous PR 
level (Figure 5-1). But at this stage there was no real outlier that I could exclude from 
further analysis. 
At the gene level, exon data were summarized by mean value to obtain one expression 
value per gene. This data were then analyzed using the ANOVA statistical model to 
determine significance in gene expression for each gene between control and test 
groups. Figure 5-3 shows that signal intensity across the samples is comparable and 
there is no outlier in this plot. Figure 5-4 shows that the majority of variation in this 
experiment cannot be attributed to external error but is inherent within the samples, 
therefore, the variation observed in groups is more likely to be real (dependents on the 
p value). However, majority of the variation in this comes from the attribute (cell 
groups B, D, and F) rather than the condition (7, 9, 10, 13, 15, 16, 19, 21, and 22). 
Comparison of this data was carried out and gene lists were generated to check for 
any significant differentially expressed genes between treatment groups (Appendix 1 
to Appendix 16). 
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Figure 5-2 Principal Component Analysis mapping.  
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Left, the PCA plot for the three different cell sample (B, D, and F) groupings based on colour. Right, the PCA plot 
for the 9 different conditions (7, 9, 10, 13, 15, 16, 19, 21, and 22) is based on colour and cell grouping (B, D, and 
F) is based on shape. 
 
Figure 5-3 A histogram representing the signal intensity across all arrays. 
 
Figure 5-4 Sources of Variation at the gene level. 
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5.2.3. Top functions of gene networks 
A web based microarray pathway analysis program called Ingenuity was used to 
characterise the expression pattern of the regulated genes, their location within 
cellular pathways and functions in each gene network. Eight gene lists were generated 
by combining of top 50 up-regulated and top 50 down-regulated genes from each 
comparison (Table 5-4 Function analysis of eligible genes in each comparison.). In 
each list, genes were further filtered based on the p value. Only the genes with p value 
less than 0.05 were eligible to be analysed.  
Table 5-4 Function analysis of eligible genes in each comparison. 
Name of the 
comparison 
Top functions Details 
siNT vs. siNT (MPA) 1. Cardiovascular System Development and Function, Connective Tissue 
Development and Function, Organismal Development 
2. Cell Death, Hematological System Development and Function, Gene 
Expression 
3. Cellular Assembly and Organization, Gene Expression, Cellular 
Movement 
4. Cell Death, Renal Necrosis/Cell Death, Cell-To-Cell Signaling and 
Interaction 
Appendix 17 
siNT vs. siNT (P4) 1. Cellular Development, Cellular Growth and Proliferation, 
Hematological System Development and Function 
2. Cellular Assembly and Organization, Lipid Metabolism, Small 
Molecule Biochemistry 
Appendix 18 
siNT vs. siGR 1. Gene Expression, Cellular Movement, Neurological Disease Appendix 19 
siNT vs. siPR 1. Cell-To-Cell Signaling and Interaction, Cellular Growth and 
Proliferation, Skeletal and Muscular System Development and Function 
2. Inflammatory Response, Cell-To-Cell Signaling and Interaction, 
Cellular Growth and Proliferation 
3. Cell Death, DNA Replication, Recombination, and Repair, Tumor 
Morphology 
Appendix 20 
siNT vs. siGR (MPA) 1. Cell Death, Lipid Metabolism, Small Molecule Biochemistry 
2. Immunological Disease, Cardiac Arrythmia, Cardiovascular Disease 
Appendix 21 
siNT vs. siGR (P4) 1. Infection Mechanism, Cell Death, Gene Expression 
2. Protein Trafficking, Cardiovascular Disease, Lipid Metabolism 
Appendix 22 
siNT vs. siPR (MPA) 1. Connective Tissue Development and Function, Organismal Functions, 
Skeletal and Muscular System Development and Function 
2. Carbohydrate Metabolism, Molecular Transport, Small Molecule 
Biochemistry 
3. Cell Cycle, Neurological Disease, Cellular Development 
4. Cellular Movement, Hematological System Development and Function, 
Immune Cell Trafficking 
Appendix 23 
siNT vs. siPR (P4) 1. Lipid Metabolism, Small Molecule Biochemistry, Vitamin and Mineral 
Metabolism 
2. Lipid Metabolism, Small Molecule Biochemistry, Endocrine System 
Development and Function 
Appendix 24 
5.2.4. Identification and validation of candidate genes 
Based on the fold change, the function analysis and the signaling pathways which are 
known to be involved in human parturition, several genes were selected from the 
microarray results. They were FKBP5, ERBB receptor feedback inhibitor 1 
(ERRFI1), dual specificity phosphatase 1 (DUSP1), ATP-binding cassette, sub-family 
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A, member 1 (ABCA1) and HSD11β1 [MPA and/or P4 up-regulated]; heat shock 
70kDa protein 7 (HSPA7), interleukin 33 (IL33), tumor necrosis factor receptor 
superfamily, member 11b (TNFRSF11B), interleukin 17A (IL17A) and COX-2 [MPA 
and/or P4 down-regulated]; IL-1β, potassium voltage-gated channel subfamily E 
member 4 (KCNE4), hydroxy-delta-5-steroid dehydrogenase, 3 beta (HSD3β1) and 
ectodysplasin A2 receptor (EDA2R) [siPR and/or siGR up-regulated]; protein 
phosphatase 1, regulatory (inhibitor) subunit 8 (PPP1R8), ubiquilin 4 (UBQLN4), 
potassium voltage-gated channel subfamily E member 2 (KCNE2) and AHA1, 
activator of heat shock 90kDa protein ATPase homolog 2 (AHSA2) [siPR and/or 
siGR down-regulated]. To confirm the results from this cDNA microarray, 
independent studies by qPCR was performed on the candidate genes (Figure 5-5). In 
total, twelve cDNA samples coming from different cell preps, which were first 
transfected with non-target, PR, or GR siRNA and then exposed to MPA or P4 for 6 
h, were used for this validation.  
FKBP5, ERRFI1, DUSP1 and HSD11β1 can be up-regulated by both MPA and P4, 
whereas ABCA1 seems to be a pure progesterone-responsive gene and not affected by 
MPA (Figure 5-5, A-E). The pathways of MPA/P4 to increase these genes expression 
showed different patterns. For instance, GR mediated the effect of MPA/P4 on both 
ERRFI1 and DUSP1 as only GR knockdown blocked the MPA/P4-driven these two 
genes expression (Figure 5-5, B and C). In the case of HSD11β1, the effect of MPA 
was mediated by GR, while P4 played its role via PR (Figure 5-5, E). Similarly, the 
effect of MPA on FKBP5 expression was also mediated by GR but P4-induced 
increase in FKBP5 was distinct as both PR and GR were shown to be implicated 
(Figure 5-5, A). Intriguingly, the up-regulation of ABCA1 by P4 was not attenuated 
by the knockdown of either PR or GR; rather the trend was for it to enhance P4’s 
effect (Figure 5-5, D). 
Another five genes were identified as MPA/P4 repressed genes. Among them, HSPA7 
and IL33 were only down-regulated by MPA in a GR-dependent manner (Figure 5-5, 
I and J). GR also mediated the negative effect of MPA and P4 on COX-2 and 
TNFRSF11B expression (Figure 5-5, K and L). Both PR and GR were involved in the 
down-regulation of IL-1β by MPA and P4 (Figure 5-5, F).  
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Interestingly, not all identified target genes were regulated in a ligand-dependent 
manner. For instance, ABAC1, HSPA7 and IL-1β mRNA levels remained unchanged 
in the absence of GR, yet transfection of PR siRNA resulted in significant increases in 
their transcript levels (Figure 5-5, D, F and I). In contrast, GR silencing increased the 
expression of KCNE4 and EDA2R while PR knockdown had no effect (Figure 5-5, G, 
and H). This suggests that even unliganded PR and GR play a role in regulating gene 
expression in human USMCs. 
Although several genes showed inconsistent results with the microarray, some of 
them displayed a completely distinct pattern, in which the differences occurred among 
cell preps rather than conditions. In one set of experiment containing cDNAs from six 
different cell preps, the mRNA levels of HSD3β1 and IL17A in three cell preps were 
remarkably higher than the others (Figure 5-6).  
To dissect out the role of GR in mediating MPA/P4-responsive genes, USMCs were 
treated with dexamethasone (Dex), a relatively GR-preferential agonist. I found that 
all five identified MPA/P4-repressed genes (COX-2, IL-1β, TNFRSF11B, IL33 and 
HSPA7) were also down-regulated by Dex. These reductions were only abolished by 
the knockdown of GR but not PR (Figure 5-7, A-E). On the other hand, GR also 
mediated Dex-induced increases of FKBP5, HSD11β1, DUSP1 and ERRFI1, which 
were also induced by MPA and P4 (Figure 5-7, F-I). ABCA1, which is a putative 
progesterone-responsive gene, had no change upon the treatment of Dex compared 
with baseline; however, in the absence of GR, Dex significantly induced its 
expression (Figure 5-7, J).  
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Figure 5-5 Validation of putative MPA/P4-responsive and PR/GR-dependent genes. 
For microarray validation, USMC cultures were first transfected with non-target, PR, or GR siRNA and then 
treated with MPA or P4 for 6 h, and mRNA levels of candidate genes were measured using qPCR. Data are shown 
as the median, the 25th and 75th percentiles and the range, and were compared using Wilcoxon matched pairs test 
for data that were not normally distributed and paired t test for data that were normally distributed. * indicates a 
significant difference of p<0.05, **, of p<0.01, and ***, of p<0.001. * on top of a condition indicates the 
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comparison between that condition and baseline; * on top of a capped line indicates the comparison between that 
two conditions (n=12).  
 
Figure 5-6 Quantitation analysis of HSD3β1 and IL17A. 
mRNA levels of HSD3β1(top panel) and IL17A (bottom panel) were measured by qPCR. Amplification curve of 
each sample was shown in log scale. The curves were separated into two groups and marked with black circles and 
squares (n=6).  
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Figure 5-7 The effect of GR selective agonist (Dex) on MPA/P4-responsive genes. 
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USMC cultures were first transfected with non-target, PR, or GR siRNA and then treated with Dex for 6 h, and 
mRNA levels of candidate genes were measured using qPCR. Data are shown as the median, the 25th and 75th 
percentiles and the range, and were compared using Wilcoxon matched pairs test for data that were not normally 
distributed and paired t test for data that were normally distributed. * indicates a significant difference of p<0.05, 
and **, of p<0.01. * on top of a condition indicates the comparison between that condition and baseline; * on top 
of a capped line indicates the comparison between that two conditions (n=6). 
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5.3. Summary and Discussion 
As one of the pleiotropic hormones, progesterone plays an essential role in regulating 
all aspects of female reproduction, including ovulation, embryo implantation and 
parturition. The actions of progesterone in gestational tissues appear to be 
predominantly mediated by PRs, which function as ligand-activated modulators of 
gene expression. In humans, elevated progesterone levels suggest a functional 
progesterone withdrawal at the onset of labour by the alteration of PR. However, 
some studies indicate that GR is also involved in regulating labour-associated gene 
expression [231, 368], which implies an important role of GR in human parturition. 
Given that GR can also be activated by progesterone binding, some of progesterone 
actions may also be mediated by GR.  
The myometrium is maintained in a quiescent state by progesterone for most of the 
pregnancy, but once activated, it is said to become one of the strongest muscles in the 
human body, which contracts until birth is achieved [369]. Thus, understanding the 
mode of action of progesterone on the myometrium is a very important topic. It 
appears that progesterone relaxes the myometrium by down-regulating the expression 
of genes encoding CAPs, which induce labour. Although it has been suggested that 
there is an interaction between PR and other transcription factors on the promoters of 
CAP genes and a production of specific micro-RNAs [369], more studies are still 
required to uncover the true molecular mechanisms. 
In this chapter, gene networks and cellular functions regulated by P4 or MPA in the 
presence or absence of PR and GR in USMCs were investigated by microarray 
analysis. A number of candidate genes were selected and the validation was 
performed by qPCR. Eight genes were confirmed to be regulated by P4. Among them, 
only one gene (HSD11β1) was purely mediated by PR, whereas four genes (ERRFI1, 
DUSP1, COX-2 and TNFRSF11B) were GR dependent. FKBP5 and IL-1β were 
shown to be mediated by both steroid receptors. The up-regulation of ABCA1 by P4 
was not affected by either GR or PR knockdown, although silencing PR increased its 
expression from the basal level, supporting the concept that its regulation is via a 
distinct mechanism.  
MPA, a 17-OH P4 derivative, is widely used to simulate progesterone action in many 
in vitro studies. As expected, almost all the P4-responsive genes, except ABCA1, 
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were also regulated by MPA in USMCs and most of their expression regulations 
shared the same mechanism as seen in response to P4. However, besides the 
progestogenic property, MPA also has glucocorticoid effects [370], suggesting that 
some genes might be differentially regulated compared with P4. This is most clearly 
demonstrated in the case of FKBP5 and HSD11β1, for which the effect of MPA is 
mediated by GR; whereas P4 induces their expression mainly via PR. MPA also acts 
specifically via GR to up-regulate IL33 and HSPA7, which are unaffected by P4. 
These data suggest that GR mediates P4 effects on some progesterone-responsive 
genes in USMCs.  
To further confirm GR function, cells were exposed to Dex, which is GR specific 
agonist, and the expressions of GR-mediated genes were detected by qPCR. The 
results indicated that Dex drives the same GR-mediated genes as defined in response 
to MPA and P4 and also in a GR-dependent manner. Although ABCA1 is not 
mediated by both steroid receptors and is only response to P4, GR knockdown 
significantly increased its expression in the presence of Dex, implying that Dex, like 
P4, might be able to act through other mechanisms in the absence of its receptor. 
All the P4-responsive genes can be generally divided into two groups based on the up-
regulation or down-regulation by progesterone. It appears that the P4-repressed genes 
are all inflammation-related. IL-1β (a very important pro-inflammatory cytokine) and 
COX-2 (the central enzyme responsible for the prostaglandin biosynthesis) have 
already been discussed in the previous chapters. TNFRSF11B, also named 
osteoprotegerin (OPG), is another P4 down-regulated gene, which belongs to the 
TNF-receptor superfamily. It acts as a decoy receptor for the receptor activator of 
nuclear factor kappa B ligand (RANKL), which plays a crucial role for bone 
remodeling. Clinically, the OPG level in maternal plasma is higher in the third 
trimester than in the first trimester of pregnancy, suggesting its involvement in the 
regulation of bone turnover in order to meet the demands of fetal skeleton 
development during pregnancy [371]. In contrast, to perform the formation and 
activation of osteoclasts and bone resorption, RANKL needs to bind with RANK 
(receptor activator of nuclear factor kappa B). Given its importance, this 
OPG/RANKL/RANK system has been extensively studied. A number of cytokines 
and hormones were found to be able to modulate this system, such as IL-1β and TNF-
α (increased RANKL) [372], glucocorticoids (increased RANKL and decreased OPG 
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expression) [373, 374], and estrogen (increased OPG expression) [374, 375]. 
Similarly, a reduction of OPG by Dex was shown in my data. Compared with the 
increasing effect of estrogen on OPG, progesterone decreased its expression in 
USMCs, which also appears to be consistent with their opposing roles in controlling 
uterine contractility.  
I have previously discussed the function of FKBP5, HSD11β1 and DUSP1 (also 
named MKP-1) in the other chapters. Here two other genes were found to be up-
regulated by P4, ERRFI1 and ABCA1. ERRFI1 (also known as Mig-6) is an 
immediate early response gene, which increases in response to various mitogens [376, 
377]. It functions as a negative regulator of epidermal growth factor receptor (EGFR)-
mediated mitogenic signaling. Several studies have identified it to be a tumor 
suppressor gene [378-381], but very little is known about its role in reproductive 
biology. Recently, Mig-6 was found to be regulated by progesterone in mice [382] 
and its expression was down-regulated in endometrial RNA taken from women with 
endometriosis [383]. Another animal study reported an important role of Mig-6 in 
uterine physiology by showing that it can regulate the ability of progesterone to 
attenuate estrogen signaling [384]. More importantly, this study demonstrated that the 
regulatory effect of progesterone on Mig-6 was mediated by PR and SRC-1 in all 
compartments of the endometrium including the epithelium and stroma but not 
myometrium [384]. This supports my data in which Mig-6 was GR dependently 
regulated by both P4 and MPA in USMCs. 
ABCA1, which has a unique regulatory pattern in my list of progesterone-responsive 
genes, is a member of the ATP-binding cassette transporter superfamily. It mainly 
functions as a cholesterol efflux pump mediating the transport of cholesterol, 
phospholipids, and other lipophilic molecules across cellular membranes [385]. It is 
highly expressed in various human tissues, such as uterus, prostate and placenta [386]. 
More recently, a number of cell types in human placenta have been found to express 
ABCA1, such as cytotrophoblast cells, amnion epithelial cells, and macrophages 
[387], which suggests its involvement in maternal-fetal cholesterol delivery. As the 
precursors of steroid hormone biosynthesis (Figure 1-8), cholesterol and its 
derivatives might be affected by aberrations in ABCA1 leading to the alteration of 
steroid homeostasis. In a rat smooth muscle cell line, the expression of ABCA1 was 
found to be up-regulated by cAMP via the increased expression of prolactin 
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regulatory element-binding (PREB) protein, which is a transcription factor that 
regulates prolactin promoter activity [388]. Given that progesterone can increase 
cAMP release in human myometrium [389], it could be possible that in my study the 
increase of ABCA1 in response to P4 was mediated through cAMP/PREB pathway.  
Although HSD3β1 and IL17A did not pass the validation, they displayed a very 
intriguing result with remarkable difference among cell preps, which suggested that 
their expression was more likely to be affected by the factors inherit in the patient 
rather than any exogenous stimuli which the cells were exposed to. HSD3β1 is one of 
3β-hydroxysteroid dehydrogenase (3βHSD) isoforms, which play a crucial role in the 
steroid hormone biosynthesis [390]. It is primarily expressed in the placenta, whereas 
the other isoform HSD3β2 mainly localizes in the ovary, adrenal gland, and testis 
[390-392]. Given that placenta becomes the source of progesterone production after 7-
8 weeks of gestation, HSD3β1 appears to be essential for the placental progesterone 
biosynthesis and the maintenance of human pregnancy. The regulation of this enzyme 
was first investigated in mouse trophoblast cells and two transcription factors: AP-2γ 
and Dix-3 were identified to determine its expression [392]. In humans, although the 
corresponding AP-2γ and Dix-3 binding sites were also found in the promoter, neither 
of them was involved in regulating its expression. Instead, transcription enhance 
factor (TEF)-5 and GATA-like protein were demonstrated to control HSD3β1 
expression in human trophoblast cells by site-specific mutations [393]. The difference 
in the regulation of the placental-specific HSD3β1 expression between humans and 
mice might reflect the different mechanism of progesterone withdrawal in these two 
species.  
IL17A belongs to IL17 family, which consists of several related cytokines (IL17A-F). 
The major source of IL17A is memory T lymphocytes, but it has also been detected in 
some other cell types, such as eosinophiles, neutrophils and splenocytes [394-396]. As 
a pro-inflammatory cytokine, IL17A activates NF-κB and stimulates the production of 
other inflammatory cytokines and chemokines including IL-6, IL-8, GM-CSF and 
MCP-1 [397-399]. Recently, the expression of IL17A has been found in the human 
placenta [400] and preterm delivery has shown to be associated with low maternal 
serum IL17 [401], suggesting the involvement of this cytokine in human pregnancy. 
The regulation of IL17 has been widely investigated and two patterns have been 
identified. In the first pattern, IL23 mediates IL17 production via the activation of 
Chapter 5: Affymetrix microarray analysis 
- 146 - 
Jak2, PI3K/Akt, STAT3 and NF-κB signaling pathways. In contrast, the second 
pattern is IL23 independent, which was found in TGF-β and IL-6-induced IL17 
expression. However, further studies are required to understand the role of HSD3β1 
and IL17A in human myometrium and how the difference among cell preps correlates 
with different patients. 
In summary, I have shown that the MPA and P4 generally regulate distinct gene 
networks and cellular functions in USMCs due to, at least in part, the glucocorticoid 
effect of MPA [370, 402], while only a small proportion of genes are sensitive to both 
MPA and P4. Interestingly, in comparison to PR, GR governs the expression of the 
majority of progesterone-responsive genes, suggesting a more important role of GR in 
regulating myometrium function in human parturition. More studies are required to 
define the role played by GR in human myometrium and to elucidate the molecular 
mechanisms involved. Although animal studies have been providing some clues, the 
differences in progesterone withdrawal between humans and laboratory animals limit 
their importance. Therefore, by using primary cultured USMCs, the gene lists 
generated from this microarray could provide more direct and valuable information 
for future studies.   
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Preterm labour is one of the major problems in obstetrics and the most important 
cause of perinatal mortality and morbidity. Currently, no effective treatment has been 
found because the mechanisms of controlling the process of human birth are still 
unclear, although progesterone administration can reduce the risk of preterm labour in 
singleton pregnancy. Nevertheless, it has been suggested that the changes of 
endocrine, mechanical and biochemical events occurring throughout the pregnancy 
affect the transformation of the uterus from relative quiescence to contractility and 
control the timing of labour. In line with this suggestion, the studies in this thesis have 
focused on investigating the actions of progesterone in human myometrium and how 
these actions and the mechanical and biochemical events interact with each other 
during pregnancy and labour.  
Firstly, the mutual effects between progesterone and mechanical stretch in USMCs 
were investigated. The data showed that progesterone did not inhibit stretch-induced 
ERK1/2 activation and gene expression including COX-2, IL-8 and OTR. This 
suggested that different mechanisms are probably involved in stretch- and IL-1β-
induced COX-2 expression and may explain why progesterone is ineffective in the 
prevention of preterm labour in multiple pregnancy. In another series of in vitro 
experiments, I found that the mechanical stretch can reduce PR-B expression via NF-
κB signalling pathway and increase unliganded PR-B-driven PRE activity. However, 
this was not sufficient to affect the ability of progesterone to regulate gene expression, 
drive PR-B activity and repress IL-1β-induced COX-2 expression, suggesting that 
stretch may not be responsible for the functional progesterone withdrawal seen with 
the onset of labour.  
Secondly, I have investigated the relationship between progesterone and the pro-
inflammatory cytokine IL-1β as the biochemical events involved in parturition 
resemble an inflammatory reaction including pro-inflammatory cytokines production 
and the prostaglandin biosynthesis. The results from luciferase studies showed that 
IL-1β repress the MPA-induced PR-B-driven PRE activity in a NF-κB-dependent 
manner. This was supported by both NF-κBp65 overexpression and knockdown. 
Furthermore, the physical interaction between p65 and liganded PR-B was confirmed 
by co-immunoprecipitation studies in USMCs, suggesting that the reduction of 
liganded PR-B activity by IL-1β is via the trans-repression effect of p65. Conversely, 
progesterone also inhibited IL-1β-driven COX-2 mRNA expression. The mechanism 
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has been reported in cell lines pointing to a crucial role of PR in this process [290]. 
However, GR, but not PR, was found to mediate the negative effect of progesterone 
on IL-1β-driven COX-2 expression in primary cultured USMCs by using steroid 
receptor antagonists and gene silencing. The regulation of a progesterone-responsive 
gene, FKBP5, further confirmed the ability of GR to mediate progesterone action. To 
understand the mechanism of how progesterone-activated GR represses IL-1β-
induced increase in COX-2, several hypotheses were tested. Although there is also a 
physical interaction between GR and p65, IL-1β-induced p65 phosphorylation, 
nuclear translocation and NF-κB DNA binding activity on COX-2 promoter were not 
affected by progesterone-activated GR. It was also suggested that GRIP-1 was 
recruited to p65-GR-DNA complex and contributed to COX-2 repression [308]. 
However, the silencing of GRIP-1 did not alter progesterone action in this context. 
Nevertheless, the inhibition of MKP-1 reversed the ability of P4/GR to repress IL-1β 
activity, suggesting that this explains at least in part the P4/GR inhibition of IL-1β-
induced COX-2 expression in USMCs. 
Subsequently, microarray analysis was performed to further explore gene networks 
and cellular functions regulated by progesterone via PR and/or GR in USMCs. In 
order to simplify the information, the large amount of data obtained was filtered 
according to the p value and the fold change and the top 50 genes were listed from 
each comparison. Several of the most interesting genes, which are known to be 
relevant to human parturition, were validated by qPCR. The expression of the 
majority of these genes in response to progesterone was mediated by GR, suggesting 
that the cross-talk between progesterone and GR may play an essential role in 
governing myometrial functions. Additionally, the database generated from this 
microarray study and the one from Chapter 3 will help us uncover the gene networks 
involved in both the short- and long-term progesterone response of USMCs.  
In conclusion, the data presented in this thesis suggest that progesterone actions 
mainly affect the biochemical events rather than the mechanical events in human 
labour and in turn, these biochemical events may play the major role in the functional 
progesterone withdrawal. 
Based on the findings in this thesis, a list of my future potential work is as follows: 
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1. Investigate the mechanism of stretch to enhance IL-1β-driven COX-2 protein 
synthesis in USMCs.  
2. Identify the target transcription factors of MKP-1 on COX-2 promoter in USMCs. 
3. Detect the levels of PR, GR and other genes of interest obtained from the 
microarray in myometrial tissue samples. 
4. Generate the Cre/loxP mice in which PR or GR can be specifically deleted in 
myometrium at any given time point. 
5. Investigate the role of PR and GR in myometrium by combining the prolonged 
pregnancy mouse model and the Cre/loxP mouse model. 
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Appendices 
Appendix 1 Top 50 up-regulated genes by MPA. 
gene_assignment Gene Symbol RefSeq 
 [siNT down vs. 
siNT (MPA)] 
FK506 binding protein 5 FKBP5 NM_001145775 -10.1806 
ERBB receptor feedback inhibitor 1 ERRFI1 NM_018948 -4.7261 
glutamate-ammonia ligase GLUL NM_002065 -3.92993 
carboxypeptidase M CPM NM_001874 -3.34205 
serpin peptidase inhibitor, clade E SERPINE1 NM_000602 -3.17567 
LIM domain only 3 LMO3 NM_018640 -3.02374 
acyl-CoA synthetase long-chain family member 1 ACSL1 NM_001995 -3.00662 
TSC22 domain family, member 3 TSC22D3 NM_198057 -2.95099 
ADAM metallopeptidase with thrombospondin type 1 ADAMTS1 NM_006988 -2.87867 
leucine rich repeat containing 16A LRRC16A NM_017640 -2.85091 
metallothionein 1X MT1X NM_005952 -2.77447 
dual specificity phosphatase 1 DUSP1 NM_004417 -2.67883 
chromosome 13 open reading frame 15 C13orf15 NM_014059 -2.67738 
forkhead box O3B pseudogene FOXO3B NR_026718 -2.62036 
LIM and cysteine-rich domains 1 LMCD1 NM_014583 -2.60417 
leucine rich repeat (in FLII) interacting protein 1 LRRFIP1 NM_001137550 -2.51611 
FYVE, RhoGEF and PH domain containing 4 FGD4 NM_139241 -2.47239 
LOC100131826 LOC100131826 AY358789 -2.38424 
glucosaminyl (N-acetyl) transferase 1 GCNT1 NM_001490 -2.38064 
amyloid beta (A4) precursor protein-binding, family B APBB2 NM_004307 -2.3805 
LAG1 homolog, ceramide synthase 6 LASS6 NM_203463 -2.3765 
fibulin 5 FBLN5 NM_006329 -2.37051 
stomatin STOM NM_004099 -2.36929 
monoamine oxidase A MAOA NM_000240 -2.35942 
metallothionein 1E MT1E NM_175617 -2.3566 
enolase 1, (alpha) ENO1 NM_001428 -2.34723 
cysteine-rich secretory protein LCCL domain CRISPLD2 NM_031476 -2.30339 
hypothetical protein DKFZp686O24166 DKFZp686O24166 NR_026750 -2.30305 
integrin, alpha 5 ITGA5 NM_002205 -2.27655 
slingshot homolog 2 SSH2 NM_033389 -2.2759 
PHD finger protein 17 PHF17 NM_199320 -2.2746 
laminin, beta 1 LAMB1 NM_002291 -2.27239 
interleukin-1 receptor-associated kinase 3 IRAK3 NM_007199 -2.26938 
podoplanin PDPN NM_006474 -2.26006 
adaptor protein, phosphotyrosine interaction APPL2 NM_018171 -2.25611 
hippocampus abundant transcript-like 1 HIATL1 NM_032558 -2.2281 
nidogen 1 NID1 NM_002508 -2.19888 
ribosomal protein L10 RPL10 NR_026898 -2.14762 
peptidase domain containing associated with muscle 
regeneration PAMR1 NM_015430 -2.12378 
fibrillin 2 FBN2 NM_001999 -2.07049 
transforming growth factor, beta receptor II TGFBR2 NM_001024847 -2.06922 
glucosidase, alpha; neutral AB GANAB NM_198335 -2.06723 
24-dehydrocholesterol reductase DHCR24 NM_014762 -2.06649 
midline 2 MID2 NM_012216 -2.0651 
immunoglobulin heavy constant alpha 1 IGHA1 AK128476 -2.06414 
transforming growth factor, beta receptor III TGFBR3 NM_003243 -2.05633 
platelet-derived growth factor receptor, alpha PDGFRA NM_006206 -2.04788 
solute carrier family 7 SLC7A2 NM_003046 -2.0312 
tubulin, beta polypeptide 4, member Q TUBB4Q NM_020040 -2.01811 
NHP2 non-histone chromosome protein 2-like 1 NHP2L1 NM_005008 -2.00347 
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Appendix 2 Top 50 down-regulated genes by MPA. 
gene_assignment Gene Symbol RefSeq 
 [siNT up vs. 
siNT (MPA)] 
Similar to LOC166075 LOC401097 NM_001168214 8.93239 
tumor necrosis factor receptor superfamily, member 11b TNFRSF11B NM_002546 3.14793 
interleukin 33 IL33 NM_033439 3.13668 
cytochrome c oxidase subunit VIIb COX7B NM_001866 3.12023 
chemokine (C-C motif) ligand 7 CCL7 NM_006273 2.89512 
regulator of G-protein signaling 4 RGS4 NM_001102445 2.80386 
fibroblast growth factor 9 FGF9 NM_002010 2.52337 
histone cluster 1 HIST1H2AJ NM_021066 2.48431 
zinc finger protein 594 ZNF594 NM_032530 2.4486 
pleckstrin homology domain containing, family A PLEKHA3 NM_019091 2.28099 
chemokine (C-X-C motif) ligand 10 CXCL10 NM_001565 2.25363 
integrin, beta 8 ITGB8 NM_002214 2.23566 
matrix metallopeptidase 16 MMP16 AL136588 2.21571 
keratinocyte growth factor-like protein 1 KGFLP1 NR_003674 2.21059 
similar to tumor protein, translationally-controlle LOC389787 XM_001717250 2.16611 
CD209 molecule CD209 NM_021155 2.14151 
zinc finger protein 552 ZNF552 NM_024762 2.14084 
transient receptor potential cation channel, subfamily A,  TRPA1 NM_007332 2.12316 
histidine triad nucleotide binding protein 3 HINT3 NM_138571 2.11933 
hyaluronan synthase 2 HAS2 NM_005328 2.11382 
tumor necrosis factor, alpha-induced protein 6 TNFAIP6 NM_007115 2.10245 
protein phosphatase 1, regulatory (inhibitor) subunit 3C PPP1R3C NM_005398 2.07711 
small nucleolar RNA, H/ACA box 73A SNORA73A NR_002907 2.05823 
microRNA let-7a-2 MIRLET7A2 NR_029477 2.05731 
small Cajal body-specific RNA 9 SCARNA9 NR_002569 2.05246 
chemokine (C-C motif) receptor-like 1 CCRL1 NM_178445 2.05087 
prostaglandin-endoperoxide synthase 2 PTGS2 NM_000963 2.01315 
zinc finger protein 737 ZNF737 NM_001159293 1.99689 
corepressor interacting with RBPJ, 1 CIR1 NM_004882 1.98874 
zinc finger protein 277 ZNF277 ENST00000421043 1.95975 
epithelial cell adhesion molecule EPCAM NM_002354 1.9583 
microRNA 181b-1 MIR181B1 NR_029612 1.9518 
5-hydroxytryptamine (serotonin) receptor 2B HTR2B NM_000867 1.95012 
 small nucleolar RNA, C/D box 13 SNORD13 NR_003041 1.9483 
small nucleolar RNA, C/D box 47 SNORD47 NR_002746 1.94199 
guanine nucleotide binding protein (G protein), gamma 
2 GNG2 NM_053064 1.93202 
zinc finger and BTB domain containing 38 ZBTB38 NM_001080412 1.92741 
proteasome (prosome, macropain) subunit, alpha type, 3 PSMA3 NM_002788 1.92135 
deleted in lymphocytic leukemia 2 DLEU2 NR_002612 1.91282 
progesterone immunomodulatory binding factor 1 PIBF1 NM_006346 1.91097 
chromosome 4 open reading frame 46 C4orf46 NM_001008393 1.89835 
centrosomal protein 170kDa CEP170 NM_014812 1.89833 
RNA binding motif protein 7 RBM7 NM_016090 1.89793 
N-myc (and STAT) interactor NMI NM_004688 1.89785 
heat shock 70kDa protein 7 (HSP70B) HSPA7 NR_024151 1.89072 
latexin LXN NM_020169 1.88829 
stanniocalcin 1 STC1 NM_003155 1.88245 
RNA binding motif protein, Y-linked, family 1, member 
A1 RBMY1A1 NM_005058 1.87843 
R-spondin 3 homolog RSPO3 NM_032784 1.85957 
chromosome 21 open reading frame 34 C21orf34 NR_027790 1.85644 
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Appendix 3 Top 50 up-regulated genes by P4. 
gene_assignment Gene Symbol RefSeq 
 [siNT down 
vs. siNT(P4)] 
ATP-binding cassette, sub-family A (ABC1), member 
1 ABCA1 NM_005502 -2.75844 
FK506 binding protein 5 FKBP5 NM_001145775 -2.72812 
LOC100131826 LOC100131826 AY358789 -2.64534 
small nucleolar RNA, C/D box 26 SNORD26 NR_002564 -2.50998 
hippocampus abundant transcript-like 1 HIATL1 NM_032558 -2.23635 
vaccinia related kinase 2 VRK2 
ENST0000042802
1 -2.10109 
ERBB receptor feedback inhibitor 1 ERRFI1 NM_018948 -2.09597 
small nucleolar RNA, H/ACA box 70G SNORA70G NR_033335 -2.06689 
hypothetical protein DKFZp686O24166 DKFZp686O24166 NR_026750 -2.06126 
mitochondrial ribosomal protein L45 MRPL45 NM_032351 -2.05865 
transmembrane protein 199 TMEM199 NM_152464 -2.04879 
postmeiotic segregation increased 2-like 1 pseudogene PMS2L1 NR_003613 -2.03471 
transmembrane protein 111 TMEM111 NM_018447 -2.00364 
microRNA 622 MIR622 NR_030754 -1.99393 
fatty acid binding protein 3, muscle and heart FABP3 NM_004102 -1.99212 
cirrhosis, autosomal recessive 1A CIRH1A NM_032830 -1.98269 
small nuclear ribonucleoprotein polypeptide A SNRPA1 NM_003090 -1.97423 
adaptor-related protein complex 4, beta 1 subunit AP4B1 NM_006594 -1.97143 
solute carrier family 31 (copper transporters), member 
1 SLC31A1 NM_001859 -1.94897 
eukaryotic translation initiation factor 3, subunit L EIF3L NM_016091 -1.94246 
solute carrier family 37 SLC37A3 NM_207113 -1.9315 
polymerase (RNA) II (DNA directed) polypeptide G POLR2G NM_002696 -1.92569 
cytochrome b5 reductase 1 CYB5R1 NM_016243 -1.91244 
retinol dehydrogenase 11 RDH11 NM_016026 -1.91228 
Niemann-Pick disease, type C1 NPC1 NM_000271 -1.912 
amyloid beta (A4) precursor protein-binding, family B APBB2 NM_004307 -1.90965 
acetyl-CoA carboxylase alpha ACACA NM_198839 -1.90307 
membrane protein, palmitoylated 1 MPP1 NM_002436 -1.90278 
NHP2 non-histone chromosome protein 2-like 1 NHP2L1 NM_005008 -1.8907 
presenilin associated, rhomboid-like PARL NM_018622 -1.87751 
glutamic-oxaloacetic transaminase 1 GOT1 NM_002079 -1.86537 
zinc finger protein 90 ZNF90 AK298173 -1.85633 
Der1-like domain family, member 1 DERL1 NM_024295 -1.85021 
eukaryotic translation initiation factor 3, subunit I EIF3I NM_003757 -1.84026 
elongation factor Tu GTP binding domain containing 1 EFTUD1 NM_024580 -1.83168 
3-hydroxy-3-methylglutaryl-CoA reductase HMGCR NM_000859 -1.82625 
bifunctional apoptosis regulator BFAR NM_016561 -1.82429 
SMG1 homolog, phosphatidylinositol 3-kinase-related kinase  SMG1 NM_015092 -1.82221 
LAG1 homolog, ceramide synthase 5 LASS5 NM_147190 -1.81841 
transforming growth factor, beta receptor II TGFBR2 NM_001024847 -1.815 
adaptor-related protein complex 3, mu 2 subunit AP3M2 NM_001134296 -1.81218 
excision repair cross-complementing rodent repair deficiency ERCC3 NM_000122 -1.80516 
peptidase domain containing associated with muscle 
regeneration PAMR1 NM_015430 -1.79952 
sushi, von Willebrand factor type A SVEP1 NM_153366 -1.78903 
keratin 18 KRT18 NM_000224 -1.78758 
Williams Beuren syndrome chromosome region 22 WBSCR22 NM_017528 -1.78287 
trafficking protein particle complex 4 TRAPPC4 NM_016146 -1.78025 
tubby like protein 3 TULP3 NM_003324 -1.7782 
X-prolyl aminopeptidase (aminopeptidase P) 3 XPNPEP3 NM_022098 -1.77432 
karyopherin alpha 2 KPNA2 NM_002266 -1.7725 
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Appendix 4 Top 50 down-regulated genes by P4. 
gene_assignment Gene Symbol RefSeq 
 [siNT up vs. 
siNT(P4)] 
P antigen family, member 2B PAGE2B NM_001015038 2.28506 
ubiquilin 4 UBQLN4 NM_020131 2.10163 
heat shock 70kDa protein 7 HSPA7 NR_024151 1.88413 
hypothetical LOC644903 FLJ38668 AK095987 1.82833 
small nucleolar RNA, C/D box 82 SNORD82 NR_004398 1.8244 
hypothetical LOC29075 HSPC072 AF161557 1.79756 
FLJ35934 FLJ35934 ENST00000407600 1.78747 
hypothetical protein LOC644714 LOC644714 BC047037 1.70843 
espin ESPN NM_031475 1.69171 
keratin associated protein 9-2 KRTAP9-2 ENST00000318329 1.68136 
deleted in lymphocytic leukemia 2 DLEU2 NR_002612 1.67862 
microRNA 520c MIR520C NR_030198 1.66648 
Src homology 2 domain containing F SHF NM_138356 1.65105 
glioma tumor suppressor candidate region gene 2 GLTSCR2 NM_015710 1.64847 
Meis homeobox 3 MEIS3 NM_020160 1.61703 
hypothetical LOC100128364 
LOC10012836
4 AK096229 1.61476 
lectin, galactoside-binding, soluble, 9B LGALS9B NM_001042685 1.61059 
histone cluster 1, H4d HIST1H4D NM_003539 1.60916 
chromosome 12 open reading frame 68 C12orf68 NM_001013635 1.60534 
zinc finger protein 257 ZNF257 NM_033468 1.60445 
vault RNA 1-3 VTRNA1-3 NR_026705 1.60179 
similar to zinc finger protein 208 
LOC10013314
2 XM_001718400 1.58483 
histone cluster 1, H2aj HIST1H2AJ NM_021066 1.58158 
similar to cDNA sequence BC021523 LOC441956 AK125677 1.57678 
hypothetical gene supported by AK131040 LOC388022 AK131040 1.57601 
cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1B1 NM_000104 1.57088 
chromosome 20 open reading frame 107 C20orf107 BC105792 1.56979 
killer cell lectin-like receptor subfamily C, member 2 KLRC2 NM_002260 1.56674 
chromosome 20 open reading frame 106 C20orf106 NM_001012971 1.55923 
gamma-glutamyltransferase light chain 1 GGTLC1 NM_178311 1.55603 
Similar to LOC166075 LOC401097 NM_001168214 1.55556 
G patch domain containing 3 GPATCH3 NM_022078 1.5555 
glutamate dehydrogenase 1 GLUD1 NM_005271 1.55502 
chromosome 21 open reading frame 32 C21orf32 ENST00000430662 1.55114 
hypothetical LOC100134868 
LOC10013486
8 NR_004846 1.54482 
myosin XVB pseudogene MYO15B NR_003587 1.54327 
fibroblast growth factor 9 (glia-activating factor) FGF9 NM_002010 1.54266 
olfactory receptor, family 1, subfamily A, member 2 OR1A2 NM_012352 1.53729 
interleukin 17A IL17A NM_002190 1.53559 
TAF13 RNA polymerase II TAF13 NM_005645 1.53426 
CMT1A duplicated region transcript 1 CDRT1 NM_006382 1.53405 
chloride channel 7 CLCN7 NM_001287 1.53363 
zinc finger protein 724 (pseudogene) ZNF724P AK301230 1.52592 
catenin (cadherin-associated protein), alpha 3 CTNNA3 NM_013266 1.5221 
zinc finger protein 492 ZNF492 NM_020855 1.52102 
chromosome 14 open reading frame 156 C14orf156 NM_031210 1.51983 
phospholipase A2, group IIA PLA2G2A NM_000300 1.51819 
zinc finger protein 277 ZNF277 ENST00000421043 1.51681 
transmembrane protein 130 TMEM130 NM_001134450 1.51529 
chromosome 21 open reading frame 70 C21orf70 AF391113 1.51414 
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Appendix 5 Top 50 up-regulated genes upon GR knockdown. 
gene_assignment Gene Symbol RefSeq 
 [siNT down 
vs. siGR] 
LOC100131826 LOC100131826 AY358789 -2.66404 
hippocampus abundant transcript-like 1 HIATL1 NM_032558 -2.17914 
peptidase domain containing associated with muscle 
regeneration PAMR1 NM_015430 -2.15581 
Williams Beuren syndrome chromosome region 22 WBSCR22 NM_017528 -2.06406 
small nucleolar RNA, H/ACA box 70G 
(retrotransposed) SNORA70G NR_033335 -2.05113 
leucine rich repeat (in FLII) interacting protein 1 LRRFIP1 NM_001137550 -2.04784 
mitochondrial ribosomal protein L45 MRPL45 NM_032351 -2.04637 
eukaryotic translation initiation factor 3, subunit I EIF3I NM_003757 -2.03477 
vaccinia related kinase 2 VRK2 
ENST0000042802
1 -1.97789 
enolase 1, (alpha) ENO1 NM_001428 -1.96122 
ribosomal protein L10 RPL10 NR_026898 -1.95797 
eukaryotic translation initiation factor 3, subunit L EIF3L NM_016091 -1.93887 
hypothetical LOC100130876 LOC100130876 AK130278 -1.93783 
cytochrome b5 reductase 1 CYB5R1 NM_016243 -1.93773 
translocase of outer mitochondrial membrane 22 
homolog TOMM22 NM_020243 -1.91193 
cirrhosis, autosomal recessive 1A (cirhin) CIRH1A NM_032830 -1.90791 
postmeiotic segregation increased 2-like 1 pseudogene PMS2L1 NR_003613 -1.89599 
NHP2 non-histone chromosome protein 2-like 1 NHP2L1 NM_005008 -1.88529 
killer cell immunoglobulin-like receptor, three domains KIR3DL1 NM_013289 -1.86571 
solute carrier family 31 (copper transporters), member 1 SLC31A1 NM_001859 -1.86351 
small nucleolar RNA, C/D box 38B SNORD38B NR_001457 -1.85059 
transmembrane protein 199 TMEM199 NM_152464 -1.84846 
hypothetical protein DKFZp686O24166 
DKFZp686O2416
6 NR_026750 -1.83728 
small nucleolar RNA, C/D box 26 SNORD26 NR_002564 -1.83699 
elongation factor Tu GTP binding domain containing 1 EFTUD1 NM_024580 -1.8342 
ribosomal protein L13a pseudogene 20 RPL13AP20 NR_003932 -1.83138 
coiled-coil domain containing 127 CCDC127 NM_145265 -1.82979 
transmembrane protein 147 TMEM147 NM_032635 -1.8266 
CMT1A duplicated region transcript 1 CDRT1 NM_006382 -1.82497 
ectodysplasin A2 receptor EDA2R NM_021783 -1.82253 
cytochrome b5 reductase 2 CYB5R2 NM_016229 -1.81952 
tRNA methyltransferase 11-2 homolog TRMT112 NM_016404 -1.81408 
family with sequence similarity 38, member B FAM38B NM_022068 -1.81383 
polymerase (RNA) II (DNA directed) polypeptide G POLR2G NM_002696 -1.80587 
ubiquinol-cytochrome c reductase hinge protein UQCRH NM_006004 -1.80528 
cathepsin K CTSK NM_000396 -1.80314 
zinc finger protein 90 ZNF90 AK298173 -1.80217 
WD repeat and FYVE domain containing 1 WDFY1 NM_020830 -1.79332 
mitochondrial ribosomal protein L21 MRPL21 NM_181515 -1.79058 
presenilin associated, rhomboid-like PARL NM_018622 -1.78157 
transmembrane protein 111 TMEM111 NM_018447 -1.77568 
LAG1 homolog, ceramide synthase 5 LASS5 NM_147190 -1.77156 
microRNA 622 MIR622 NR_030754 -1.76545 
solute carrier family 5 SLC5A3 NM_006933 -1.76342 
glutathione S-transferase mu 5 GSTM5 NM_000851 -1.76315 
exosome component 1 EXOSC1 NM_016046 -1.75751 
phosphogluconate dehydrogenase PGD NM_002631 -1.75538 
hexosaminidase A (alpha polypeptide) HEXA NM_000520 -1.75003 
membrane protein, palmitoylated 1 MPP1 NM_002436 -1.74775 
succinate dehydrogenase complex assembly factor 2 SDHAF2 NM_017841 -1.74426 
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Appendix 6 Top 50 down-regulated genes upon GR knockdown. 
gene_assignment Gene Symbol RefSeq 
 [siNT up vs. 
siGR] 
nuclear receptor subfamily 3, group C, member 1 NR3C1 NM_000176 2.69052 
ankyrin repeat domain 11 ANKRD11 NM_013275 2.06678 
histone cluster 1, H2aj HIST1H2AJ NM_021066 2.0578 
zinc finger protein 594 ZNF594 NM_032530 2.03485 
small nucleolar RNA, C/D box 13 SNORD13 NR_003041 2.00297 
P antigen family, member 2B PAGE2B NM_001015038 1.98419 
ubiquilin 4 UBQLN4 NM_020131 1.94736 
golgin A6 family, member A GOLGA6A NM_001038640 1.84525 
similar to cDNA sequence BC021523 LOC441956 AK125677 1.83595 
small nucleolar RNA, C/D box 13 pseudogene 1 SNORD13P1 X58061 1.8187 
zinc finger protein 277 ZNF277 
ENST0000042104
3 1.80439 
late cornified envelope 4A LCE4A NM_178356 1.79481 
chromosome 6 open reading frame 99 C6orf99 
ENST0000036707
3 1.78552 
hypothetical LOC339674 LOC339674 NR_024355 1.72782 
CMT1A duplicated region transcript 1 CDRT1 NM_006382 1.71721 
RNA binding motif protein, Y-linked, family 1, member 
A1 RBMY1A1 NM_005058 1.71568 
similar to TRIMCyp LOC392352 XM_002342942 1.6943 
glycerol-3-phosphate acyltransferase, mitochondrial GPAM AK172782 1.67198 
apolipoprotein B mRNA editing enzyme APOBEC3B NM_004900 1.67076 
chromosome 21 open reading frame 32 C21orf32 
ENST0000043066
2 1.6535 
tubulin, beta 2C TUBB2C NM_006088 1.62898 
Rho GTPase activating protein 23 ARHGAP23 NM_020876 1.61649 
microRNA let-7c MIRLET7C NR_029480 1.61633 
keratin associated protein 9-2 KRTAP9-2 
ENST0000031832
9 1.61159 
cysteine-rich secretory protein 1 CRISP1 NM_001131 1.60557 
zinc finger protein 578 ZNF578 NM_001099694 1.60107 
potassium voltage-gated channel, Isk-related family KCNE2 NM_172201 1.5986 
hypothetical protein FLJ25715 FLJ25715 AK098581 1.58952 
killer cell lectin-like receptor subfamily C, member 2 KLRC2 NM_002260 1.58759 
chromosome 20 open reading frame 107 C20orf107 BC105792 1.5873 
hypothetical protein PRO2268 PRO2268 
ENST0000045616
5 1.58405 
deleted in lymphocytic leukemia 2 DLEU2 NR_002612 1.58108 
non-protein coding RNA 164 NCRNA00164 NR_027020 1.58084 
double homeobox, 4-like LOC441056 NM_001177376 1.57909 
CD209 molecule CD209 NM_021155 1.57521 
espin ESPN NM_031475 1.57364 
small nucleolar RNA, H/ACA box 58 SNORA58 NR_002985 1.5697 
hypothetical FLJ36000 FLJ36000 NR_027084 1.566 
TPTE pseudogene psiTPTE22 NR_001591 1.56254 
microRNA 122 MIR122 NR_029667 1.54716 
BCL2-antagonist/killer 1 BAK1 NM_001188 1.54674 
histone cluster 1, H2bn HIST1H2BN NM_003520 1.54659 
glucuronidase, beta-like 2 GUSBL2 NR_003660 1.54461 
family with sequence similarity 86, member A hCG_1990547 
ENST0000031054
2 1.54285 
RNA, U5B small nuclear 1 RNU5B-1 NR_002757 1.5423 
non-protein coding RNA 87 NCRNA00087 NR_024493 1.54205 
zinc finger protein 552 ZNF552 NM_024762 1.54159 
G-protein signaling modulator 3 GPSM3 NM_022107 1.53931 
glutamate dehydrogenase 1 GLUD1 NM_005271 1.53663 
FLJ35934 protein FLJ35934 
ENST0000040760
0 1.53555 
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Appendix 7 Top 50 up-regulated genes upon PR knockdown. 
gene_assignment Gene Symbol RefSeq 
 [siNT down 
vs. siPR] 
kinesin family member 5A KIF5A AF063608 -2.56705 
protease, serine, 2 (trypsin 2) PRSS2 NM_002770 -2.08498 
LOC100131826 LOC100131826 AY358789 -2.07857 
family with sequence similarity 38, member B FAM38B NM_022068 -2.07243 
glutathione S-transferase mu 5 GSTM5 NM_000851 -1.98719 
SPHK1 interactor, AKAP domain containing SPHKAP NM_001142644 -1.98557 
olfactory receptor, family 52, subfamily K, member 3 
pseudogene OR52K3P AF143328 -1.97554 
DnaJ (Hsp40) homolog, subfamily B, member 7 DNAJB7 NM_145174 -1.96945 
KIAA0146 KIAA0146 AK301677 -1.95189 
SPANX family, member N3 SPANXN3 NM_001009609 -1.92531 
misato homolog 2 pseudogene MSTO2P NR_024117 -1.87231 
ribosomal protein L13a pseudogene 20 RPL13AP20 NR_003932 -1.82195 
immunoglobulin superfamily, member 9B IGSF9B NM_014987 -1.80567 
centromere protein C 1 CENPC1 NM_001812 -1.78448 
chromosome 8 open reading frame 48 C8orf48 NM_001007090 -1.77602 
glutathione S-transferase mu 1 GSTM1 NM_000561 -1.76971 
ribosomal protein L10 RPL10 NR_026898 -1.74806 
acyloxyacyl hydrolase (neutrophil) FAM183B NR_028347 -1.73801 
tetratricopeptide repeat domain 30B TTC30B NM_152517 -1.73036 
RAB43, member RAS oncogene family RAB43 NM_198490 -1.73028 
tripartite motif-containing 50 TRIM50 NM_178125 -1.71605 
interleukin 1, beta IL1B NM_000576 -1.70918 
aldo-keto reductase family 1, member C3 AKR1C3 NM_003739 -1.69892 
TNFAIP3 interacting protein 3 TNIP3 NM_024873 -1.69679 
hydroxy-delta-5-steroid dehydrogenase, 3 beta HSD3B1 NM_000862 -1.69622 
embigin homolog EMB NM_198449 -1.69459 
family with sequence similarity 169, member A FAM169A NM_015566 -1.69324 
actin, gamma-like LOC100130331 NR_027247 -1.6884 
RFT1 homolog RFT1 NM_052859 -1.68699 
methyltransferase like 1 METTL1 NM_005371 -1.68493 
ubiquitin-conjugating enzyme E2M pseudogene 1 UBE2MP1 NR_002837 -1.66442 
myeloproliferative disease associated tumor antigen 5 LOC613206 AY567967 -1.65717 
2'-5'-oligoadenylate synthetase 3 OAS3 NM_006187 -1.65618 
chromosome 3 open reading frame 47 C3orf47 NR_026991 -1.65344 
zinc finger protein 676 ZNF676 NM_001001411 -1.65258 
hypothetical LOC402483 tcag7.907 
ENST0000041541
8 -1.65157 
RNA binding motif protein 8A RBM8A BC017770 -1.64952 
similar to cytochrome b LOC100288871 XR_078322 -1.63961 
tripartite motif-containing 56 TRIM56 NM_030961 -1.63741 
ataxin 7-like 1 ATXN7L1 NM_020725 -1.6319 
defensin, beta 128 DEFB128 NM_001037732 -1.63087 
potassium voltage-gated channel, Isk-related family KCNE4 NM_080671 -1.62848 
trypsinogen C TRY6 NR_001296 -1.62609 
zinc finger protein 730 ZNF730 
ENST0000032786
7 -1.62522 
regulated endocrine-specific protein 18 RESP18 NM_001007089 -1.62023 
eyes shut homolog EYS NM_001142800 -1.61916 
IMP1 inner mitochondrial membrane peptidase-like IMMP1L NM_144981 -1.61616 
chromosome 6 open reading frame 226 C6orf226 NM_001008739 -1.61464 
AP2 associated kinase 1 AAK1 NM_014911 -1.61283 
carbonic anhydrase VB pseudogene CA5BP NR_026551 -1.61195 
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Appendix 8 Top 50 down-regulated genes upon PR knockdown. 
gene_assignment Gene Symbol RefSeq 
 [siNT up 
vs. siPR] 
hypothetical gene supported by AK131040 LOC388022 AK131040 2.51838 
G protein-coupled receptor 125 GPR125 NM_145290 2.29523 
small nucleolar RNA, H/ACA box 73A SNORA73A NR_002907 2.18471 
translocase of inner mitochondrial membrane 8 homolog B TIMM8B NR_028383 2.17127 
succinate dehydrogenase complex, subunit C SDHC NM_003001 2.16311 
heat shock 70kDa protein 7 (HSP70B) HSPA7 NR_024151 2.14913 
hCG2040210 LOC391169 XR_039983 2.12863 
Meis homeobox 3 MEIS3 NM_020160 2.06567 
RAS p21 protein activator 4 RASA4 NM_006989 1.99159 
small nucleolar RNA, C/D box 30 SNORD30 NR_002561 1.98027 
POM121 membrane glycoprotein POM121 NM_172020 1.95553 
protein phosphatase 1, regulatory (inhibitor) subunit 8 PPP1R8 NM_014110 1.93407 
RNA binding motif, single stranded interacting protein 2 RBMS2 NM_002898 1.89745 
galactosidase, alpha GLA NM_000169 1.88688 
N-acylsphingosine amidohydrolase ASAH2 NM_019893 1.85337 
zinc finger protein 737 ZNF737 NM_001159293 1.84508 
microtubule-associated protein, RP/EB family, member 1 MAPRE1 NM_012325 1.82659 
palmitoyl-protein thioesterase 1 PPT1 NM_000310 1.82099 
apolipoprotein B mRNA editing enzyme APOBEC3B NM_004900 1.80125 
chromosome 21 open reading frame 70 C21orf70 AF391113 1.80047 
potassium channel tetramerisation domain containing 18 KCTD18 NM_152387 1.79299 
phosphoribosyl pyrophosphate synthetase 2 PRPS2 NM_001039091 1.79118 
microRNA 199a-2 MIR199A2 NR_029618 1.78989 
transmembrane protein 203 TMEM203 NM_053045 1.78536 
hypothetical LOC100130876 
LOC10013087
6 AK130278 1.77639 
ADP-ribosylation factor-like 2 binding protein ARL2BP NM_012106 1.77626 
HAUS augmin-like complex, subunit 6 HAUS6 NM_017645 1.77178 
etoposide induced 2.4 mRNA EI24 NM_004879 1.76761 
P antigen family, member 2B PAGE2B NM_001015038 1.75586 
tRNA-yW synthesizing protein 1 homolog B TYW1B NM_001145440 1.75586 
chromosome 17 open reading frame 42 C17orf42 NM_024683 1.74701 
RNA binding motif protein 12B RBM12B NM_203390 1.74385 
Rho GTPase activating protein 11B ARHGAP11B NM_001039841 1.74223 
popeye domain containing 3 POPDC3 NM_022361 1.74009 
CMT1A duplicated region transcript 1 CDRT1 NM_006382 1.7291 
TIMELESS interacting protein TIPIN NM_017858 1.71928 
small nucleolar RNA, C/D box 13 SNORD13 NR_003041 1.71344 
matrix-remodelling associated 7 MXRA7 NM_198530 1.71212 
small nucleolar RNA, H/ACA box 50 SNORA50 NR_002980 1.70681 
glutaredoxin 5 GLRX5 NM_016417 1.70108 
AHA1, activator of heat shock 90kDa protein ATPase 
homolog AHSA2 NM_152392 1.701 
RNA, U1 small nuclear 1 RNU1-1 NR_004430 1.69291 
transmembrane protein 194B TMEM194B NM_001142645 1.68884 
murine retrovirus integration site 1 homolog MRVI1 NM_130385 1.68847 
solute carrier family 40 SLC40A1 NM_014585 1.68727 
golgin A6 family, member A GOLGA6A NM_001038640 1.68629 
chromosome 20 open reading frame 107 C20orf107 BC105792 1.68512 
chromosome 15 open reading frame 44 C15orf44 AK296134 1.68262 
programmed cell death 7 PDCD7 NM_005707 1.67892 
betaine--homocysteine S-methyltransferase 2 BHMT2 NM_017614 1.67872 
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Appendix 9 Top 50 up-regulated genes by MPA in the absence of GR. 
gene_assignment Gene Symbol RefSeq 
 [siGR down vs. 
siGR (MPA)] 
FK506 binding protein 5 FKBP5 NM_001145775 -2.26051 
small nucleolar RNA, H/ACA box 29 SNORA29 NR_002965 -2.11718 
chromosome 6 open reading frame 99 C6orf99 
ENST0000036707
3 -2.04625 
ankyrin repeat domain 11 ANKRD11 NM_013275 -1.91261 
family with sequence similarity 131, member C FAM131C NM_182623 -1.89378 
fatty acid binding protein 4, adipocyte FABP4 NM_001442 -1.86499 
glycerol-3-phosphate acyltransferase, mitochondrial GPAM AK172782 -1.85959 
taste receptor, type 2, member 19 TAS2R19 NM_176888 -1.71187 
coiled-coil domain containing 85C CCDC85C NM_001144995 -1.70621 
nuclear receptor co-repressor 1 pseudogene C20orf191 NR_003678 -1.69295 
killer cell lectin-like receptor subfamily A, member 1 KLRA1 NR_028045 -1.6901 
small nucleolar RNA, C/D box 45B SNORD45B NR_002748 -1.68869 
replication factor C (activator 1) 3 RFC3 NM_002915 -1.6699 
KIAA1586 KIAA1586 NM_020931 -1.66562 
LOC400986 LOC400986 
ENST0000045655
6 -1.66405 
hypothetical LOC339674 LOC339674 NR_024355 -1.62956 
HAUS augmin-like complex, subunit 6 HAUS6 NM_017645 -1.62207 
similar to RAN binding protein 1 LOC389842 XM_942610 -1.6183 
microRNA 122 MIR122 NR_029667 -1.60252 
olfactory receptor, family 2, subfamily M, member 5 OR2M5 NM_001004690 -1.59486 
male-specific lethal 3-like 2 MSL3L2 NM_001166217 -1.5855 
fibroblast growth factor 14 FGF14 NM_175929 -1.57522 
interleukin-1 receptor-associated kinase 3 IRAK3 NM_007199 -1.5726 
double homeobox, 4-like LOC441056 NM_001177376 -1.56615 
cholinergic receptor, muscarinic 4 CHRM4 NM_000741 -1.55025 
dihydrofolate reductase DHFR BC000192 -1.54617 
zinc finger protein 501 ZNF501 NM_145044 -1.54163 
eukaryotic translation initiation factor 4A2 EIF4A2 AB209021 -1.53972 
solute carrier family 29 SLC29A4 NM_001040661 -1.53103 
isopentenyl-diphosphate delta isomerase 1 IDI1 NM_004508 -1.52612 
family with sequence similarity 105, member A FAM105A NM_019018 -1.52191 
karyopherin alpha 5 KPNA5 NM_002269 -1.5192 
phosphatidylinositol glycan anchor biosynthesis, class 
H PIGH NM_004569 -1.51566 
ATP/GTP binding protein 1 AGTPBP1 NM_015239 -1.50881 
small nucleolar RNA, H/ACA box 20 SNORA20 NR_002960 -1.50783 
sterol-C5-desaturase SC5DL NM_006918 -1.50729 
THAP domain containing 9 THAP9 NM_024672 -1.5062 
keratin 81 KRT81 NM_002281 -1.50411 
double C2-like domains, beta DOC2B NM_003585 -1.50213 
dual specificity phosphatase 5 pseudogene DUSP5P AK055963 -1.50201 
epididymal protein 3B EDDM3B NM_022360 -1.50178 
non-metastatic cells 5 NME5 NM_003551 -1.50157 
1-acylglycerol-3-phosphate O-acyltransferase 9 AGPAT9 NM_032717 -1.49908 
olfactory receptor, family 10, subfamily A, member 2 OR10A2 NM_001004460 -1.49795 
dynein, axonemal, light chain 1 DNAL1 NM_031427 -1.49381 
protease, serine, 48 PRSS48 NM_183375 -1.49214 
microRNA let-7c MIRLET7C NR_029480 -1.4887 
taste receptor, type 2, member 46 TAS2R46 NM_176887 -1.48456 
centromere protein Q CENPQ NM_018132 -1.48345 
chromosome 20 open reading frame 203 C20orf203 NM_182584 -1.48286 
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Appendix 10 Top 50 down-regulated genes by MPA in the absence of GR. 
gene_assignment Gene Symbol RefSeq 
 [siGR up vs. 
siGR (MPA)] 
family with sequence similarity 120A FAM120A NM_014612 2.29936 
FLJ44896 protein FLJ44896 AK126844 2.02038 
eukaryotic translation initiation factor 3, subunit I EIF3I NM_003757 1.97887 
ribosomal protein L10 RPL10 NM_006013 1.95987 
eukaryotic translation initiation factor 3, subunit K EIF3K NM_013234 1.88149 
peroxiredoxin 5 PRDX5 NM_012094 1.8784 
mediator complex subunit 27 MED27 NM_004269 1.86931 
ribosomal protein L13a pseudogene 5 RPL13AP5 NR_026712 1.847 
NKF3 kinase family member SGK269 NM_024776 1.82084 
processing of precursor 7 POP7 NM_005837 1.81033 
fibroblast growth factor (acidic) intracellular binding protein FIBP NM_198897 1.80722 
small nucleolar RNA, C/D box 13 SNORD13 NR_003041 1.80579 
keratin 18 KRT18 NM_000224 1.78054 
ankyrin repeat domain 20B ANKRD20B NR_003366 1.77696 
zinc finger, DHHC-type containing 16 ZDHHC16 NM_198046 1.77424 
solute carrier family 16, member 2 SLC16A2 NM_006517 1.76735 
ectodysplasin A2 receptor EDA2R NM_021783 1.76108 
GRB2-related adaptor protein GRAP NM_006613 1.75985 
ariadne homolog 2 ARIH2 NM_006321 1.75912 
ubiquitin-conjugating enzyme E2Z UBE2Z NM_023079 1.75911 
enolase 1 ENO1 NM_001428 1.7535 
ATPase, H+ transporting, lysosomal 38kDa, V0 subunit 
d1 ATP6V0D1 NM_004691 1.75027 
ubiquinol-cytochrome c reductase hinge protein UQCRH NM_006004 1.74176 
aldo-keto reductase family 1, member B1 AKR1B1 NM_001628 1.73684 
ERGIC and golgi 3 ERGIC3 NM_198398 1.7329 
D4, zinc and double PHD fingers family 2 DPF2 NM_006268 1.73089 
peptidase domain containing associated with muscle 
regeneration 1 PAMR1 NM_015430 1.73048 
ribosomal protein L13a pseudogene 20 RPL13AP20 NR_003932 1.72806 
histone cluster 1, H2bk HIST1H2BK NM_080593 1.72465 
tubulin, alpha 1c TUBA1C NM_032704 1.72416 
hypothetical protein LOC728690 LOC728690 AK094642 1.71863 
trafficking protein particle complex 3 TRAPPC3 NM_014408 1.71509 
retinoic acid receptor responder (tazarotene induced) 2  RARRES2 NM_002889 1.71002 
tubulin, beta TUBB NM_178014 1.70874 
small nucleolar RNA, C/D box 95 SNORD95 NR_002591 1.70805 
RAB5C, member RAS oncogene family RAB5C NM_201434 1.69167 
prolactin regulatory element binding PREB NM_013388 1.6916 
lectin, galactoside-binding, soluble, 1 LGALS1 NM_002305 1.68865 
ATP synthase, H+ transporting, mitochondrial F0 
complex ATP5I NM_007100 1.6846 
inhibitor of kappa light polypeptide gene enhancer in B-
cell IKBKB NM_001556 1.68218 
casein kinase 2, beta polypeptide CSNK2B NM_001320 1.67748 
KIAA1199 KIAA1199 NM_018689 1.67581 
glutaminyl-tRNA synthetase QARS NM_005051 1.6729 
sialidase 1 (lysosomal sialidase) NEU1 NM_000434 1.67199 
splicing factor 3b, subunit 3 SF3B3 NM_012426 1.67148 
succinate dehydrogenase complex assembly factor 2 SDHAF2 NM_017841 1.67118 
ornithine decarboxylase antizyme 1 OAZ1 NM_004152 1.66594 
extended synaptotagmin-like protein 1 ESYT1 NM_015292 1.66325 
alanyl-tRNA synthetase AARS NM_001605 1.66323 
IQ motif containing with AAA domain 1-like IQCA1L XR_018506 1.66275 
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Appendix 11 Top 50 up-regulated genes by P4 in the absence of GR. 
gene_assignment Gene Symbol RefSeq 
 [siGR down vs. 
siGR (P4)] 
chromosome 6 open reading frame 99 C6orf99 
ENST0000036707
3 -2.37857 
glycerol-3-phosphate acyltransferase, mitochondrial GPAM AK172782 -2.18778 
microRNA 122 MIR122 NR_029667 -1.90711 
transmembrane protein 120B TMEM120B NM_001080825 -1.83974 
killer cell lectin-like receptor subfamily A, member 1 KLRA1 NR_028045 -1.82658 
fumarylacetoacetate hydrolase domain containing 2A FAHD2A NM_016044 -1.78151 
zinc finger protein 502 ZNF502 NM_033210 -1.74475 
developmental pluripotency associated 3 DPPA3 NM_199286 -1.73821 
family with sequence similarity 181, member B FAM181B NM_175885 -1.6901 
isopentenyl-diphosphate delta isomerase 1 IDI1 NM_004508 -1.68368 
THAP domain containing, apoptosis associated protein 
2 THAP2 NM_031435 -1.68341 
family with sequence similarity 159, member B FAM159B NM_001164442 -1.67978 
hypothetical LOC441233 LOC441233 AK128010 -1.67358 
sterol-C4-methyl oxidase-like SC4MOL NM_006745 -1.65975 
dynamin 1 pseudogene C15orf51 
ENST0000042324
8 -1.6446 
LOC100289668 
LOC10028966
8 
ENST0000042673
0 -1.6446 
glucosaminyl (N-acetyl) transferase 4 GCNT4 NM_016591 -1.6418 
kinesin family member 27 KIF27 NM_017576 -1.62629 
olfactory receptor, family 2, subfamily T, member 4 OR2T4 NM_001004696 -1.61899 
nucleophosmin (nucleolar phosphoprotein B23, 
numatrin) NPM1 NM_001037738 -1.61561 
microRNA let-7c MIRLET7C NR_029480 -1.61499 
olfactory receptor, family 4, subfamily A, member 47 OR4A47 NM_001005512 -1.60108 
hypothetical LOC100133075 
LOC10013307
5 XR_039086 -1.59776 
golgin A6 family, member A GOLGA6A NM_001038640 -1.59662 
chromosome 1 open reading frame 146 C1orf146 NM_001012425 -1.59457 
paraneoplastic antigen like 6A PNMA6A NM_032882 -1.58528 
3-hydroxy-3-methylglutaryl-CoA synthase 1 HMGCS1 NM_001098272 -1.58154 
coiled-coil domain containing 85C CCDC85C NM_001144995 -1.57529 
protogenin homolog PRTG NM_173814 -1.57508 
beta-1,3-glucuronyltransferase 3 B3GAT3 NM_012200 -1.56872 
double homeobox, 4-like LOC441056 NM_001177376 -1.56811 
hypothetical LOC100133091 
LOC10013309
1 NR_029411 -1.56197 
linker for activation of T cells LAT NM_014387 -1.55944 
La ribonucleoprotein domain family, member 1B LARP1B NM_018078 -1.55222 
solute carrier family 28 SLC28A3 NM_022127 -1.5444 
TBC1 domain family, member 2B TBC1D2B NM_144572 -1.544 
chemokine (C-C motif) receptor 2 CCR2 NM_001123041 -1.53778 
hypothetical LOC645188 LOC645188 BC042039 -1.53429 
zinc finger protein 277 ZNF277 
ENST0000042104
3 -1.52958 
sterol-C5-desaturase SC5DL NM_006918 -1.5244 
high mobility group AT-hook 2 HMGA2 NM_003483 -1.52342 
yrdC domain containing YRDC NM_024640 -1.52154 
chorionic somatomammotropin hormone 2 CSH2 NM_022644 -1.52123 
glucuronidase, beta-like 2 GUSBL2 NR_003660 -1.52053 
acyloxyacyl hydrolase FAM183B NR_028347 -1.51803 
mitogen-activated protein kinase kinase kinase kinase 3 MAP4K3 NM_003618 -1.50906 
coiled-coil domain containing 29 CCDC29 
ENST0000034046
0 -1.50782 
small nucleolar RNA, C/D box 42A SNORD42A NR_000014 -1.49931 
kelch domain containing 1 KLHDC1 NM_172193 -1.49754 
excision repair cross-complementing rodent repair 
deficiency ERCC6L NM_017669 -1.49203 
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Appendix 12 Top 50 down-regulated genes by P4 in the absence of GR. 
gene_assignment Gene Symbol RefSeq 
 [siGR up vs. 
siGR (P4)] 
thioredoxin interacting protein TXNIP NM_006472 3.80321 
translocase of outer mitochondrial membrane 22 
homolog TOMM22 NM_020243 3.04636 
ubiquinol-cytochrome c reductase hinge protein UQCRH NM_006004 2.67655 
tRNA methyltransferase 11-2 homolog TRMT112 NM_016404 2.24388 
keratin associated protein 5-5 KRTAP5-5 NM_001001480 2.20555 
small nucleolar RNA, C/D box 13 SNORD13 NR_003041 2.19215 
hypothetical LOC100130876 
LOC10013087
6 AK130278 2.14199 
hCG2040210 LOC391169 XR_039983 2.1341 
ribosomal protein, large, P0 RPLP0 NM_053275 2.12651 
actin related protein 2/3 complex, subunit 1A ARPC1A NM_006409 2.08493 
peroxiredoxin 5 PRDX5 NM_012094 2.03943 
CDC-like kinase 4 CLK4 BC063116 2.03346 
peptidase domain containing associated with muscle 
regeneration PAMR1 NM_015430 2.03292 
epithelial cell adhesion molecule EPCAM NM_002354 2.02553 
eukaryotic translation initiation factor 3, subunit K EIF3K NM_013234 2.01347 
TH1-like TH1L NM_198976 2.0116 
NKF3 kinase family member SGK269 NM_024776 1.98983 
small nuclear ribonucleoprotein 40kDa SNRNP40 NM_004814 1.98015 
golgin A6 family, member A GOLGA6A NM_001038640 1.97203 
histone deacetylase 1 HDAC1 NM_004964 1.95149 
leucine rich repeat (in FLII) interacting protein 1 LRRFIP1 NM_001137550 1.93405 
small nucleolar RNA, C/D box 38B SNORD38B NR_001457 1.92079 
stromal cell-derived factor 2 SDF2 NM_006923 1.90643 
GRB2-related adaptor protein GRAP NM_006613 1.90484 
casein kinase 2, beta polypeptide CSNK2B NM_001320 1.90441 
hypothetical gene supported by AK131040 LOC388022 AK131040 1.89081 
myxovirus (influenza virus) resistance 1 MX1 NM_002462 1.88331 
coiled-coil-helix-coiled-coil-helix domain CHCHD3 
ENST0000042363
5 1.87937 
serpin peptidase inhibitor, clade F SERPINF1 NM_002615 1.86458 
enolase 1 ENO1 NM_001428 1.86296 
coatomer protein complex, subunit zeta 2 COPZ2 NM_016429 1.84096 
eukaryotic translation initiation factor 3, subunit I EIF3I NM_003757 1.83196 
intraflagellar transport 46 homolog IFT46 NM_020153 1.82494 
endogenous retroviral sequence 3 ERV3 NM_001007253 1.8216 
polymerase (RNA) II (DNA directed) polypeptide G POLR2G NM_002696 1.81417 
glutathione S-transferase mu 1 GSTM1 NM_000561 1.81379 
polymerase (RNA) II (DNA directed) polypeptide H POLR2H NM_006232 1.80569 
mitochondrial ribosomal protein L21 MRPL21 NM_181515 1.80113 
KIAA0174 KIAA0174 NM_014761 1.80072 
solute carrier family 31 (copper transporters), member 
1 SLC31A1 NM_001859 1.79853 
glycoprotein Ib (platelet), beta polypeptide GP1BB L20860 1.79724 
interleukin enhancer binding factor 2 ILF2 NM_004515 1.7955 
ERGIC and golgi 3 ERGIC3 NM_198398 1.7917 
ribosomal protein L13a pseudogene 5 RPL13AP5 NR_026712 1.783 
dynein, light chain, LC8-type 1 DYNLL1 NM_001037495 1.78192 
solute carrier family 5 SLC5A3 NM_006933 1.78155 
ubiquitin B UBB NM_018955 1.78061 
zinc finger protein 512 ZNF512 NM_032434 1.77348 
capping protein (actin filament) muscle Z-line, beta CAPZB NM_004930 1.76875 
exosome component 1 EXOSC1 NM_016046 1.76456 
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Appendix 13 Top 50 up-regulated genes by MPA in the absence of PR. 
gene_assignment Gene Symbol RefSeq 
 [siPR down vs. 
siPR (MPA)] 
FK506 binding protein 5 FKBP5 
NM_00114577
5 -10.1159 
ERBB receptor feedback inhibitor 1 ERRFI1 NM_018948 -6.63831 
glutamate-ammonia ligase GLUL NM_002065 -5.89311 
LIM domain only 3 LMO3 NM_018640 -3.89801 
chromosome 13 open reading frame 15 C13orf15 NM_014059 -3.77166 
hypothetical LOC100130876 
LOC10013087
6 AK130278 -3.36431 
carboxypeptidase M CPM NM_001874 -3.17945 
acyl-CoA synthetase long-chain family member 1 ACSL1 NM_001995 -3.07627 
POM121 membrane glycoprotein POM121 NM_172020 -2.98084 
stomatin STOM NM_004099 -2.96571 
leucine rich repeat containing 16A LRRC16A NM_017640 -2.93314 
FYVE, RhoGEF and PH domain containing 4 FGD4 NM_139241 -2.90072 
interleukin-1 receptor-associated kinase 3 IRAK3 NM_007199 -2.89105 
metallothionein 1X MT1X NM_005952 -2.88986 
ADAM metallopeptidase with thrombospondin type 1 
motif ADAMTS1 NM_006988 -2.86363 
fibulin 5 FBLN5 NM_006329 -2.84262 
serpin peptidase inhibitor, clade E SERPINE1 NM_000602 -2.7836 
G protein-coupled receptor 125 GPR125 NM_145290 -2.73952 
cysteine dioxygenase, type I CDO1 NM_001801 -2.64144 
TSC22 domain family, member 3 TSC22D3 NM_198057 -2.6248 
histone deacetylase 1 HDAC1 NM_004964 -2.61596 
glucosaminyl (N-acetyl) transferase 1 GCNT1 NM_001490 -2.6043 
cirrhosis, autosomal recessive 1A CIRH1A NM_032830 -2.54408 
B-cell CLL/lymphoma 6 BCL6 NM_001706 -2.49069 
adaptor protein, phosphotyrosine interaction APPL2 NM_018171 -2.48071 
G protein-coupled receptor 126 GPR126 NM_020455 -2.45737 
forkhead box O3B pseudogene FOXO3B NR_026718 -2.4136 
LIM and cysteine-rich domains 1 LMCD1 NM_014583 -2.4114 
fibrillin 2 FBN2 NM_001999 -2.40784 
LAG1 homolog, ceramide synthase 6 LASS6 NM_203463 -2.39707 
peroxisomal biogenesis factor 11 beta PEX11B NM_003846 -2.39443 
chromosome 21 open reading frame 70 C21orf70 AF391113 -2.3832 
loss of heterozygosity, 3, chromosomal region 2, gene A  LOH3CR2A AF086709 -2.37937 
carbohydrate (chondroitin 4) sulfotransferase 11 CHST11 NM_018413 -2.37287 
casein kinase 2, beta polypeptide CSNK2B NM_001320 -2.37025 
midline 2 MID2 NM_012216 -2.36795 
transmembrane protein 203 TMEM203 NM_053045 -2.33974 
hypothetical gene supported by AK131040 LOC388022 AK131040 -2.33913 
hydroxysteroid (11-beta) dehydrogenase 1 HSD11B1 NM_005525 -2.33503 
phosphogluconate dehydrogenase PGD NM_002631 -2.32956 
glycoprotein Ib (platelet), beta polypeptide GP1BB L20860 -2.32928 
MpV17 mitochondrial inner membrane protein MPV17 NM_002437 -2.31987 
hippocampus abundant transcript-like 1 HIATL1 NM_032558 -2.28787 
coatomer protein complex, subunit zeta 2 COPZ2 NM_016429 -2.27636 
solute carrier family 35, member B1 SLC35B1 NM_005827 -2.26821 
translocase of inner mitochondrial membrane 8 homolog 
B TIMM8B NR_028383 -2.26488 
etoposide induced 2.4 mRNA EI24 NM_004879 -2.26084 
fat mass and obesity associated FTO 
NM_00108043
2 -2.24308 
thioredoxin interacting protein TXNIP NM_006472 -2.2419 
aldehyde oxidase 1 AOX1 NM_001159 -2.24154 
 
  
Appendices 
- 164 - 
Appendix 14 Top 50 down-regulated genes by MPA in the absence of PR. 
gene_assignment Gene Symbol RefSeq 
 [siPR up vs. 
siPR (MPA)] 
Similar to LOC166075 LOC401097 NM_001168214 6.34696 
tumor necrosis factor receptor superfamily, member 
11b TNFRSF11B NM_002546 3.0884 
histone cluster 1, H2aj HIST1H2AJ NM_021066 2.77566 
matrix metallopeptidase 16 MMP16 AL136588 2.51035 
SPANX family, member N3 SPANXN3 NM_001009609 2.45283 
zinc finger protein 277 ZNF277 
ENST0000042104
3 2.37781 
interleukin 33 IL33 NM_033439 2.31366 
microRNA 122 MIR122 NR_029667 2.29423 
microRNA let-7c MIRLET7C NR_029480 2.25849 
chemokine (C-C motif) ligand 7 CCL7 NM_006273 2.25345 
histone cluster 1, H2bb HIST1H2BB NM_021062 2.24877 
kinesin family member 5A KIF5A AF063608 2.22863 
hypothetical protein PRO2268 PRO2268 
ENST0000045616
5 2.19858 
SPHK1 interactor SPHKAP NM_001142644 2.15687 
regulator of G-protein signaling 4 RGS4 NM_001102445 2.10579 
deleted in lymphocytic leukemia 2 DLEU2 NR_002612 2.1015 
heterogeneous nuclear ribonucleoprotein C-like 1 HNRNPCL1 NM_001013631 2.1014 
hypothetical LOC100134868 
LOC10013486
8 NR_004846 2.08943 
tripartite motif-containing 50 TRIM50 NM_178125 2.08241 
MST131 MST131 
ENST0000042332
2 2.02693 
protein phosphatase 1, regulatory (inhibitor) subunit 3C PPP1R3C NM_005398 2.01722 
TNFAIP3 interacting protein 3 TNIP3 NM_024873 1.99493 
tumor necrosis factor, alpha-induced protein 6 TNFAIP6 NM_007115 1.99372 
interferon-induced protein with tetratricopeptide 
repeats  IFIT2 NM_001547 1.9797 
MADD domain containing 2C DENND2C BC063894 1.9696 
vault RNA 1-3 VTRNA1-3 NR_026705 1.95371 
RNA binding motif protein, Y-linked, family 1, 
member A1 RBMY1A1 NM_005058 1.948 
chemokine (C-C motif) receptor 2 CCR2 NM_001123041 1.93529 
hypothetical LOC100133746 
LOC10013374
6 
ENST0000044768
2 1.92526 
small nucleolar RNA, C/D box 42A SNORD42A NR_000014 1.92442 
R-spondin 3 homolog RSPO3 NM_032784 1.92366 
SPANX family, member B1 SPANXB1 NM_032461 1.91683 
tetratricopeptide repeat domain 30B TTC30B NM_152517 1.91367 
prostaglandin-endoperoxide synthase 2 PTGS2 NM_000963 1.89635 
N-myc (and STAT) interactor NMI NM_004688 1.89347 
acetyl-CoA acyltransferase 1 ACAA1 AK127051 1.88458 
fibroblast growth factor 9 FGF9 NM_002010 1.87029 
leucine zipper protein 2 LUZP2 NM_001009909 1.869 
olfactory receptor, family 4, subfamily N, member 4 OR4N4 NM_001005241 1.86646 
zinc finger protein 676 ZNF676 NM_001001411 1.84163 
similar to hCG1645603 LOC732275 NR_024406 1.82722 
RNA binding motif protein 8A RBM8A BC017770 1.82288 
high mobility group protein B3-like protein-like LOC441795 
ENST0000044740
8 1.82265 
lectin, galactoside-binding, soluble, 9 LGALS9 NM_009587 1.81871 
olfactory receptor, family 52, subfamily E, member 2 OR52E2 NM_001005164 1.81489 
regulator of G-protein signaling like 1 RGSL1 NM_001137669 1.81108 
protease, serine, 2 PRSS2 NM_002770 1.80636 
transmembrane protein 200A TMEM200A NM_052913 1.80151 
ribosomal RNA processing 7 homolog B RRP7B BC014647 1.79571 
zinc finger protein 705A ZNF705A NM_001004328 1.77323 
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Appendix 15 Top 50 up-regulated genes by P4 in the absence of PR. 
gene_assignment Gene Symbol RefSeq 
 [siPR down vs. 
siPR (P4)] 
G protein-coupled receptor 125 GPR125 NM_145290 -3.73773 
hippocampus abundant transcript-like 1 HIATL1 NM_032558 -3.05889 
ERBB receptor feedback inhibitor 1 ERRFI1 NM_018948 -2.87891 
POM121 membrane glycoprotein POM121 NM_172020 -2.74985 
phosphogluconate dehydrogenase PGD NM_002631 -2.74369 
cirrhosis, autosomal recessive 1A CIRH1A NM_032830 -2.71681 
transmembrane protein 203 TMEM203 NM_053045 -2.58123 
solute carrier family 37 SLC37A3 NM_207113 -2.55911 
karyopherin alpha 2 KPNA2 NM_002266 -2.50193 
ATP-binding cassette, sub-family A (ABC1), member 1 ABCA1 NM_005502 -2.49884 
fibulin 5 FBLN5 NM_006329 -2.49172 
ubiquitin specific peptidase 10 USP10 NM_005153 -2.43718 
Niemann-Pick disease, type C1 NPC1 NM_000271 -2.41787 
histone deacetylase 1 HDAC1 NM_004964 -2.41731 
eukaryotic translation initiation factor 3, subunit L EIF3L NM_016091 -2.38501 
PMS2 postmeiotic segregation increased 2 PMS2 NM_000535 -2.37466 
tetraspanin 5 TSPAN5 NM_005723 -2.35328 
hypothetical LOC100130876 LOC100130876 AK130278 -2.32835 
solute carrier family 35, member B1 SLC35B1 NM_005827 -2.3209 
rhomboid domain containing 1 RHBDD1 NM_032276 -2.31595 
nuclear receptor coactivator 1 NCOA1 NM_147223 -2.30522 
hypothetical gene supported by AK131040 LOC388022 AK131040 -2.30388 
fat mass and obesity associated FTO NM_001080432 -2.30341 
phosphatidylserine synthase 1 PTDSS1 NM_014754 -2.30022 
ectonucleotide pyrophosphatase/phosphodiesterase 2 ENPP2 NM_006209 -2.29343 
seryl-tRNA synthetase SARS NM_006513 -2.28538 
glycosyltransferase 8 domain containing 2 GLT8D2 NM_031302 -2.28407 
CAP, adenylate cyclase-associated protein, 2 CAP2 NM_006366 -2.28386 
X-prolyl aminopeptidase (aminopeptidase P) 1 XPNPEP1 NM_020383 -2.2703 
casein kinase 2, beta polypeptide CSNK2B NM_001320 -2.26343 
3-hydroxy-3-methylglutaryl-CoA reductase HMGCR NM_000859 -2.23692 
LETM1 domain containing 1 LETMD1 NM_015416 -2.23593 
splicing factor 3b, subunit 3 SF3B3 NM_012426 -2.23234 
GTPase activating protein and VPS9 domains 1 GAPVD1 NM_015635 -2.20793 
microtubule-associated protein, RP/EB family, member 1 MAPRE1 NM_012325 -2.19452 
B-cell CLL/lymphoma 6 BCL6 NM_001706 -2.18445 
COP9 constitutive photomorphogenic homolog subunit 6 COPS6 NM_006833 -2.17584 
asparagine-linked glycosylation 9 ALG9 NM_024740 -2.1716 
chromosome 16 open reading frame 62 C16orf62 BC050464 -2.16771 
etoposide induced 2.4 mRNA EI24 NM_004879 -2.1573 
translocase of outer mitochondrial membrane 22 
homolog TOMM22 NM_020243 -2.15256 
bifunctional apoptosis regulator BFAR NM_016561 -2.14648 
fatty acid binding protein 3 FABP3 NM_004102 -2.13338 
death associated protein 3 DAP3 NM_033657 -2.1283 
ubiquitination factor E4B UBE4B NM_001105562 -2.12227 
transcription factor B1, mitochondrial TFB1M NM_016020 -2.12045 
N-acylsphingosine amidohydrolase ASAH2 NM_019893 -2.10834 
coatomer protein complex, subunit alpha COPA NM_001098398 -2.10365 
exportin 6 XPO6 NM_015171 -2.08761 
enolase 1 ENO1 NM_001428 -2.08683 
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Appendix 16 Top 50 down-regulated genes by P4 in the absence of PR. 
gene_assignment Gene Symbol RefSeq 
 [siPR up vs. 
siPR (P4)] 
protease, serine, 2 (trypsin 2) PRSS2 NM_002770 2.39632 
Similar to LOC166075 LOC401097 NM_001168214 2.38528 
hypothetical LOC100134868 LOC100134868 NR_004846 2.28232 
kinesin family member 5A KIF5A AF063608 2.13542 
lipocalin 8 LCN8 ENST00000371686 2.10698 
hypothetical protein PRO2268 PRO2268 ENST00000456165 2.08432 
deleted in lymphocytic leukemia 2 DLEU2 NR_002612 1.99468 
similar to hCG1645603 LOC732275 NR_024406 1.97356 
hypothetical LOC100133746 LOC100133746 ENST00000447682 1.9655 
hypothetical locus LOC388666 FLJ36116 AK093435 1.96017 
tetratricopeptide repeat domain 30B TTC30B NM_152517 1.95007 
tripartite motif-containing 50 TRIM50 NM_178125 1.94585 
zinc finger protein 277 ZNF277 ENST00000421043 1.92161 
adenosine deaminase domain containing 2 ADAD2 NM_139174 1.89948 
small nucleolar RNA, C/D box 13 SNORD13 NR_003041 1.89413 
IMP1 inner mitochondrial membrane peptidase-like IMMP1L NM_144981 1.88556 
SPANX family, member B1 SPANXB1 NM_032461 1.87733 
paired box 5 PAX5 NM_016734 1.86679 
matrix metallopeptidase 16 MMP16 AL136588 1.86306 
hypothetical LOC100133091 LOC100133091 NR_029411 1.84865 
claudin 23 CLDN23 NM_194284 1.83546 
immunoglobulin lambda-like polypeptide LOC91316 NR_024448 1.82493 
zinc finger protein 257 ZNF257 NM_033468 1.82346 
FLJ16171 protein FLJ16171 AK131247 1.81449 
hypothetical LOC645188 LOC645188 BC042039 1.8116 
small nucleolar RNA, H/ACA box 71D SNORA71D NR_003018 1.79584 
cytochrome P450, family 1, subfamily B, polypeptide 1 CYP1B1 NM_000104 1.78877 
translocase of inner mitochondrial membrane 8 homolog A TIMM8A NM_004085 1.77713 
high mobility group protein B3-like protein-like LOC441795 ENST00000447408 1.77247 
olfactory receptor, family 4, subfamily N, member 4 OR4N4 NM_001005241 1.77007 
histone cluster 1, H2aj HIST1H2AJ NM_021066 1.76901 
coiled-coil domain containing 88C CCDC88C NM_001080414 1.76134 
histone cluster 1, H2bb HIST1H2BB NM_021062 1.75681 
protein immuno-reactive with anti-PTH polyclonal LOC400986 ENST00000456556 1.75568 
CCCTC-binding factor (zinc finger protein)-like CTCFL BC137482 1.75503 
small nucleolar RNA, C/D box 13 pseudogene 1 SNORD13P1 X58061 1.74873 
Nmicrotubule-associated protein 1 light chain 3 gamma MAP1LC3C NM_001004343 1.74525 
ribosomal RNA processing 7 homolog B RRP7B BC014647 1.74275 
hypothetical locus FLJ25758 FLJ25758 NR_024372 1.73679 
small nucleolar RNA, C/D box 116-6  SNORD116-6 NR_003321 1.73393 
olfactory receptor, family 52, subfamily K, member 3 
pseu OR52K3P AF143328 1.73334 
leucine zipper protein 2 LUZP2 NM_001009909 1.72544 
KIAA1586 KIAA1586 NM_020931 1.72088 
vault RNA 1-3 VTRNA1-3 NR_026705 1.71624 
LOC100131508 LOC100131508 ENST00000431141 1.7076 
family with sequence similarity 169, member A FAM169A NM_015566 1.70434 
microRNA let-7c MIRLET7C NR_029480 1.70299 
KIAA0146 KIAA0146 AK301677 1.70018 
microRNA 302a MIR302A NR_029835 1.69811 
chemokine (C-C motif) receptor 2 CCR2 NM_001123041 1.68386 
 
  
Appendices 
- 167 - 
Appendix 17 Networks and top functions of MPA regulated genes. 
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Appendix 18 Networks and top functions of P4 regulated genes. 
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Appendix 19 Networks and top functions of GR regulated genes. 
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Appendix 20 Networks and top functions of PR regulated genes. 
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Appendix 21 Networks and top functions of MPA regulated genes in the absence of GR. 
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Appendix 22 Networks and top functions of P4 regulated genes in the absence of GR. 
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Appendix 23 Networks and top functions of MPA regulated genes in the absence of PR. 
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Appendix 24 Networks and top functions of P4 regulated genes in the absence of PR. 
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